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ABSTRACT 
 
Cancer multidrug resistance (MDR) is a major cause of therapeutic failure. MDR is 
mainly due to the overexpression of drug efflux pumps, such as P-glycoprotein (P-gp). 
Nevertheless, there are no P-gp inhibitors being used in the current clinical practice, due to 
toxicity problems, drug interactions or pharmacokinetic issues. Curcumin is a secondary 
metabolite isolated from the turmeric of Curcuma longa L. which has been associated with 
several biological activities, particularly P-gp modulatory activity. However, curcumin shows 
extensive metabolism and instability, which has justified the recent and intensive search for 
analogs of curcumin that maintain the P-gp modulatory activity but have enhanced stability.  
Besides overexpression of drug efflux pumps, other molecular mechanisms are 
involved in the MDR phenotype, including metabolic alterations. Indeed, some recent 
studies showed that it is possible to revert the MDR phenotype by inhibition of glycolysis 
with specific modulators.  
Extracellular vesicles (EVs) are a group of vesicles, that include exosomes and 
microvesicles, released by all cells. Since they carry a specific cargo (such as proteins and 
microRNAs) and are present in several body fluids (such as blood), they can be easily 
collected from cancer patients and could become the source of biomarkers of cancer 
diagnosis, prognosis or drug resistance. Additionally, several studies have highlighted the 
relevance of extracellular vesicles (EVs) in metabolism since it was shown that metabolic 
alterations could affect the shedding and cargo of EVs released by cells.  
This thesis aimed to: 1) identify new targets for overcoming P-gp mediated MDR in 
cancer, 2) identify potential biomarkers of MDR in EVs released by cancer cells and 3) find 
novel molecules to overcome MDR, by identifying curcumin derivatives with improved P-gp 
inhibitory effect.  
In order to achieve this, two pairs of MDR and drug-sensitive counterpart cell lines 
were used (from chronic myeloid leukaemia and non-small cell lung cancer), in which the 
MDR phenotype was mainly due to overexpression of P-gp. Proteins from the cells and their 
EVs (which were properly characterized by size with Dynamic Light Scattering and 
Transmission Electron Microscopy and by molecular markers with Western Blot and Flow 
cytometry) were investigated by proteomics and data was confirmed by Western blot 
analysis. The metabolic profile was accessed in the cells before and after treatments with 
specific inhibitors and following incubation with EVs released from the MDR cells.  
We have shown that MDR (P-gp overexpressing) cells have a different metabolic 
profile from the drug-sensitive counterpart cells, exhibiting: (i) a decrease in the pentose 
phosphate pathway and in the oxidative phosphorylation rate; (ii) an increase in the 
		x	
glycolysis rate and in the methylation index; (iii) alterations in the glutathione metabolism 
and in the methionine/S-adenosylmethionine pathway.  
 Moreover, our results showed that in both cancer cell models, the EVs isolated from 
MDR cells were bigger, when compared to the EVs released from the drug-sensitive 
counterpart cells. In addition, CHMP4, CD63, TSG101, Syntenin-1 and Clathrin LCB 
proteins (previously known to be involved in the biogenesis of exosomes) were less present 
in the EVs shed by MDR cells. On the other hand, P-gp was only present in the EVs shed 
by the MDR cell lines. Together, this data indicated that MDR tumour cells secrete more 
microvesicles, whereas drug-sensitive tumour cells secrete more exosomes. Remarkably, 
these EVs, from MDR cells, were capable of causing a metabolic switch in the drug-
sensitive cancer cells, towards a MDR phenotype.  
Finally, in this study, the antitumor and P-gp modulatory activities of a small library 
of new curcumin derivatives were also tested. For that, the compounds were analysed in 
the two MDR tumour cell lines (with P-gp overexpression) and their drug-sensitive 
counterparts. From the series of synthesized curcumin derivatives, a newly synthesized 
derivative (1,7-bis(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)hepta-1,6-diene-3,5-dione) 
presenting more potent antitumor and anti-P-gp activities than curcumin itself was identified. 
In addition, this compound arrested cell cycle at the G2/M phase and induced cell death by 
apoptosis, in the MDR chronic myeloid leukaemia cell line.  
Overall, the work presented in this thesis contributes to the growing knowledge on 
metabolic alterations in MDR cells and the role of a specific population of EVs in the 
intercellular transfer of MDR. The specific metabolic alterations identified in this study may 
be further developed as targets for overcoming MDR. Also, the specific size and protein 
signature that we have identified in the EVs shed by the MDR cells may have diagnostic 
significance in cancer, as a source of biomarkers to identify P-gp mediated MDR phenotype. 
Furthermore, this work also shows the potential of synthetizing new curcumin derivatives to 
improve curcumin stability and characterized the promising dual activity (antitumor and anti-
P-gp) of a novel curcumin derivative.  
 
 
 
Keywords: Cancer Multidrug Resistance; P-glycoprotein; Metabolism; Glycolysis; 
Oxidative Phosphorylation; Extracellular Vesicles; Curcumin. 
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RESUMO 
 
A resistência a múltiplos fármacos (RMF) é uma das maiores causas de falha 
terapêutica no tratamento do cancro. A RMF é devida sobretudo à sobre-expressão de 
bombas de efluxo de fármacos, tais como a glicoproteína P (P-gp). Contudo, na atual 
prática clinica ainda não são usados inibidores da P-gp, devido a problemas de toxicidade, 
de interação de fármacos ou problemas farmacocinéticos. A curcumina é um metabolito 
secundário isolado da Curcuma longa L, que tem sido associada a várias atividades 
biológicas, em particular à atividade moduladora da P-gp. Contudo, a curcumina apresenta 
um extenso metabolismo e instabilidade, justificando uma procura recente e intensiva de 
análogos da curcumina que mantenham a atividade moduladora da P-gp mas que 
apresentem maior estabilidade. 
Para além da sobre-expressão de bombas de efluxo, existem outros mecanismos 
moleculares envolvidos no fenótipo de RMF, tais como alterações metabólicas. De facto, 
alguns estudos recentes mostraram que é possível reverter o fenótipo de RMF por inibição 
da glicólise com moduladores específicos. 
 As vesículas extracelulares (VEs) são um grupo de vesículas libertadas por todas 
as células e que incluem os exosomas e as microvesiculas. Uma vez que as VEs 
transportam uma carga específica (tal como proteínas e microRNAs) e estão presentes em 
vários fluidos corporais (tais como o sangue), podem ser facilmente obtidas de doentes 
com cancro e poderão eventualmente vir a ser uma fonte de biomarcadores de diagnóstico, 
prognóstico ou resistência tumoral. Para além disso, vários estudos têm chamado à 
atenção para a relevância das VEs no metabolismo, uma vez que foi demonstrado que 
alterações de metabolismo poderiam afetar a libertação e a carga das VEs libertadas pelas 
células. 
Esta tese teve como objetivos: 1) identificar novos alvos para superar a RMF mediada 
pela P-gp em cancro, 2) identificar potenciais biomarcadores de RMF em VEs libertadas 
por células tumorais e 3) encontrar novas moléculas que permitam superar a RMF, 
identificando novos derivados da curcumina com um aumento do efeito inibidor da P-gp. 
Para atingir esses objetivos, foram utilizados dois pares de linhas celulares com RMF 
e as homólogas sensíveis a fármacos (de leucemia mieloide crónica e de cancro do pulmão 
de células não pequenas), nos quais o fenótipo de RMF era devido sobretudo à sobre-
expressão da P-gp As proteínas das células e das respetivas VEs (que foram devidamente 
caracterizadas segundo o seu tamanho usando Difração de Luz Dinâmica e Microscopia 
Eletrónica de Transmissão e pela presença de marcadores moleculares com Western blot 
e citometria de fluxo) foram analisadas por proteómica e os resultados foram confirmados 
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por Western blot. O perfil metabólico das células foi analisado antes e depois destas serem 
tratadas com inibidores específicos e após incubação com as VEs libertadas pelas células 
com fenótipo de RMF.  
Mostrámos que as células com RMF (com sobre-expressão da P-gp) apresentam 
um perfil metabólico diferente do observado nas células homólogas sensíveis a fármacos, 
mostrando: (i) uma diminuição na via das pentoses fosfato e na fosforilação oxidativa; (ii) 
um aumento da taxa glicolítica e do índice de metilação; (iii) alterações no metabolismo da 
glutationa e na via da metionina/S-adenosilmetionina. 
 Para além disso, os nossos resultados mostraram que em ambos os modelos 
tumorais, as VEs libertadas pelas células com RMF eram maiores, quando comparadas 
com as VEs libertadas pelas células homólogas sensíveis a fármacos. Adicionalmente, as 
proteínas CHMP4, CD63, TSG101, Syntenin-1 e Clathrin LCB (conhecidas por estarem 
envolvidas na biogénese dos exosomas) estavam presentes em menor quantidade nas 
VEs libertadas pelas células com RMF. Por outro lado, a P-gp estava presente apenas nas 
VEs libertadas pelas células com RMF. Em conjunto, estes resultados mostraram que as 
células cancerígenas com RMF libertam mais microvesiculas, enquanto que as células 
cancerígenas sensíveis a fármacos libertam mais exosomas. Notavelmente, as VEs 
libertadas pelas células com RMF foram capazes de causar alterações metabólicas nas 
células sensíveis a fármacos, no sentido do fenótipo de RMF. 
Por último, neste estudo, a atividade anti-tumoral e anti-P-gp de uma pequena 
livraria de novos derivados da curcumina foram também testadas. Para isso, os compostos 
foram analisados nas duas linhas celulares tumorais com RMF (com sobre-expressão da 
P-gp) e nas células homólogas sensíveis a fármacos. De entre os vários novos derivados 
da curcumina sintetizados, um deles [o 1,7-bis(3-methoxy-4-(prop-2-yn-1-
yloxy)phenyl)hepta-1,6-diene-3,5-dione] mostrou ter maior atividade anti-tumoral e anti-P-
gp do que a própria curcumina. Adicionalmente, este composto parou o ciclo celular na 
fase G2/M e induziu morte celular por apoptose nas células de leucemia mieloide crónica 
com RMF. 
De um modo geral, o trabalho apresentado nesta tese contribui para o aumento de 
conhecimento na área das alterações metabólicas nas células com RMF e no papel de 
uma população específica de VEs na transferência intercelular de RMF. As alterações 
metabólicas específicas identificadas neste estudo podem ser futuramente desenvolvidas 
como alvos para ultrapassar a RMF em cancro. Adicionalmente, o tamanho e assinatura 
proteica específicos que identificamos nas VEs libertadas pelas células com RMF podem 
vir a ter significado diagnóstico no cancro, como fonte de biomarcadores para identificação 
do fenótipo de RMF mediada pela P-gp. Para além disso, este trabalho também mostrou o 
potencial de sintetizar novos derivados da curcumina com o objetivo de melhorar a sua 
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estabilidade e caracterizou a promissora atividade dupla (anti-tumoral e anti-P-gp) de um 
novo derivado da curcumina. 
 
 
 
 
 
 
Palavras-chave: Resistência cancerígena a múltiplos fármacos; Glicoproteína P; 
Metabolismo; Glicólise; Fosforilação oxidativa; Vesículas extracelulares; Curcumina. 
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1. Multidrug resistance in cancer 
 
The use of chemotherapeutic agents is one of the most common and effective 
approaches to treat cancer 1. However, although conventional chemotherapeutic agents 
affect the growth of rapidly dividing cancer cells, they also affect normal cells, causing 
devastating secondary effects 2. New advances in cancer therapy have been focused in 
targeted therapies (aiming at molecular targets or pathways which are specific or 
overexpressed in cancer), since they seem to be more effective and less harmful than 
conventional chemotherapy 3. Nevertheless, the inefficacy of all of these agents (either 
conventional or targeted therapies) is frequent and commonly associated with the 
resistance of cancer cells to anticancer drugs 4. 
In some cases of drug resistance, cancer cells may exhibit cross-resistance against 
multiple unrelated drugs which are structurally and/or functionally different, a phenomenon 
named multidrug resistance (MDR) 5,6. MDR may be classified as: i) intrinsic MDR, which 
occurs naturally, before any drug treatment; or ii) acquired MDR, caused by drug selective 
pressure and developed during or after the course of treatment, or upon recurrence of the 
disease 5,6. 
Several studies have shown that, for some tumours, treatment failure may be 
attributed to the presence of cancer stem cells (CSCs), which are extremely resistant to 
different therapeutic approaches 7. Indeed, CSCs may differentiate into different types of 
cells according to a specific condition or environment (i.e. each new population of cells 
originated from CSCs has the capacity to either remain a CSC or change to other types of 
more specialized cells with a defined function) and therefore they are extremely challenging 
from the point of view of cancer therapy 8.  
Drug resistance in general, and MDR in particular, is a current clinical problem hard 
to overcome, particularly due to the great degree of genetic and phenotypic heterogeneity 
of tumours 9-11. During treatment, the main cell populations are normally destroyed by the 
drugs but the more resistant cells, which are smaller cell populations (and which may be 
CSCs), survive and remain quiescent. Occasionally, the selective pressure (e.g. caused by 
drug treatment) may cause these quiescent cells to suffer genetic alterations (such as 
mutations or chromosomal translocations) which allow them to acquire advantageous 
characteristics, becoming able to proliferate and establish another clone of tumour cells, 
which is then resistant to the first line of treatment 12. 
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1.1. MDR mechanisms – an overview 
 
There are several mechanisms involved in intrinsic or acquired MDR (Table 1). 
Usually, two or more of these mechanisms act simultaneously in each cancer type, thus 
making it very difficult to overcome MDR 13.  
 
Table 1 – Examples of cellular mechanisms involved in MDR in cancer.  
 
MDR mechanism 
 
Examples 
 
References 
 
 
Cellular alterations Cancer model 
 
ATP-dependent drug 
efflux 
Overexpression of ABC 
transporters (e.g. P-gp) 
Several cancers 14 
Increase in drug 
detoxification 
 
Overexpression of 
glutathione S-
transferases 
Primary ovarian 
cancer and 
osteosarcoma 
15,16 
Increase in DNA damage 
repair 
 
Decreased expression 
of MLH1 
Breast cancer 17 
 
Cell cycle arrest 
deregulation 
 
Mutations in p53 
Breast cancer and 
ovarian carcinoma 
18,19 
Deregulation of apoptosis 
 
Overexpression of anti-
apoptotic proteins (e.g. 
Bcl-2) 
Breast cancer and 
Non-Hodgkin’s 
Lymphoma 
20,21 
 
Alterations in the 
expression of some 
microRNAs 
 
Overexpression of 
microRNA-21 
Neuroblastoma 22 
Metabolic alterations 
 
Increased glycolysis 
 
Breast cancer 23 
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ATP-dependent drug efflux 
 Drug-efflux, usually resulting from an increased efflux of the cytotoxic drugs by cell-
membrane transporters, is the most widely studied MDR mechanism 24. This mechanism 
causes a decrease in the intracellular concentrations of anticancer drugs to levels below 
the therapeutic concentrations, therefore allowing cells to survive treatment14. The most 
common mechanism involves the ATP-binding cassette (ABC) membrane transporters 24. 
ABC transporters are usually expressed in several tissues and play a natural role in 
extruding xenobiotics from the body 14. To date, 49 ABC transporters have been identified 
in the humans, which have been divided into seven different categories according to their 
sequence and structural homology (ABCA to ABCG) 14. Among them, the most extensively 
studied ABC transporters are ABCB1/MDR1 (which codes for P-glycoprotein, P-gp), 
ABCC1/MRP1 (which codes for multidrug resistance associated protein-1) and 
ABCG2/BCRP (which codes for breast cancer resistant protein) 25. The role of the ABC 
transporter P-gp will be described further in this thesis, in section 1.2. “The particular role 
of P-glycoprotein in MDR”.  
 
Increase in drug detoxification  
 An increase in drug detoxification is another significant mechanism of MDR. The 
effect of cytotoxic drugs that enter the cells is reduced by specific drug-metabolizing 
enzymes which may be overexpressed in cancer cells, such as cytochrome P4503A, 
glutathione-S-transferases (GST) and aldehyde dehydrogenases-related phase II enzymes 
26. For example, GST is responsible for the inactivation of some chemotherapeutic drugs, 
such as carboplatin and cisplatin, by conjugating them with glutathione. These conjugates 
are then substrates for some ABC-transporters (e.g. MRP1) which cause their efflux from 
the cell 27.  
 
Increase in DNA damage repair 
The ability of cancer cells to recover from DNA damage caused by 
chemotherapeutic drugs can determine tumour resistance 28. The DNA damage repair is a 
complex process involving several important genes which mainly participate in some 
functionally combined pathways: homologous recombination, non-homologous and joining 
recombination, nucleotide excision repair, base excision repair and mismatch repair 29. 
Many chemotherapeutic drugs (such as platinum drugs, topoisomerase inhibitors 
and alkylating agents) induce cell death via DNA damage induction 28. In fact, usually cells 
undergo apoptosis following an incomplete DNA repair28. However, in some cases, cells 
are capable of overcoming the DNA damage and continue to proliferate, giving rise to cells 
		8	
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with a more resistant phenotype (e.g. the MDR phenotype). Currently, an approach used to 
overcome the alterations in the DNA repair machinery is the inhibition by specific agents of 
the DNA damage repair system of malignant cells 30. 
 
Cell cycle arrest deregulation  
The fundamental processes of progression through the cell cycle involve the 
complex interaction of several families of proteins (such as oncogenes and tumour 
suppressor genes) in a systematic and coordinated manner 31. Specifically, p53, a tumour 
suppressor gene that is responsible for the cell cycle arrest  32, determines the destiny of 
the cells with damaged DNA i.e., determines if the cell arrests its cell cycle to allow DNA 
repair and cell survival, or if the damaged cell enters apoptosis. By doing this, the production 
of a “daughter” cell with damaged DNA is prevented 32. However, p53 is often mutated in 
cancer and the lack of a functional p53 may cause the cell cycle to continue even with the 
damaged DNA, which may cause a MDR phenotype 33-35. 
 
Deregulation of apoptosis 
 Some chemotherapeutic agents induce apoptosis and necrosis of the tumour cells 
35. However, alterations in apoptosis have been described as a major cause of MDR 35,36. 
This is normally caused by deregulations (usually overexpression) of some anti-apoptotic 
genes 37,38. Currently, targeting and activating some apoptosis-inducing proteins in tumour 
cells has proven to be useful, by conferring a higher sensitivity to drugs and survival rate 
for some cancer patients 30. 
 
Alterations in the expression of some microRNAs 
 Some studies have linked alterations in microRNAs expression with the MDR 
development 39. There are several factors involved in the deregulation of microRNAs in 
cancer 40. This deregulation could potentially lead to defective microRNAs biogenesis 
pathways, epigenetic modifications (such as methylation of the CpG islands) and 
deregulation of gene expression 41, all of which may be associated with both increased 
sensitivity or resistance to anticancer drugs 30. This dual function (specifically related to the 
P-gp expression) will be described further in this thesis, in section 1.2.: “The particular role 
of P-glycoprotein in MDR”.  
 
Metabolic alterations  
The link between tumour metabolism and MDR is highly complex. It depends on 
multiple parameters, such as oxygen and nutrient availability or the specific drugs that are 
being used. Several studies have been published relating MDR to alterations in cellular 
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metabolism: i) upregulation of hypoxia-induced factor 1 (HIF-1) was associated with 
chemoresistance 42; ii) leukaemia models with higher glycolytic rates showed resistance to 
glucocorticoids 43; iii) modulation of cellular metabolic pathways contributed to acquired 
resistance in multiple myeloma cells 44; iv) glycolytic pyruvate was capable of regulating P-
gp expression in multicellular tumour spheroids 45;  and v) hypoxia induced MDR and 
glycolysis in a orthotopic MDR tumour model in nude mice 46. 
The identification of all the metabolic alterations may facilitate overcoming the MDR 
problem and developing novel therapeutics for cancer. This will be further described in this 
thesis, in section 1.3: “Metabolic Alterations in MDR”. 
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1.2. The particular role of P-glycoprotein in MDR 
 
P-glycoprotein was the first discovered member of the ABC transporters, when in 
1976 Juliano and Ling characterized a 170 kDa glycoprotein overexpressed in colchicine 
resistant cell lines that was able to modify drug permeability on those cells 47. Since then, 
overexpression of P-gp has been shown to contribute to the MDR phenotype of many 
cancer cells. As previously referred, this overexpression results in increased cellular drug 
efflux, causing lower intracellular drug concentration and reducing drugs’ efficacy. 24. 
Although being mainly described as a transmembranar protein, P-gp is also found in other 
cellular organelles such as cytoplasmic membrane 48, endoplasmic reticulum 49, nucleus 50 
and endosomes 51. This suggests that P-gp may have other cellular functions that could 
contribute to drug resistance 39. 
P-gp expression may be regulated by several microRNAs, which may contribute to 
the drug resistant phenotype. In the following section, it is  presented a review paper titled: 
“The Network of P-glycoprotein and microRNAs interactions” 39, in which the web of 
interactions between P-gp and microRNAS is described, following an initial description of 
the importance of P-gp in MDR. 
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1.2.1. REVIEW ARTICLE: The network of P-glycoprotein and 
microRNAs interactions 
 
 
Vanessa Lopes-Rodrigues, Hugo Seca, Diana Sousa, Emília Sousa, Raquel T. Lima, M. 
Helena Vasconcelos 
 
Published in International Journal of Cancer: 135, 253–263 (2014) 
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The network of P-glycoprotein and microRNAs interactions
Vanessa Lopes-Rodrigues1,2,3, Hugo Seca1,4, Diana Sousa1,2, Em!ılia Sousa2,5,
Raquel T. Lima1,2 and M. Helena Vasconcelos1,4
1 Cancer Drug Resistance Group, Institute of Molecular Pathology and Immunology of the University of Porto, IPATIMUP, Porto, Portugal
2 Center of Medicinal Chemistry of the University of Porto, CEQUIMED-UP, Porto, Portugal
3 Institute of Biomedical Sciences Abel Salazar, University of Porto, ICBAS-UP, Porto, Portugal
4 Department of Biological Sciences, Laboratory of Microbiology, Faculty of Pharmacy, University of Porto, Porto, Portugal
5 Department of Chemical Sciences, Laboratory of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, University of Porto, Porto, Portugal
Overexpression of P-glycoprotein (P-gp) contributes to the multidrug resistance (MDR) phenotype found in many cancer cells.
P-gp has been identified as a promising molecular target, although attempts to find successful therapies to counteract its
function as a drug efflux pump have largely failed to date. Apart from its role in drug efflux, P-gp may have other cellular func-
tions such as being involved in apoptosis, and is found in various locations in the cell. Its expression is highly regulated,
namely by microRNAs (miRNAs or miRs). In addition, P-gp may regulate the expression of miRs in the cell. Furthermore, both
P-gp and miRs may be found in microvesicles or exosomes and may be transported to neighboring, drug-sensitive cells. Here,
we review this current issue together with recent evidence of this network of interactions between P-gp and miRs.
P-glycoprotein is Responsible for Drug Resistance in
Various Cancers
Overexpression of P-glycoprotein (P-gp) represents one of
the main mechanisms, which contribute to the multidrug
resistance (MDR) phenotype. Drug resistance associated with
high P-gp expression levels may have two main causes,
according to the tumor cell type: (a) high basal P-gp levels in
the tumor tissue or, (b) induction of P-gp expression after
chemotherapy treatment.1
P-gp is usually found in the colon, liver, kidney and adrenal
gland, where it has a secretory function.2 Therefore, as
expected, high levels of P-gp have been found in cancers arising
from these tissues. On the other hand, haematological malig-
nancies such as leukemias, lymphomas and multiple myelomas
are characterized by low P-gp expression levels at diagnosis but
increased levels after drug treatment and relapse.1,2
Indeed, the relevance of P-gp in hematological malignancies
has been reported by several authors over the last 20 years.3–17
Although some discrepancies exist in the published results, they
predominantly report the same conclusion: P-gp levels are often
increased following chemotherapy treatment. Published data
reports evidence for the relevance of P-gp expression for the
prognosis of acute myeloid leukemia (AML) and acute lympho-
blastic leukemia (ALL) in an age-dependent manner18 and
reveals the induction of P-gp expression during repeated expo-
sure to cytostatic drugs,19,20 which results in an increase in drug
resistance of these haematological malignancies.
In addition to hematological malignancies, many other
tumor types such as colon and renal cancers express high levels
of P-gp (Table 1). Expression of P-gp has also been related to
the pathological grading of colorectal carcinoma, being higher
in well differentiated tumors and lower in poorly differentiated
ones.21,22 The mechanisms underlying drug resistance caused
by high P-gp levels in colorectal cancer have been unravelled.
In fact, the contribution of cyclooxygenase (COX2) to P-gp
mediated drug resistance, via phosphorylation of c-Jun, has
been described.23 Moreover, the activation role of some p53
mutants on P-gp promoter has been reported24,25 as well as the
identification of P-gp as a target of transactivation by the b-
catenin complex=T cell factor 4, which is thought to be the
basis of tumorigenesis in colorectal cancer26 (Fig. 1—panel a).
P-gp expression has also been associated with renal cell car-
cinoma (RCC), one of the most intrinsically chemoresistant
tumor types.27 Indeed, MDR-1 transcripts or P-gp protein
have been identified in the majority of RCC samples.28–30
Studies from the National Cancer Institute also support this
evidence, reporting high P-gp mRNA levels in several renal
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tumor cell lines31,32 as well as increased P-gp transcripts asso-
ciated with in vitro resistance of cell lines or primary cultures
to paclitaxel and doxorubicin.33,34
P-gp was also found to be downregulated during differen-
tiation of pluripotent stem cells.35 Most interestingly, P-gp lev-
els have been also related to apoptosis. For example, it has
been shown that P-gp may confer drug resistance to caspase-
mediated apoptosis.36,37 In addition, ceramide (an inducer of
apoptosis) increased glucosylceramide synthase, which in turn
induced MDR-1 overexpression (via b-catenin mediated MDR-1
Table 1. Increased levels of P-gp in several tumors were found to be associated with cancer drug resistance
Tumour Type Featured findings References
AML (Acute Myeloid
Leukemia)
! Approximately 50% of patients had leukemic blasts that expressed P-gp, with a
slightly greater rate of expression and at higher levels in elderly patients.
! Patients with refractory and/or relapsed AML frequently expressed more P-gp than
de novo patients.
4–8
ALL (Acute Lymphoblastic
Leukemia)
! P-gp is observed in 38% of cases of ALL.
! Even though some authors did not find significant association between P-gp and prognosis
of ALL, others found a correlation between P-gp and poor drug response.
! Expression of P-gp in adult ALL patients was higher than in children.
10–14
NHL (Non-Hodgking’s
Lymphoma)
! In NHL, P-gp expression increased from 2-49% in untreated patients
to 64% in post-treated patients.
3
Multiple Myeloma (MM) ! 10-30% of MM patients expressed MDR-1 gene at diagnosis compared to 50-80%
of patients with relapsed or resistant disease.
! In some studies P-gp expression was described as an independent
predictor of poor clinical outcome.
167–169
Colorectal Cancer ! In adenomatous polyps from patients with familial adenomatous polyposis
syndrome, P-gp expression was significantly increased and correlated with
b-catenin, a protein involved in the tumourigenesis of colorectal cancer.
! P-gp expression related with pathological grading of colorectal carcinoma,
(being higher in well differentiated tumours and lower in poorly differentiated ones).
! siRNAs targeting MDR-1 in cells suppressed P-gp expression,
reverting multidrug resistance in colon cancer cells.
21–24,26
Renal Cancer ! P-gp transcripts or protein identified in normal renal proximal tubules and in the
majority of renal cell carcinoma samples indicated that this efflux pump is
implicated in both intrinsic and acquired resistance.
27–33
Liver Cancer ! Overexpression of P-gp (but not MRP1) mainly contributes to the
MDR of SMMC-7721/ADM cells.
! The upregulation of P-gp and BCRP (but not of MRP1 and LRP) were
involved in the MDR of HepG2/ADM cells.
! Overexpression of P-gp associated with the MDR phenotype of a
taxol resistant cell line, QGY-TR50.
170–172
Small and Non-small Cell
Lung Cancer (SCLC and
NSCLC, respectively)
! Stronger evidence of an association of P-gp expression with outcome in SCLC than
in NSCLC; however, some studies reported a significant correlation between tumour
P-gp detection and response to paclitaxel/platinum and cisplatin/ ifosfamide/
vinblatine/ radiation in NSCLC.
! In chemo-naive NSCLC patients, P-gp transcripts/ protein were identified in 11-32%
of surgical specimens, but increased in 61% of tumours that had been treated with
chemotherapy.
173–175
Ovarian Cancer ! A meta-analysis showed that, among other potential biomarkers, P-gp is not yet
useful as a predictor of prognosis; however, high P-gp expression is associated
with poor overall survival as well as with poor progression-free survival
in epithelial ovarian cancer.
! In cisplatin-resistant ovarian cancer cell line, P-gp can be upregulated as a
generalised stress response rather than as a specific response to a substrate.
176–178
Breast Cancer ! Increased activity of P-gp in breast carcinomas was demonstrated using a
substrate recognized by this efflux pump.
! A meta-analysis indicated that P-gp expression in breast tumours associated
with poor response to chemotherapy (patients with tumours expressing P-gp
were three times more likely to fail responding to chemotherapy).
179,180
Glioblastoma ! The uptake of erlotinib has proven ineffective in clinical trials due to the actions
of P-gp in conjunction with BCRP1.
! Elevated glycolysis in tumour spheroids of glioblastoma cells was
correlated to increased P-gp expression.
181–183
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promoter activation) and increased P-glycoprotein efflux, regu-
lating cancer drug resistance.38 Moreover, the overexpression of
P-gp is frequently accompanied by an increase in intracellular
pH; since apoptosis is often preceded by intracellular acidifica-
tion, it is possible that increased pH (promoted by P-gp overex-
pression) could render cells relatively resistant to multiple forms
of caspase-dependent cell-death stimuli.39 All of these processes
are relevant to cancer development=therapy (Fig. 1—Panel a).
Downregulation of P-gp Levels and Activity as
Therapeutic Approaches
P-gp silencing studies have shown promising results in cell lines.
For example, some of us have found that downregulation of P-
gp caused an increase in drug sensitivity of a resistant chronic
myelogenous leukemia cell line (overexpressing P-gp).40,41 In
addition, stable transfection of siRNAs for P-gp was shown to
reverse the P-gp dependent MDR of colon cancer cells42 and
short hairpin RNA-mediated P-gp silencing was shown to
enhance the sensitivity of ovarian cancer cells to paclitaxel.43
These studies, together with the high levels of P-gp
observed in cancer patients, illustrate the relevance of this
drug efflux pump in the drug resistance phenotype of cancer
cells. Consequently, some authors agree that the overexpres-
sion of P-gp in itself is a poor prognosis factor. Nevertheless,
an idea which has gained ground recently, describes the P-gp
associated MDR phenotype as a result of a complex network
of signalling pathways and drug resistant proteins.2,44
To achieve a more effective chemotherapy, strategies to
silence P-gp or develop P-gp inhibitors to block=decrease its
activity have been used. To date, four generations of P-gp inhibi-
tors have been described, many of them having reached clinical
trials.45–47 Nevertheless, clinical trials with such inhibi-
tors=modulators have not yet obtained satisfactory results, due
to high toxicity of the compounds and poor patient selection cri-
teria.48 Indeed, P-gp has to date not been successfully translated
in therapeutics.
P-gp Synthesis, Cellular Localization, Expression
and Function
P-gp is the best characterized efflux pump mediating MDR. It is
a 170 kDa membrane protein, member of the ATP-binding cas-
sette (ABC) superfamily of transporters,49 which acts to prevent
the absorption of orally ingested or airborne toxins, xenobiotics
or drugs.50
P-gp is encoded by the human MDR-1 gene located at chro-
mosome 7, being synthesized in the endoplasmic reticulum (ER)
Figure 1. Complex interaction between P-gp, miRs and other cellular proteins to reinforce MDR. (a) Different stimuli (such as chemotherapy)
may induce different signaling pathways which regulate the expression of proteins involved in MDR-1 gene transcription and drug resis-
tance. The effect of P-gp on the intracellular pH levels has been suggested to affect apoptosis and drug resistance. (b) MDR-1 mRNA levels
may be regulated by miRs (directly, indirectly or at the transcriptional level), which will regulate P-gp protein levels and drug resistance. In
addition, P-gp may regulate the expression of one miR, which regulates apoptosis and drug resistance. Both P-gp and miRs may be trans-
ported to other cells by microvesicles or exosomes. GCS: Glucosylceramide synthase; Glc-Cer: Glucosylceramide; HAT: Histone Acetyltrans-
ferases; HDAC: Histone Deacetylase Inhibitors.
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as a glycosylated intermediate. It contains 1,280 amino acids
arranged in two halves, each encompassing a transmembrane
domain (TMD) which spans the membrane and two intracellu-
lar nucleotide-binding domains (NBD).51 The glycosyl moiety
in the first extracellular loop of P-gp appears to have a role in
the trafficking or stability of P-gp to the cell surface, although it
does not seem to be essential for drug transport52 (Fig. 1—Panel
b). Although there is still no X-ray data on human P-gp, the
structures of mouse53 and Caenorhabditis elegans54 P-gp were
recently obtained at 3.8 and 3.4 Å resolution, respectively. The
obtained P-gp 3-D structures highlighted the importance of
membrane partitioning when a drug accesses the transporter in
the membrane.54 Apo P-gp structures have an inverted “V”
shape inward-facing conformation for drug entry, whereas they
have an outward-facing conformation for releasing the substrate
to the extracellular medium53 (Fig. 1—Panel b).
P-gp is mainly localized in the plasma membrane. Since
the depth of the cellular membrane is about 4 nm, half the
P-gp is included in the phospholipid bilayer of the mem-
brane.55 P-gp is also found at intracellular membranes,2,56,57
and is frequently observed in the nucleus58–60 while also
being described in the ER,61 Golgi apparatus,62,63 endo-
somes64 and lysosomes65 (organelles which are involved in its
intracellular trafficking).57 The presence of P-gp has also
been described in mitochondria, where it may be involved in
the protection of mitochondrial DNA.66 Furthermore, protec-
tion of the nucleus from drugs has also been suggested as a
role for mitochondrial P-gp in MDR cells.67 However, studies
using P-gp-EGFP fusion protein or wild-type P-gp showed
no co-localization with a mitochondrial marker.57,64,68 P-gp
may also be present in intracellular vesicles actively contrib-
uting to drug sequestration and removal from cells.66,69
Several studies have suggested that intracellular P-gp also
contributes to drug resistance.58,70 Indeed, studies using leuke-
mic cell lines and AML patient samples have shown that the
levels of total P-gp (protein or mRNA) correlated better with
drug efflux than those of surface P-gp protein.69 Furthermore,
a strong association between intracellular P-gp and intrinsic
resistance was observed in a human colon carcinoma clone,
which did not express P-gp on the plasma membrane.70
Nevertheless, other studies claim that intracellular P-gp does
not seem to have a (major) role in drug resistance.61,64
Therefore, it is important to better understand how P-gp
is regulated, which seems to be a complex and highly con-
trolled process.2 Indeed, several signalling pathways and tran-
scription factors have been described as being involved in the
regulation of P-gp expression, such as Wnt=b-catenin,
Ras=Raf, MAPK=ERK, p53, NF-jB and PKC.71–77 Moreover,
several extracellular stimuli such as heat shock,78 UV radia-
tion,79 reactive oxygen species80,81 and cytotoxic drugs82,83
induce P-gp expression (Fig. 1—Panel a).
Although occurring predominantly at the transcriptional
level,71 regulatory mechanisms of P-gp expression may also
be present post-transcriptionally. In fact, in addition to alter-
ations in gene transcription and gene amplification,84 P-gp
expression has also been associated with (i) alternative pro-
moter usage,85 (ii) DNA methylation and histone acetyla-
tion,86–88 (iii) alterations in MDR-1 mRNA stability89,90 and
(iv) P-gp turnover and intracellular trafficking.90 More
recently, microRNAs (miRNAs or miRs) have emerged in the
literature as regulators of the expression of proteins related to
drug resistance, including P-gp.73
microRNAs as Regulators of P-gp Gene Expression
miRs are a class of single-stranded ncRNAs (non-coding
RNAs) ranging from 19 to 25 nucleotides in length and
having significant roles in gene regulation. The mRNA-miR
pairing occurs mostly through the binding of the miR to the
target mRNA 3’-UTR; however, binding to the coding region
or to the 5’UTR may also occur.91 Association of miRs with
mRNAs leads to post-transcriptional suppression of the tar-
geted mRNA expression: full complementarity between miR
and mRNA leads to mRNA cleavage while partial comple-
mentarity leads to translational repression.92–94 One miR
may target several mRNAs. On the other hand, one mRNA
may “enclose” several binding sites for the same miR or may
have binding sites for different miRs.95,96 Indeed, different
miRs can target the same mRNA for a cooperative regulation,
demonstrating how complex the regulation of miRs is.97–99
In addition to their canonical function, miRs can also func-
tion as positive regulators of gene expression,100–102 through
binding to other regions of the mRNA such as protein-coding
exons103 or to the 5’UTR region.91,104 It has been suggested that
miRs may also bind to the promoter region of genes.104–106
miR-mediated regulation allows the expression of a multi-
tude of different mRNAs involved in multiple key cellular proc-
esses to be controlled.107–111 Therefore, miRs biogenesis and
their relative abundance must also be tightly regulated,112,113
especially in what concerns their transcription, processing and
cellular localization levels.114–116 Indeed, transcription factors,
enhancers and chromatin modifications may alter miR expres-
sion levels, either positively or negatively.117,118 Ultimately, miRs
“control” the cellular phenotype in processes such as develop-
ment119 and differentiation.120 Moreover, their aberrant expres-
sion is often associated with a wide variety of diseases, from
diabetes121 to cardiovascular disease122 and several cancers.123–127
Some studies have been published linking the altered
expression of some miRs, in different cancer types, to altera-
tions in MDR-1=P-gp expression and consequently with the
MDR phenotype. Therefore, this section describes the miRs
which have already been reported as MDR-1=P-gp regulators
(Fig. 1—Panel b). This regulation may occur post-
transcriptionally through the binding of miRs to the 3’-UTR
of MDR-1 (direct regulation) or by miRs targeting and affect-
ing other factors, which modulate P-gp expression (indirect
regulation). In addition, regulation may possibly also occur at
the transcriptional level, by interaction of miRs with the
MDR-1 promoter (direct hybridization) or by triplex structure
formation (double-stranded DNA=RNA).128 Figure 2 outlines
a schematic representation of the miRs that interact with P-gp.
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miRs acting at the post-transcriptional level - direct
regulation
Several miRs have been described as direct regulators of P-gp,
by direct interaction with the 3’-UTR of the MDR-1 mRNA
region (Fig. 2 and Table 2). In this direct regulation, an
inverse correlation between the expression levels of some
miRs and P-gp mRNA levels has been observed.128
miR-451 was found to regulate P-gp expression through a
unique binding site within the MDR-1 3’-UTR. By increasing
the cellular levels of miR-451, in a doxorubicin-resistant
breast cancer cell line (MCF-7=DOX), a decrease in MDR-1
expression and more importantly, an increase in cellular sen-
sitivity to doxorubicin were observed.129
Direct regulation of MDR-1 has also been described for
miR-331-5p (with the description of a putative miR-331-5p
binding site) in resistant K562=DOX leukemia cells.130 In this
study, an inverse correlation between MDR-1 expression and
miR-331-5p levels was shown. Furthermore, miR-331-5p
overexpression was shown to increase the sensitivity of resist-
ant K562=DOX cells to doxorubicin, through the inhibition
of MDR-1 gene expression.130
Impaired processing of miR-298 (due to low expression of
Dicer enzyme) has been associated with the modulation of P-
gp expression.131 One study reported that miR-298 directly
binds to the MDR-1 30-UTR and that miR-298 downregula-
tion increased P-gp expression and induced resistance to
doxorubicin in breast cancer cells (MDA-MB-231).131
In addition, miR-145 negatively regulates P-gp expression
and function through the repression of MDR-1 mRNA. Over-
expression of miR-145 in a human embryonic kidney cancer
cell line decreased MDR-1 mRNA levels.132 Interestingly,
downregulation of miR-145 in a human colon carcinoma cell
line (Caco-2) also increased P-gp expression and P-gp medi-
ated activity, but not MDR-1 mRNA level, suggesting that in
this cell line miR-145 might regulate P-gp through transla-
tional repression of MDR-1 mRNA.132
Finally, miR-27a was reported to directly regulate MDR-1
in a chronic myeloid leukemia cell line (K562).130 miR-27a
expression was shown to inversely correlate with MDR-1
expression and to increase cell sensitivity to doxorubicin.130
miRs acting at the post-transcriptional level—possible
indirect regulation
Several miRs have been described as “indirect regulators” of
P-gp, by targeting other mRNAs, which code for intermediate
proteins or transcription factors involved in MDR-1 gene
activation128 (Fig. 2 and Table 2).
miR-451, which was mentioned above as a direct regula-
tor, has also been described as an indirect regulator of MDR-
1=P-gp expression in ovarian and cervical cancer cells.
Figure 2. Different mechanisms by which miRs regulate P-gp expression. The regulation of P-gp by miRs may occur post-transcriptionally by:
(i) direct binding of miRs to the 3’-UTR of MDR-1 mRNA (direct regulation) or, (ii) miRs targeting other mRNAs and therefore altering the lev-
els of other proteins, which modulate P-gp expression (indirect regulation). In addition, regulation may possibly also occur at the transcrip-
tional level, through interaction of miRs with the MDR-1 promoter. Often, miRs regulate P-gp levels by mechanisms not yet fully
understood. Question marks (?) indicate that the intermediate target is unknown. Solid arrows: direct regulation; Dashed dot arrows: (possi-
ble) indirect regulation; Round dot arrows: possible transcriptional regulation.
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Indeed, miR-451 expression was found increased in MDR
cells and its inhibition resulted in decreased expression of
both P-gp and MDR-1 mRNA. Therefore, in these cases, the
effect of miR-451 in MDR-1 may be indirect, although the
precise mechanisms require further investigation.73
Similarly, miR-27a has also been described as being both
a direct and indirect regulator of P-gp. In ovarian and cervi-
cal cancer cell lines (A2780 and KB-3-1), MDR-1 mRNA
expression was shown to be positively regulated by miR-27a,
favoring its role as a possible indirect regulator.73
miR-21 is an accepted oncomiR.133,134 Its expression has
been shown to be involved in cellular proliferation,135,136
apoptosis135 and autophagy.137 In addition, its expression is
associated with chemoresistance in a variety of cancer
cells.138–140 Interestingly, miR-21 has also been described to
indirectly regulate MDR-1 expression.141 A novel hyaluronan
(HA)-CD44-mediated PKC signalling mechanism which reg-
ulates a stem cell marker (Nanog) has been associated with
miR-21 production. Indeed, the presence of hyaluronan
increased miR-21 levels (via Nanog phosphorylation) leading
to a reduction in the levels of the tumor suppressor protein
PDCD4 (programmed cell death 4). These two events con-
tributed to an increase in the translation rate of diverse tran-
scripts, including MDR-1, in breast cancer cells (MCF-7). In
addition, the downregulation of miR-21 significantly
attenuated the HA-CD44 activated expression of P-gp.141
A recent study carried out in an ovarian cancer cell line
(SKOV3)142 indicated that miR-130a might be associated with
MDR-1=P-gp mediated drug resistance. By decreasing miR-
130 expression, an indirect inhibition of MDR-1 mRNA and P-
gp expression were observed and resistance of these cells to cis-
platin, which is an inducer of P-gp expression, was reverted.
Finally, it has been shown that miR-let-7 may indirectly
regulate MDR-1 in ovarian cancer cells. This seems to occur
through the downregulation of IMP-1, a RNA binding pro-
tein, causing destabilization of the MDR-1 mRNA and there-
fore downregulation of P-gp expression (Fig. 2).143 These
findings were further substantiated by analysing samples
from ovarian cancer patients, where a correlation between
downregulation of miR-let-7 and upregulation of both IMP-1
and P-gp proteins was found.143
miRs acting at the transcriptional level
In addition to the previously described miRs acting at post-
transcriptional level, speculation has arisen regarding the
involvement of two miRs with MDR-1 regulation at the
Table 2. Reported miRs that regulate P-gp in different cancer cells
Post-Transcriptional
regulation
Direct
Possibly
Indirect
regulation
Possibly
Transcriptional
regulation
Not fully
understood
regulation Human Tumour Cells Performed assays References
miR-451 x Breast adenocarcinoma Luciferase assays 129
x Ovarian and cervical cancer Transfection of miR
mimics and antimiR
73
miR-331-5p x Chronic myeloid leukaemia Transfection of miR mimics
Luciferase assays
130
miR-298 x Metastatic breast cancer Luciferase assays 131
miR-145 x Embryonic kidney and
Colon cancer
Luciferase assays
Transfection of miR mimics
Rodhamine 123 assay
132
miR-27a x Chronic myeloid leukaemia Luciferase assays
Transfection of miR mimics
130
x Ovarian and cervical cancer Transfection of miR
mimics and antimiR
73
x Esophageal squamous cell
carcinoma and Gastric cancer
Transfection of antimiR
luciferase assays
106,144
miR-21 x Breast adenocarcinoma Transfection of antimiR 141
miR-130a x Ovarian cancer Transfection of antimiR 142
miR-let-7 x Ovarian cancer Transfection of siRNA
Rodhamine 123 assay
143
miR-138 x Promyelocytic leukaemia Luciferase assays
Transfection of miR mimics
105
miR-200c x Breast adenocarcinoma Transfection of miR mimcs 145
miR-122 x Hepatocellular carcinoma Transfection of miR mimcs 147
miR-455-3p x Acute lymphoblastic
leukaemia
Microarray analysis
Microvesicles transfer
148
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transcriptional level, implying that these miRs might regulate
MDR-1 by interfering with the gene promoter region128 (Fig.
2 and Table 2).
In this context, the association between P-gp expression
and miR-138 in promyelocytic leukemia cells (HL-60) has
been reported. In these cells, upregulation of miR-138 could
reverse the MDR phenotype by downregulation of P-gp lev-
els. A luciferase reporter assay permitted the regulatory
effects of miR-138 on the MDR-1 promoter to be analysed,
suggesting that the regulation of P-gp through miR-138
might occur at the transcriptional level.105
Interestingly, miR-27a (already referred above to be both
a direct and possibly indirect regulator) has also been
claimed to be a transcriptional regulator of P-gp in esopha-
geal squamous cell carcinoma and gastric cancer cells (ECA-
109, TE-13 and MKN45).106,144 These studies indicated that
downregulation of miR-27a might reverse drug resistance
and decrease the expression of P-gp.106,144 In addition, when
trying to elucidate the regulatory effects of miR-27a on the
promoter activity of MDR-1, results suggested that miR-27a
might be a modulator of the MDR-1 promoter.106
miRs regulating P-gp through mechanisms of regulation
not fully understood
Other miRNAs have been described to associate with MDR-1
expression, although their mechanisms of action remain
unknown (Fig. 2 and Table 2).
miR-200c expression seems to be associated, at least in
part, with MDR-1=P-gp expression. The upregulation of miR-
200c in breast cancer cells (MCF-7), resulted in reduced
expression of MDR-1 mRNA and P-gp, providing evidence
for the role of miR-200c in drug resistance, through a mecha-
nism of regulation not yet understood.145 miR-200c has also
been associated with chemotherapy response in patients.
Indeed, in breast cancer patients who had received neoadju-
vant chemotherapy, it was observed that miR-200c was
downregulated in non-responder patients when compared to
responders.145
miR-122 is a liver specific miR, which is downregulated in
hepatocellular carcinoma human patients and animal mod-
els.146 Overexpression of miR-122 in hepatocellular carci-
noma cells caused a decrease in the expression of MDR
related genes, including MDR-1.147
miR-455-3p has been related to P-gp levels in human
ALL cell lines by mechanisms not fully understood, as will be
referred in “P-gp and the microRNAs Involved in its Regula-
tion May Be Present in Microvesicles and Exosomes, and
May Be Transferred Between Cells” below.148
P-gp Regulates microRNAs Involved in Drug
Resistance
To date, only one study has reported the regulation of miRs by
P-gp.149 A possible association between P-gp and radiation
sensitivity has been found. Curiously, this study observed over-
expression of P-gp, high miR-16 levels and radiation sensitivity
in a MDR hepatocellular carcinoma cell line, when compared
to its parental counterpart (HepG2). In addition, the transfec-
tion of a parental cell line with an MDR-1 vector induced high
levels of miR-16. The authors suggested that P-gp upregulated
miR-16, which in turn downregulated Bcl-2 (Fig. 1—Panel b),
leading to enhanced radiation-induced apoptosis.149 However,
the pathways linking P-gp to miR-16 remain to be fully identi-
fied. Nonetheless, this evidence supports a novel role for P-gp
in miR regulation, reinforcing the diversity of P-gp functions
in cancer cells.
P-gp and the MicroRNAs Involved in its Regulation
May Be Present in Microvesicles and Exosomes, and
May Be Transferred Between Cells
Increasing interest in microvesicles and exosomes as media-
tors of intercellular communication has recently emerged
amongst the scientific community, due to their ability to
transfer intracellular content from donor to recipient cells.150
Indeed, the concept of non-genetic acquisition of functional
P-gp in MDR has previously been described151 and this could
be mediated by microvesicles (50–1000 nm in diameter) or
exosomes (40–120 nm)152 which, once secreted from cells by
mechanisms not yet fully understood, could provide vehicles
for the intercellular transfer of P-gp from MDR donor to
drug-sensitive recipient cells.153,154
miRs have also been shown to be included into microve-
sicles and exosomes and to be capable to targeting neighbor-
ing cells,155–157 entering the blood stream and reaching
distant cells.158,159 Indeed, very recently, microvesicles and
exosomes from resistant leukemia and breast cancer cells
were shown to incorporate and transfer both P-gp protein
and transcripts, together with miRs, to drug-sensitive recipi-
ent cells. This transfer resulted in the acquisition, by the
recipient cells, of the drug resistant characteristics of the
donor cells.153,160,161 In a recent study, the authors analysed
the molecular basis for the acquired traits, looking for some
miRs which had previously been reported73,106,129,130,144 (and
described above) as enhancers of P-gp expression in drug
resistant cancer cells (miR-27a and miR-451). They demon-
strated that the transfer of transcripts and miRs through
microvesicles plays an important role in conferring MDR by
“retemplating” recipient cells in order to reflect the donor
cell (P-gp overexpressed) phenotype.160
Other recent work also demonstrated that some miRs that
are shed from microvesicles play an important role in
MDR.148 The authors observed that one of the significantly
expressed and shed miRs, miR-455-3p, is possibly related to
P-gp levels. In this study, results from microarray analysis
showed that miR-455-3p was less expressed in a P-gp overex-
pressing resistant leukemia cell line, when compared with the
parental sensitive cell line. Moreover, following the transfer
of microvesicles from the resistant to the sensitive cell lines,
it was observed that the sensitive cells acquired lower miR-
455-3p and higher P-gp levels.148 The mechanisms involved
in the regulation of P-gp by this miR are not understood
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(as previously mentioned in “miRs regulating P-gp through
mechanisms of regulation not fully understood” section).
More recently, the same research group demonstrated that
microvesicles from a resistant human breast adenocarcinoma
cell line could transfer a stable MDR trait in vivo (in a
murine tumor xenograft model). They observed that, follow-
ing a single injected dose of microvesicles, P-gp was trans-
ferred with those microvesicles, co-localized within the
xenografted tumor and remained stable for at least 2 weeks.
These authors also reported that the transfer of P-gp via
microvesicles (in vitro) is “cell type selective,” depending on
the donor cells. Indeed, microvesicles from a resistant leuke-
mia cell line, transferred P-gp to both malignant (sensitive
leukemia cell line) and non-malignant cells (human osteo-
blasts). Nonetheless, microvesicles from resistant breast can-
cer cell line only transferred P-gp to malignant cells
(sensitive breast adenocarcinoma cell line). The authors
observed that this could be due to the involvement of a
cytoskeletal protein (Ezrin) which is selectively present only
in some of the donor cells studied (breast cancer cell line
model).162
In addition, it is known that miRs involved in P-gp regu-
lation could also be transferred via cell-to-cell contact and
drive chemoresistance. Indeed, miR-21 was shed via contact-
dependent intercellular transfer, mediated by a transmem-
brane channel (SIDT1—systemic RNA interference defective
family of channels).163
Future Perspectives
Targeting the transfer of P-gp, and-or miRs that regulate=are
regulated by P-gp, to neighboring cells may be an approach to
overcome some cases of drug resistance. A possible approach to
avoid the transfer of P-gp via microvesicles=exosomes would be
the use of small molecules or siRNAs to reduce the amount of P-
gp in the donor cells, thus reducing the amount of P-gp that
would be transferred in such vesicles. Molecules that reduce P-gp
protein levels have been described, such as curcumin164,165 or
bortezomib,166 and theoretically they should reduce the amount
of P-gp transferred from drug resistant to drug-sensitive cells.
Alternatively, silencing P-gp gene expression should also reduce
the transfer of P-gp from drug resistant to drug-sensitive cells.
Our group is currently studying these hypotheses.
In addition, extracellular vesicles themselves constitute a
novel class of therapeutic targets to overcome drug resist-
ance.152 Four strategies should be capable of reducing extrac-
ellular vesicle trafficking, namely: (i) inhibition of their
formation; (ii) inhibition of their release; (iii) inhibition of
their uptake by other cells and (iv) blockage of their specific
components.152 The approach of reducing extracellular vesicle
trafficking could theoretically reduce the transfer of both
P-gp and miRs from drug resistant to drug-sensitive cells.
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1.2.2. Inhibitors of P-gp synthesis and function 
 
Decreasing P-gp expression and/or function (i.e., drug efflux) with P-gp inhibitors 
would result in an increased bioavailability of the drugs that are normally effluxed by P-gp. 
To date, four generations of P-gp inhibitors have been described, with many of their 
representatives having reached clinical trials 52. However, none of these compounds has 
been successful, due to undesirable side effects as well as low effectiveness (drug 
interactions or pharmacokinetic issues) 54,55. Therefore, it is essential to identify novel 
inhibitors of P-gp activity or expression 53. 
Some of the most effective cancer drugs to date are derived from natural products. 
Indeed, natural products and their synthetic derivatives comprise more than half of the 
anticancer drug candidates developed in the last decades 54. Curcumin, a secondary 
metabolite isolated from the turmeric of Curcuma longa L., has been associated with a 
beneficial P-gp inhibitory effect (both in terms of function and expression inhibition). 
However, the poor availability and extensive metabolism of the curcumin molecule have 
enhanced the search for more efficient and stable novel synthetized analogs of curcumin 
54.  
The following review, titled: “Curcumin as a modulator of P-glycoprotein in cancer: 
challenges and perspectives”, summarizes and compares the effects of curcumin and 
curcumin analogs on P-glycoprotein function and expression. 
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Abstract: Multidrug resistance (MDR) presents a serious challenge to the efficiency of 
cancer treatment and may be associated with the overexpression of drug efflux pumps.  
P-glycoprotein (P-gp) is a drug efflux pump often found overexpressed in cases of acquired 
MDR. Nevertheless, there are no P-gp inhibitors being used in the current clinical practice, 
due to toxicity problems, drug interactions or pharmacokinetic issues. Therefore, it is 
important to identify novel inhibitors of P-gp activity or expression. Curcumin is a 
secondary metabolite isolated from the turmeric of Curcuma longa L. which has been 
associated with several biological activities, particularly P-gp modulatory activity (by 
inhibiting both P-gp function and expression). However, curcumin shows extensive 
metabolism and instability, which has justified the recent and intensive search for analogs 
of curcumin that maintain the P-gp modulatory activity but have enhanced stability. This 
review summarizes and compares the effects of curcumin and several curcumin analogs 
on P-glycoprotein function and expression, emphasizing the potential of these molecules 
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for the possible development of safe and effective inhibitors of P-gp to overcome MDR in 
human cancer. 
Keywords: P-glycoprotein, multidrug resistance; curcumin; curcumin analogs   
PACS: J0101 
 
1. P-glycoprotein as a major cause of cancer multidrug resistance  
Cancer cells may have inherent or may develop resistance to antitumor drugs. In some 
cases, cells are cross-resistant to several unrelated (structurally and mechanistically 
different) drugs, a phenomenon known as multidrug resistance (MDR) [1,2].   
Overexpression of P-glycoprotein (P-gp) is one of the main mechanisms involved in 
the development of MDR [1,2]. P-gp (encoded by the MDR1 gene, also referred to as 
ABCB1) is a drug-efflux pump from the ATP-binding cassette (ABC) transporters family, 
which efficiently removes cytotoxic drugs from the intracellular environment through an ATP 
dependent mechanism [3]. This glycoprotein is composed of two highly hydrophobic integral 
membrane domains and two hydrophilic nucleotide binding domains (Figure 1) [4]. 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of P-gp structure with two halves, each with a 
transmembrane domain (TMD1 and TMD2) and a nucleotide-binding domain (NBD1 and 
NBD2) (adapted from [5]).  
 
The TMDs, composed of six membrane α-helices (TM1-TM6 and TM7-TM12), contain 
the drug binding sites and define the translocation pathway across the membrane; the two 
cytoplasmic NBDs couple the energy associated with ATP binding and hydrolysis, which is 
necessary for drug transport [6]. 
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Different studies have shown that by inhibiting P-gp it is possible to counteract some 
cases of MDR in cancer [7]. There are many known MDR modulators belonging to several 
chemical classes, including calcium channel blockers, indole alkaloids, cyclosporine’s and 
calmodulin inhibitors [8]. However, the described modulators presented toxicity problems 
associated with the need for the use of very high doses in order to produce the required 
results [9]. To minimize these risks, new analogs of these compounds are being tested and 
developed with the goal of finding potent MDR modulators with less toxicity problems [10]. 
Some of the most effective cancer treatments to date are derived from natural products, 
such as taxol [11]. Indeed, natural products and their synthetic derivatives comprise more 
than half of the approved anticancer drug candidates developed in the last decades [12]. 
Research on natural dietary phytochemicals from foods, herbs, and dietary supplements is 
increasing due to the low toxicity expected.  
The search for P-gp inhibitors has uncovered several natural compounds with this 
activity such as flavonoids, quercetin, morin, catechins, capsaicin, and curcumin [13-15]. In 
this review, studies on the effects of curcumin and curcumin analogs on P-gp expression 
and activity are summarized, with the aim of highlighting the potential of these molecules 
for the possible development of safe and effective inhibitors of P-gp to overcome MDR in 
human cancer.  
 
 
2. Curcumin as a natural product that inhibits P-gp 
Curcumin (Figure 2) is a phytochemical obtained from the dried rhizomes of Curcuma 
longa L. (turmeric), which has been used over the last centuries as a food additive, in 
cosmetics and as a form of traditional herbal medicine [16]. It has a wide range of 
pharmacological activities and presents low levels of toxicity. 
 
 
Figure 2. Main curcuminoids isolated from turmeric of Curcuma longa L.. 
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Several studies have demonstrated a beneficial effect for curcumin in Alzheimer 
disease [17] and also in cases of high cholesterol by inhibiting the intestinal absorption of 
cholesterol and consequently reducing its blood levels [18]. Curcumin was also described 
as an anti-HIV [19] and antibacterial agent [20]. Additionally, curcumin presents strong 
antioxidant, anti-inflammatory, and antiangiogenic properties and was also described as 
having wound healing and anticancer effects [16,21]. 
Curcumin inhibits the growth of a wide variety of tumour cells, including gastric cancer 
[22] colon carcinoma [23] and breast cancer cells [24]. Curcumin was described as inhibiting 
the phosphorylation of AKT and AKT-related gene products, thereby presenting antitumor 
effects [25]. In addition, curcumin has been shown to downregulate the AKT kinase 
signaling, inhibiting proliferation and inducing apoptosis in T-cell leukaemia cell lines [26]. 
Interestingly, curcumin has been also described to be capable of suppressing P-gp 
expression and function and therefore reversing the MDR phenotype [27-29]. 
 
 
2.1. Curcumin as modulator of P-glycoprotein function 
Curcumin was described as having a role in reversing MDR through the modulation of 
P-gp. Specifically, curcumin has been described as an inhibitor of the function of P-gp in 
several in vitro and in vivo models [21,30]. 
Several studies unraveled that the role of curcumin in the modulation of MDR occurred 
through its interaction with P-gp. In 2002, Anuchapreeda and collaborators [31] 
demonstrated that curcumin reduced P-gp mediated drug-efflux in MDR cervical carcinoma 
cells, in a dose dependent manner. The authors also performed biochemical studies which 
have shown the direct interaction between P-gp and curcumin [31]. Two years later, the 
same group [32] purified the three major curcuminoids from the previous used curcumin 
mixture [31] (curcumin, demethoxycurcumin and bisdemethoxycurcumin, Figure 2) and 
analyzed the effect of the three curcuminoids on the modulation of P-gp function, in the 
same MDR human cervical carcinoma cell line [32]. The authors suggested that these three 
curcuminoids are not substrates of P-gp, since they presented similar IC50 values for 
cytotoxicity between the MDR and the drug-sensitive cell lines used in the study [32]. In 
addition, they observed that curcumin was the most effective MDR modulator among the 
three curcuminoids, and could possibly be used in combination with conventional 
chemotherapy to reverse MDR in cancer [32]. 
Curcumin was also demonstrated to reverse MDR in a different model, a gastric 
carcinoma MDR cell line, possibly through a decrease in P-gp function which was observed 
in the treated cells [33]. In addition, two different MDR human cancer cell models (cervical 
and breast carcinoma MDR cell lines) that were treated with the three major curcuminoids 
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(Figure 2), presented inhibition of P-gp function, which significantly increased the 
intracellular accumulation of rhodamine in a dose dependent manner [34]. Also, the 
interaction of one of curcumin metabolites, tetrahydrocurcumin, with the P-gp molecule was 
clearly indicated by an ATPase assay and by photo affinity labeling of P-gp [34]. 
The above mentioned studies were performed in order to study the capacity of 
curcumin to revert MDR.  However, curcumin was also shown to have an effect in 
preventing the induction of MDR [35]. This was observed in a chronic myeloid leukaemia 
cell line that was pre-treated with curcumin before being exposed for 24 hours to 
doxorubicin with the purpose of selecting for more resistant cell line (with overexpression of 
P-gp). These cells, presented an increase in the intracellular rh123 accumulation levels, 
and an increase in the sensitivity towards doxorubicin (almost comparable to cells that were 
not exposed to doxorubicin), whereas the cells that were not pretreated with curcumin (but 
exposed to doxorubicin) presented a decrease in the intracellular rh123 accumulation levels 
and became more resistant to doxorubicin [35]. 
   
 
2.2. Curcumin as modulator of P-glycoprotein expression 
Curcumin has been described not only to inhibit the function of P-gp but also the 
expression of P-gp, at the protein and at the mRNA level. This role of curcumin, as inhibitor 
of the expression of P-gp, was originally described in 2002 [31], in a work in which it was 
shown that treatment of MDR cervical carcinoma cells caused a decrease in the protein and 
in the mRNA levels of P-gp [31]. The same authors have latter on isolated the three more 
important natural curcuminoids from turmeric (Figure 2, curcumin, demethoxycurcumin and 
bisdemethoxycurcumin), and compared them for their ability to modulate P-gp expression 
in the same model (a MDR human cervical carcinoma cell line) [36]. They have 
demonstrated that bisdemethoxycurcumin was the most active of the curcuminoids present 
in turmeric, regarding the inhibition of the P-gp expression. In addition, treatment of the 
MDR cells with curcumin increased their sensitivity to vinblastine, which was consistent with 
a decrease in P-gp expression [36].  
The effect of curcumin in P-gp expression was also demonstrated in other MDR cancer 
cell models, such as in a human MDR gastric cancer cell line [33], a human MDR colon 
cancer cell line [37] and a mouse MDR leukaemia cell line [28], in which it was described 
that the inhibitory effect of curcumin in the expression of P-gp ultimately lead to MDR 
modulation and cellular sensitization to common drugs. From a mechanistic point of view, 
it was proposed that curcumin can contribute to counteract the MDR phenotype, probably 
by suppression of P-gp expression via inhibition of the PI3K/Akt/NF-kB signaling pathway 
[28].  
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The role of curcumin in preventing MDR by decreasing P-gp expression in a chronic 
myeloid leukaemia model was also shown [35]. In addition, it was found that all the three 
curcuminoids (curcumin, demethoxycurcumin and bisdemethoxycurcumin, Figure 2) were 
capable of preventing MDR induced by doxorubicin in that model (chronic myeloid 
leukaemia). However, the preventive effect of each curcuminoid was different, with 
demethoxycurcumin being the most active of the curcuminoids for prevention of MDR1 
mRNA and P-gp overexpression [38]. 
Finally, it was demonstrated that both the chemotherapeutic and chemosensitizing 
effects of curcuminoids (by downregulation of P-gp expression) in colon cancer cells were 
mediated through modulation of a microRNA (miR-27a-ZBTB10-Sp-axis) [39]. 
Although these works have demonstrated that curcumin is an effective inhibitor of P-
gp expression in vitro, animal experimentation was further required to determine if curcumin 
had potential as an effective and safe chemosensitizer. Curcumin was shown to have 
capacity to inhibit the expression of P-gp in xenografts of human colon cancer cells in mice. 
Indeed, curcumin treatment significantly reduced the expression of the MDR1 gene and of 
P-gp protein in the xenografts of mice, when compared to the control group [37]. These 
results suggested that curcumin could partially reverse the MDR phenotype. Additionally, 
curcumin inhibited xenograft growth [37]. The P-gp inhibitory activity of curcumin was also 
demonstrated in an in vivo model of colon cancer, by a novel method, the in situ cancerous 
colonic single pass perfusion method in rats [29]. 
 
 
3. Strategies for overcoming limitations of curcumin 
The previously mentioned studies suggested that curcumin could become a promising 
lead compound for overcoming MDR in cancer. However, this compound is very unstable 
and has low bioavailability in vivo [21]. Indeed, curcumin is highly hydrophobic, which 
prevent its absorption across the gut, therefore having a rapid metabolism and a limited 
tissue distribution [40] In summary, the instability of the molecule and its poor 
pharmacokinetics profile are major drawbacks for its possible clinical use. This became 
evident in a Phase I clinical trial, during which very high oral doses of curcumin (8-12 g/daily) 
resulted in peak plasma concentrations in the nanomolar range only [41,42]. Therefore, two 
strategies have been employed in order to overcome this problem: the incorporation of 
curcumin into pharmaceutical formulations to improve its delivery and the design and 
synthesis of analogues of curcumin aiming to obtain better stability and bioavailability. 
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3.1. Improving the intracellular delivery of curcumin  
It has been reported that a more pronounced downregulation of P-gp expression was 
observed when curcumin was delivered in nanoemulsion formulations (heterogeneous 
mixtures of oil in water, where the oil droplets have a nanometer size, which allow the  
solubilization  of hydrophobic compounds such as curcumin) when compared to curcumin 
alone [43].  Furthermore, it was shown that chitosan–PBCA nanoparticles decreased the 
expression levels of P-gp in the MDR cells when compared to control curcumin alone [44].  
Finally, a preparation of mixed micelles (polymeric micelles and surfactant micelles) loaded 
with curcumin caused a significant improvement in the cytotoxic activity and in the oral 
bioavailability, when compared to curcumin alone [45]. These improved effects could be 
attributed to the solubilization of the hydrophobic curcumin into the micelle core, together 
with the P-gp inhibitory effect of curcumin. 
 
 
3. 2 Curcumin derivatives and analogs as inhibitors of P-gp 
Over the past few years, several curcumin derivatives/analogs have been synthesized 
with the objective of obtaining molecules more stable and bioavailable than curcumin, while 
not losing their biological activity (Table 1). 
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Table 1 – Reported curcumin derivatives/analogs with P-gp modulatory effect 
 
Compounds MDR cancer model 
Inhibitors 
of P-gp 
function 
Inhibitors of 
P-gp 
expression 
REF 
 
Unsymmetrical curcumin 
mimics with various amide 
moieties 
 
MDR cervical 
adenocarcinoma 
X  [46] 
 
Heterocyclic cyclohexanone 
monocarbonyl analogs of 
curcumin 
 
Human embryonic 
kidney cells and canine 
kidney cells transfected 
with wild-type P-gp 
 
X  [47] 
 
Chloro and asymmetrical 
series of synthetic curcumin 
derivatives 
 
MDR acute 
lymphoblastic leukaemia 
X  [48] 
 
Diketone and cyclohexanone 
curcumin analogs 
 
MDR chronic 
myeloid leukaemia 
X X [49] 
 
 
3.2.1. Curcumin derivatives and analogs as modulators of P-glycoprotein 
function 
 
Several authors have attempted to understand the MDR modulatory effect of curcumin 
and the disadvantages that curcumin presents in terms of pharmacokinetics profile, from a 
chemical perspective. They have attempted to synthesize better compounds, i.e. 
maintaining the MDR modulatory effect while improving the stability and availability of 
curcumin. 
For instance, twelve unsymmetrical curcuminoids with various amide groups were 
synthesized and tested for MDR reversal activity. Three of the compounds presented a 
potent MDR reversal activity by inhibiting the drug efflux function of P-gp, while the others 
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were only moderately potent [46]. This work also showed, from the preliminary structure-
activity study, that only half of the curcumin symmetrical structure is a promising lead 
structure for a MDR reversal agent [46]. 
Moreover, monocarbonyl analogs of curcumin have been described to be more stable 
than curcumin, since they do not have the unstable β-diketone moiety of curcumin [50]. 
Indeed, 23 heterocyclic cyclohexanone monocarbonyl analogs of curcumin were 
synthesized and investigated for their inhibitory effects against the P-gp function (using flow 
cytometry and resistance reversal assays) [47]. Many of these compounds inhibited P-gp 
function, most of them being more potent than curcumin itself. Moreover, some of these 
analogs showed potent anticancer activity [47], which raised the possibility of using them 
as antitumor dual agents (similarly to the above described curcumin effect).   
Additionally, the cytotoxic and P-gp inhibitory activity of 19 chloro and asymmetrical 
series of synthetic curcumin derivatives was studied in a MDR acute lymphoblastic 
leukaemia model [48]. Some of the compounds caused a significant increase in doxorubicin 
uptake rates (an effect that was better than that of verapamil), indicating a remarkable 
inhibition of P-gp function (since doxorubicin is a P-gp substrate) [48].  
Finally, five diketone and four cyclohexanone curcumin analogs were synthesized and 
studied regarding the intracellular accumulation of P-gp substrates (such as rhodamine 123 
and doxorubicin), in order to evaluate their effect as inhibitors of P-gp function. Two of these 
compounds (1,7-bis-(3,4-dimethoxy-phenyl)- hepta-1,6-diene-3,5-dione and 2,6-bis-(3,4-
dimethoxy-benzylidene)-cyclo- hexanone) caused a strong inhibitory effect of P-gp function 
[49], which suggests that these analogs may be strong MDR modulators. 
 
 
3.2.2 Curcumin derivatives and analogs as modulators of P-glycoprotein 
expression 
 
From the above mentioned published studies only one study investigated the inhibitory 
activity of the analogs in terms of P-gp expression [49]. From the studied diketone and four 
cyclohexanone curcumin analogs mentioned above (section 3.2.1), three of them showed 
a strong effect as inhibitors of P-gp expression. Interestingly, one of the analogs (2,6-bis-
(3,4-dimethoxy-benzylidene)-cyclo- hexanone) caused simultaneous inhibition of the 
expression and of the function of P-gp [49]. This compound might be a very good candidate 
for an MDR modulator, since it has dual inhibitory effects (on both P-gp function and 
expression), increased the sensitivity of the MDR cells to paclitaxel and also has better 
stability than curcumin itself. 
 
		38	
INTRO DUCT ION  
 
4. Future perspectives 
It is believed that the level of P-gp in the cell lines is much higher than that in human 
tissues [51], which means that lower concentrations of P-gp modulators should be effective 
inhibitors of P-gp in vivo, when compared to in vitro studies. Therefore, even though 
curcumin and derivatives are considered to be non-toxic, a low therapeutic dose could be 
favorable in future in vivo studies.  
Future studies should also consider the synergistic effects of curcumin with other 
compounds, on P-gp transporter function and expression. Combinatorial studies with 
several natural compounds or with conventional anticancer drugs could be carried out in 
order to identify potential synergistic or additive effects.  
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1.3. Metabolic Alterations in MDR  
 
Metabolism is involved, directly or indirectly, in essentially everything a cell does. In 
fact, it is through metabolism that cells produce energy and the required precursor 
metabolites needed to fuel all cellular processes. The cellular metabolic network is 
coordinated by interacting genes and proteins, consisting of several metabolic pathways 
where enzymatic reactions connect metabolites in a related process 55. All the players and 
specific reactions are controlled by a complex regulatory structure, mostly composed by 
proteins and signalling molecules, which confer dynamism and strength to the cell 56. These 
metabolic properties are regulated through several checkpoints in normal cells 55. However, 
in cancer cells, many of these regulatory networks are deregulated in order to adapt the 
tumour cell’s metabolism to their uncontrolled growth, proliferation and survival 57. Also, it 
is possible that some metabolic alterations may be required for malignant transformation 56. 
Indeed, alterations in cellular metabolism are considered a hallmark of cancer, being as 
widespread in cancer cells as many of the other cancer-associated traits 36. 
Normal cells need to be stimulated by growth factors in order to take up nutrients 
from the environment 61. This allows preventing uncontrolled proliferation. On the other 
hand, cancer cells acquire several mutations and other alterations, which functionally alter 
signaling pathways, overcoming the dependence on growth factors to take up nutrients. 
Some of these pathways may activate the uptake and metabolism of nutrients, promoting 
cell survival and fuel to cell growth 58,59.  
Cancer cells require multiple alterations to the normal metabolism of all major 
classes of macromolecules (carbohydrates, proteins, lipids and nucleic acids), in order to 
support their basic needs for cell division. These cells require high maintenance of energy 
by rapid generation of ATP, maintenance of balanced redox status and increased 
biosynthetic capacity 56. Since MDR cancer cells are highly proliferative and require high 
energy supply 24, it has been suggested that the pharmacological modulation of metabolic 
processes in MDR cancer cells could contribute to overcoming this phenotype and improve 
the efficiency of cancer chemotherapy 60,61. Some pathways (such as the pentose 
phosphate pathway, the glutathione metabolism, the methionine/S-adenosylmethionine 
pathway, glycolysis and oxidative phosphorylation, which are going to be described below), 
could be altered and somehow implicated in the MDR phenotype.  
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1.3.1. The Warburg effect 
 
Otto Warburg observed, back in 1924, that cancer cells metabolize glucose in a 
distinct manner when compared to cells in normal tissues 62,63. Warburg discovered that 
cancer cells (unlike normal cells) produce high amounts of lactate from glucose, even when 
in the presence of enough oxygen to support mitochondrial oxidative phosphorylation 
(OXPHOS). This phenomenon was named “The Warburg’s effect” 62,63.  
The Warburg’s effect remains not fully understood, partly because it is difficult to 
understand why do proliferating cells suffer a metabolic switch to a less efficient metabolism 
in terms of ATP production (since the metabolism of glucose to lactate generates only 2 
ATPs per molecule of glucose, whereas OXPHOS generates up to 36 ATPs) 64. However, 
the inefficient ATP production is not a problem to proliferating mammalian cancer cells since 
they are exposed to a continued supply of glucose and other nutrients from the blood. In 
fact, there is evidence that ATP may never be limiting in these cells (using aerobic 
glycolysis), since they exhibit high ratios of ATP/ADP 59,65. Also, it was discovered that 
glycolysis leads to faster ATP production. Indeed, the rate of ATP production may be up to 
100 times faster in glycolysis than in OXPHOS 66, so the increased rate of ATP production 
resulting from glycolysis confers a selective growth advantage to cancer cells 67,68. In 
addition, glycolysis is much “safer” to cancer cells than OXPHOS, because OXPHOS 
produces reactive oxygen species (ROS) which can be very damaging to the delicate 
balance of ROS maintained in an abnormal cancer cell (a high ROS content in cancer cells 
renders them more susceptible to cell death induced by oxidative stress) 69. 
Another possible explanation for the metabolic switch is that cancer cells have 
additional metabolic requirements besides ATP production, to meet their biosynthetic 
needs. Such metabolic requirements are fulfilled with aerobic glycolysis (rather than with 
OXPHOS) through the production of glycolytic intermediates 70, which are then  integrated 
into various metabolic pathways to generate de novo nucleotides, lipids, amino acids, and 
NADPH 68,71,72. 
The factors that trigger the metabolic switch from OXPHOS to aerobic glycolysis in 
cancer cells are beginning to be elucidated. The first proposed trigger was tumour hypoxia 
67. However, cancer cells seem to use a glycolytic metabolism even before being exposed 
to hypoxic conditions 73,74. Indeed, recent evidence suggests that tumour hypoxia is 
important for cancer cells, but it may be a late-occurring event and not a major contributor 
to the metabolic switch towards aerobic glycolysis 70,74,75 As an alternative hypothesis, the 
triggers to the metabolic switch could be oncogenic pathways, which initiate cell-
independent nutrient uptake and proliferative metabolic program 70. 
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 The Warburg effect is also evident in the MDR tumour cells 16. Indeed, it was 
observed that some MDR tumours have an increase in glycolysis and a decrease in 
OXPHOS comparing to drug-sensitive cancer cells 45. Also, these metabolic alterations are 
associated with an increase in P-gp expression, which may indicate that both occurrences 
may be closely related 45. More recently, it was shown that a metabolic switch conforming 
to the Warburg effect, was associated with melphalan resistance in multiple myeloma cells 
44. These metabolic changes could be relevant to the MDR phenotype due to the high 
demand for rapid ATP production by  MDR cells. Indeed, cells expressing MDR transporters 
(such as P-gp), require ATP as the energy source to perform drug efflux 76.  
 
 
1.3.1.1. Glycolysis 
Glycolysis represents one of the first bio-energetic mechanisms to appear during 
the eukaryotic phylogeny 77. It is a critical catabolic process of the glucose, using one 
molecule of glucose to produce two molecules of pyruvate, giving rise to two ATP molecules 
and two reduced nicotinamide adenine dinucleotide (NADH) molecules (Figure 1) 77. 
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Figure 1 – Glycolysis pathway. The pathway of glycolysis initiates with the phosphorylation of 
glucose to glucose-6-phosphate (G6P). G6P is then converted to fructose-6-phosphate (F6P) that is 
further phosphorylated to form fructose-1,6- biphosphate (F1,6BP). Two molecules of ATP are 
consumed during these two steps of phosphorylation.  F1,6BP is then used in order to produce 
glyceraldehyde 3-P (and dihydroxiacetone-phosphate which is isomerized to glyceraldehyde 3-P), 
which is then oxidized and phosphorylated to form glyceraldehyde 1,3-P. Glyceraldehyde 1,3-P is 
converted to 3-phosphoglycerate producing a molecule of ATP via substrate-level phosphorylation. 
3-Phosphoglycerate is then isomerized to 2-phosphoglycerate, which is dehydrated to produce 
phosphoenolpyruvate. Phosphoenolpyruvate is subsequently converted to pyruvate with the 
production of another molecule of ATP. Two molecules of glyceraldehyde 3-phosphate are oxidized 
to two pyruvates, and four molecules of ATP are produced via two steps of substrate-level 
phosphorylation. The net yield is two molecules of ATP per molecule of glucose oxidized 77. 
 
 
In normal cells, the fate of pyruvate largely depends on the cellular supply of oxygen. 
In the absence (or low levels) of oxygen, pyruvate may be transformed into lactate via the 
anaerobic glycolysis pathway. On the other hand, in the presence of oxygen, pyruvate may 
be oxidized to CO2 and H2O through the oxidative phosphorylation (OXPHOS) pathway, 
resulting in the production of larger amounts of ATP 78. As already referred, cancer cells 
have abnormal glucose metabolism, characterized by aerobic glycolysis. Thus, most cancer 
cells produce large amounts of lactic acid independently of the availability of oxygen 70. 
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The energy dependence of the MDR transport suggests that MDR cells, when 
developing the resistance phenotype, probably suffer some alterations in the cell’s energy 
supply.  Indeed, it has been suggested that a MDR human breast carcinoma cell line 
presented an increase in the glycolysis rate related to an increased in the energy-dependent 
drug detoxification 79. In addition, some MDR-reversing drugs, such as verapamil, increased 
the lactate production in P-gp overexpressing tumour cells 80.  Therefore, given the fact that 
ABC transporters (such as P-gp) are ATPase dependent, glycolysis modulation may 
eventually contribute to sensitize cancer cells to chemotherapy treatment. Indeed, recent 
studies have shown that the inhibition of glycolysis sensitizes MDR cells to common 
chemotherapeutic drugs 45,23,81. They showed that the inhibition of glycolysis with energetic 
modulators, such as 2-deoxy-D-glucose and iodoacetate, reverted the MDR phenotype. 
Moreover, glycolysis inhibition in MDR cells caused downregulation of P-gp expression 23,45 
and function 23, showing a direct relationship between glycolysis and P-gp expression in 
MDR cells and the potential of glycolysis inhibitors to overcome P-gp mediated drug 
resistance. 
 
 
1.3.1.2. Oxidative Phosphorylation (OXPHOS) 
OXPHOS generates more ATP per metabolite than the glycolytic pathway 82. 
Indeed, together with the citric acid cycle, produces a total of four molecules of ATP, ten 
molecules of NADH, and two molecules of FADH2. Then, electrons from NADH and FADH2 
are transferred to molecular oxygen, coupled to the formation of an additional 32 to 34 ATP 
molecules by oxidative phosphorylation. Electron transport and oxidative phosphorylation 
are performed by several protein complexes in the inner mitochondrial membrane, serving 
as the major source of cellular energy (Figure 2).  
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Figure 2 – Electron transport and oxidative phosphorylation. During oxidative phosphorylation, 
electrons derived from NADH or FADH2 are combined with O2, and the energy released from these 
oxidation/reduction reactions is used to drive the synthesis of ATP from ADP. The transfer of 
electrons from NADH and FADH2 to O2 is an energy-yielding reaction. This energy must be produced 
gradually, by the transport of electrons through a series of carriers, which constitute the electron 
transport chain. These carriers are organized into four complexes and transporters, ubiquinone and 
cytochrome C. A fifth protein complex serves to couple the energy-yielding reactions of electron 
transport to ATP synthesis 77. I – complex I; II – complex II; III – complex III; IV – complex IV; V – 
complex V; Q- ubiquinone. 
  
Although the majority of the scientific reports showed a role for glycolysis in MDR, 
surprisingly, recent studies also showed a fundamental role for OXPHOS in cancer and 
particularly in MDR. Indeed, it was recently shown that melanoma cells are critically 
dependent on oxidative phosphorylation (OXPHOS) rather than on glycolysis 83,84. 
Furthermore, that respiratory function is essential for the tumourigenic and metastatic 
potential of breast cancer and melanoma cells 85,86. In addition, it was observed that the 
most aggressive ovarian cancer cell lines showed a marked dependence on glutamine 
rather than on glucose 87, and that CSCs from epithelial ovarian cancer patients privilege 
OXPHOS and resist glucose deprivation 88. These studies suggest that glycolysis is not the 
main pathway sustaining tumour growth in these systems.  
Particularly, regarding the role of OXPHOS in the MDR phenotype, it was recently 
shown that cisplatin-resistant cells from ovarian cancer have an increase in the oxidative 
metabolism, when compared with their sensitive counterparts. In fact, when using 
pharmacological inhibitors of mitochondrial OXPHOS (such as metformin and oligomycin) 
the cisplatin resistance was reverted 89. Also, in a different study, using transcriptomics data 
of liver metastases from chemotherapy treated and chemo-naive colon cancer patients, it 
was observed that upon chemotherapy treatment, cancer cells shift their metabolism from 
glycolysis towards OXPHOS 90. Finally, a 3-D cell model of breast cancer cells formed a 
discrete cell sub-population with elevated MDR transport capacity and with a specific 
metabolic phenotype (mixed glycolytic/oxidative energy sustenance) 91. 
		50	
INTRO DUCT ION  
1.3.2. The Pentose Phosphate Pathway (PPP) 
 
 The pentose phosphate pathway (PPP) was first described in 1926 as being 
important for cellular metabolism (when the introduction of new antimalarial drugs led to the 
first medical description of a drug-induced hemolytic anemia correlated with an intrinsic 
defect of red blood cells metabolism) 92. The PPP is now known to be not only a shunt 
pathway in the metabolism of hexose monophosphate, but also a critical pathway in cell 
redox balance and proliferative fate. 
PPP has been conserved throughout evolution, given its important role as a supplier 
of nucleic acid precursors and reducing equivalents 93. The percentage of glucose 
metabolized by the PPP varies in a tissue-dependent manner. In cells, the basal rate of 
PPP varies depending on the amount of NADP+ and other cell conditions (such as 
proliferative activity and exposure to oxidizing agents), modifying the NADP+/NADPH ratio 
94 (Figure 3). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Pentose phosphate pathway. PPP is normally divided in two branches, an oxidative 
and a non-oxidative branch. The activity of the oxidative branch is usually higher than the activity of 
the non-oxidative one 95. To begin, in the oxidative branch, glucose-6-phosphate (G6P) is oxidized 
into 6-phosphogluconolactone by glucose-6-phosphate dehydrogenase (G6PD), producing NADPH. 
The last resulting metabolite, ribulose 5-phosphate can be then converted into ribose 5-phosphate 
(R5P) and used for the synthesis of nucleotides. Then, in the non-oxidative branch of PPP, the 
reaction produces F6P and glyceraldehyde 3-phosphate, which can be either metabolized in the 
glycolytic pathway or reintroduced into the PPP. 
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Alterations in the PPP activity are frequent during the development or progression 
of cancer, since PPP provides two substrates that are necessary for the dividing cells 
(ribose 5-phosphate and NADPH) and also helps protecting cells from ROS damage 96. 
Being important for cellular transformation, it can be used as a therapeutic target. In addition 
to its role in cellular proliferation, experimental observations suggested that PPP may be 
involved in the promotion of invasion, angiogenesis and resistance to therapy 96. 
Therefore, an efficient PPP is required for tumour growth 72. Indeed, several studies 
have detected higher G6PD activity in tumour tissues when compared to normal tissues 97. 
For example, the non-oxidative branch of PPP has been suggested to be an important 
source of ribose 5-phosphate synthesis in tumour cells 98-100. 
PPP activity also plays a role in cellular escape from apoptosis. In fact, an apoptosis-
resistant clone of human promyelocytic HL-60 cells presented higher PPP activity than 
sensitive cells, having increased levels of NADPH 101. Moreover, the up-regulation of the 
PPP is normally associated with invasive and metastatic tumours. Actually, some studies 
have proposed that the activation of the non-oxidative branch of the PPP can be considered 
a hallmark of metastatic tumours 98,102.  
Additionally, since PPP is important for the control of the cellular redox balance 
(which is a critical aspect of chemotherapy success), a new and important therapeutic 
option consists in targeting PPP with selective and specific modulators. This approach may 
create new therapeutic anticancer options 96. 
In terms of therapeutics, high levels of NADPH and GSH together with an active 
PPP were found to have a role in MDR 103,104. In some studies, it was observed that the 
oxidative branch of the PPP is much more active in MDR cells than in their drug-sensitive 
counterparts. For example, the activity of PPP is two-fold higher in the resistant P388 
murine lymphocytic leukaemia cells, as a consequence of a 40% higher activity of the two 
NADPH-producing dehydrogenases G6PD and 6PGD 105. Also, a MDR human T-
lymphoblastoid model showed higher levels of GSH and G6PD activity than the sensitive 
counterpart 59. Recently, it was described that the overexpression of G6PD induces 
doxorubicin resistance in cells, which could sugest that the activation of PPP may contribute 
for an acquired MDR phenotype 106. Furthermore drug-resistant cells are more sensitive to 
G6PD inhibition than their sensitive counterpart cells  107. Therefore, it may be hypothesized 
that the detoxification mechanism for which PPP is responsible could be contributing to 
maintain the MDR phenotype. 
However, it was also described that drug resistant cells may have similar or lower 
levels of G6PD and PPP than the drug sensitive counterparts 108-111. Actually, for some 
chemotherapeutic drugs, a lower activity of G6PD could be in theory beneficial. The cells 
with low G6PD-mediated synthesis of NADPH may have advantage because, during 
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anthracycline-induced oxidative stress, the NADPH produced by G6PD could be used by 
cytochrome P450 reductase, thus triggering the conversion of doxorubicin and 
mitoxantrone to their toxic metabolites 112,113. In general, since MDR relies on different 
mechanisms, the activation or inactivation of the PPP may have opposite effects, depending 
on the drug used, the tumour type and the molecular mechanism of MDR predominant in 
the model.   
 
1.3.3.  The Glutathione (GSH) Metabolism 
 
Glutathione (GSH) is one of the most important antioxidants in the cell and has an 
important role in cell physiology, both in a normal state (e.g. in cell proliferation, apoptosis, 
immune response) and in disease (e.g. cancer, liver diseases, Parkinson disease) 114. GSH 
modulates the cellular response to redox changes, detoxifies drug metabolites, regulates 
gene expression and apoptosis and is involved in the transmembrane transport of organic 
solutes 115. Alterations in the GSH cellular pool may contribute to the accumulation of ROS 
produced by the cells, by generating an imbalance between oxidative and antioxidant 
molecules 116 (Figure 4). GSH metabolism may occur in all cell types, with the liver being 
the major producer and exporter of GSH 117. 
 
 
 
 
 
 
 
  
Figure 4 – Glutathione metabolism. The synthesis of GSH from glutamate, cysteine, and glycine 
is catalyzed sequentially by two cytosolic enzymes, the glutamylcysteine synthetase (GCS) and the 
GSH synthetase. GSH – Reduced glutathione; GSSG – Oxidized Glutathione. 
 
One of the mechanisms involved in MDR cellular acquisition by cancer cells involves the 
overexpression of enzymes responsible for the detoxification of the cell, which could inhibit 
the cytotoxic effect of antitumor drugs. In fact, several drugs which are currently used in the 
clinic (e.g. alkylating agents) are known substrates of glutathione S- transferases (GSTs) 
118. In addition, a close association between high levels of GSH and GSTs and the 
development of MDR in cancer cells has already been demonstrated 119. Moreover, an 
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association between P-gp and high level activity of the GST enzyme was reported in an 
abundant number of MDR cell lines 120. So, the therapeutic use of GST inhibitors may 
become an important way to counteract the MDR phenotype, as it has been already 
demonstrated by treating MDR cells with several GST inhibitors (e.g. ethacrynic acid and 
TLK199), sensitizing MDR cells to chemotherapy 121.  
 Another important role for GSH in MDR is its contribution for the transport activities 
(transport of several compounds after being associated with GSH) of some drug efflux 
pumps from the MRP family. In fact, drug resistance in MRP1-overexpressing cells was 
partially reversed when using an inhibitor of the GSH synthesis 122.  
 
 
1.3.4.  Methionine/ S-adenosylmethionine (SAMe) pathway 
 
 The methionine pathway is found in all types of organisms. Methionine has four 
major functions, being 123: i) required for protein synthesis; ii) a precursor of glutathione 124; 
iii) required for the formation of polyamines; and iv) a major source of methyl groups for 
methylation of DNA and other molecules 125. 
In particular, methionine plays a fundamental role in transmethylation reactions, 
being required for S-adenosylmethionine (SAMe) synthesis 126,127. SAMe is the predominant 
biological methyl group donor by methyltransferases, and plays a key role in hundreds of 
biochemical and physiological reactions 128. Cellular transmethylation reactions use the 
active methyl group of SAMe (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – Methionine metabolism. SAMe donates its methyl group and the resulting product is S-
adenosylhomocysteine (SAH). Both produced metabolites in the methylation SAMe-dependent 
reaction, MTA and S-adenosylhomocysteine, are recycled back to methionine via homocysteine in 
the methionine cycle 129. MAT – methionine-S adenosyltransferase; SAMe - S-adenosylmethionine; 
MTase – methyltransferases; SAH - S-adenosylhomocysteine; THF – tetrahydrofolate; mTHF – 5-
methyltetrahydrofolate. 
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Since the metabolic cycling of methionine is a key pathway for many methylation 
reactions, alterations in the methionine pathway are implicated in several diseases including 
cancer 130. The interface between epigenetics and metabolism is a new possibility for the 
discovery of new cancer therapeutic targets 131. Many tumour cells have an absolute need 
for methionine, whereas normal cells are relatively resistant to exogenous methionine 
restriction. In fact, it was described that an increase in the methylation index could be 
associated with the onset of hepatocellular carcinoma 132.  Therefore, inhibitors of the 
methionine cycle in cancer cells could result in novel and efficient anticancer therapies 
131,133. 
Furthermore, cancer resistance to general chemotherapeutics and their ability to 
evade apoptosis are related to the high activity of the methionine cycle in these cells (which 
permits the methylation of specific genes and activation of multiple survival pathways) 
130,134,135. In fact, when using a methylation inhibitor in a MDR acute lymphoblastic leukaemia 
cell line, it was possible to revert drug resistance 136. Moreover, treatment of MDR 
hepatocellular carcinoma cells with cobalamin (a methylation inhibitor) downregulated P-gp 
expression due to the increase in the production of SAMe and phosphatidylcholine 137. 
These results indicate that the development of resistance could also be methylation-
dependent. 
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1.4. Intercellular transfer of MDR by extracellular vesicles 
(EVs) 
 
An extracellular vesicle secretion pathway was first described in the early 1980s, 
when cells from different organisms were found capable of releasing EVs into the 
extracellular environment. During the past few years, EVs have been isolated from several 
body fluids such as blood, urine, saliva, amniotic fluid, breast milk, bile, semen, ascites and 
cerebrospinal fluid 138,139,140. The origin of these vesicles is diverse and they have been 
named differently according to their biogenesis, cargo and size.  
In the majority of the studies on the biochemical composition of EVs, a bulk of mixed 
populations of vesicles (obtained by ultracentrifugation) is analyzed. As a consequence, the 
correct composition and molecular markers of each type of EV is currently unknown 140. 
Due to the diversity in the EVs secreted by cells and since the nomenclature is still being 
debated 141, the scientific experts in EVs are alerting to the need of describing the detailed 
methodology used in their isolation.  
 
Nonetheless, it is accepted that there are three main classes of EVs: 
A) Exosomes 
The term exosome was first proposed in 1987 to define EVs with endosomal origin 
142. Exosomes are derived from the endosomal pathway and have sizes ranging from 30 to 
100 nm 143. Exosomes are formed by their release from late endosomal compartments to 
the plasma membrane, through the fusion of multivesicular bodies. The key step in 
exosome biogenesis is the reorganization of endosomal membrane proteins (CD9 and 
CD63) into microdomains. Next, endosomal sorting complexes required for transport 
(ESCRTs) are recruited to the site of budding. ESCRT-I and -II drive endosomal membrane 
budding via Alix, that simultaneously binds to TSG101 (component of the ESCRT-I) and 
CHMP4 (component of ESCRT-III) 143,144.  
Their exosomal membrane is enriched in phosphatidylserine (because of its origin) 
and several markers have been described such as tetraspanins, ESCRT components, 
TSG110, Alix and Flotilin 144. ALIX is one of the best well known molecular markers of 
exosomes; however, several recent Western blot studies have shown different bands for 
this protein, which could lead to misleading interpretations of data 145-147. 
 
B) Microvesicles 
Microvesicles are larger vesicles, with sizes ranging from 50 to 2000 nm, generated 
by budding from the plasma membrane 143. They were first characterized as products of 
activated blood platelets and erythrocytes 148. The microvesicle membrane is more similar 
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to the parental cell membrane than the exosomal membrane and presents different specific 
markers (e.g. integrins, selectins and CD40 ligand) 144. 
An usually accepted hypothesis for the microvesicles biogenesis consists in 
induction of microvesicles formation by translocation of phosphatidylserine to the outer-
membrane leaflet through the activity of flippases, leading to a typical plasma membrane 
curvature 149. Most of the proteins involved in this process (e.g. ARF6 and PLD2) are 
different from the ones involved in exosome biogenesis.  
 
C) Apoptotic bodies 
Apoptotic bodies are generated through budding of the apoptotic cells plasma 
membrane and have sizes ranging from 500 to 2000 nm 143. They have extensive amounts 
of phosphatidylserine and their content is mostly nuclear fractions and cell organelles 144. 
 
 
The EVs cargo is not a reflection of the donor cell composition but the result of a 
regulated sorting mechanism 150. The nature (and abundance) of the EVs cargo depends 
on the type and physiological or pathological condition of the donor cell and the specific 
biogenesis pathway that leads to the formation of each type of EVs 151. All the cargo proteins 
and RNAs which have been described in EVs, are included in public databases such as 
Vesiclepedia and Evpedia 152,153. The EVs cargo is highly heterogeneous since they can 
contain proteins (from the plasma membrane, the endocytic pathway or the cytosol), nucleic 
acids (fragments of DNA, mRNAs and microRNAs) and lipids (cholesterol, diglycerides, 
sphingolipids, phospholipids and glycerophospholipids) 154. 
After their formation, EVs are released into the extracellular environment by several 
mechanisms. Several molecules are involved in this process, such as: i) ceramide (that 
accumulates in the membrane of the EVs) 155, ii) Ca2+ -dependent scramblase (that allows 
the exchange of phospholipids between the two leaflets to increase membrane curvature, 
in order to facilitate the release of the EVs) 156, iii) annexin-2 156, iv) chromosome 
segregation 1-like protein 157 and v) hyaluronan synthase 158. 
After being released, EVs are capable of transferring their cargo to other cells by 
different approaches. While some release their contents into the extracellular space after 
breaking down 159, others, which maintain their structure for longer periods, are capable of 
circulating in several fluids (such as blood and lymph) and reach a target cell 160. 
Furthermore, after their release, EVs do not randomly  interact with recipient cells, often 
presenting preference for certain target cells 161. Upon contact, EVs roll over the plasma 
membrane, followed by the binding of specific membrane proteins (from the syncytin-1 
family) to their cell receptors (ASCT2). The membrane binding is then converted rapidly into 
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fusion (in a similar way to what happens with retroviruses). Specifically, proteins from the 
EVs membranes are structurally rearranged and their hydrophobic sequences are inserted 
into the target cell plasma membrane, which suffers lipid and protein reorganization 162,163. 
Interestingly, the interaction between EVs and target cells occurs not only by membrane 
fusion, but also by an active process, a specific type of endocytosis 164. Once inside the 
recipient cell, EVs fit within clathrin vesicles and might fuse with the endosome membrane 
and discharge their contents into the cytoplasm. Alternatively, they may be retained within 
the endosome lumen or may be targeted to lysosomes for degradation 164. 
EVs are important multifunctional signaling complexes for the control of fundamental 
cellular and biological functions, by participating in the maintenance of normal physiology 
165, such as stem cell maintenance 166, tissue repair 167, immune surveillance 168 and blood 
coagulation 169. Such a wide-range of cellular and biological functions indicates that EVs 
may have an important role in disease 165. One of the best understood roles for EVs in 
disease is in cancer, which has been studied over the past 17 years. EVs are secreted by 
most type of cancer cells including leukaemia, melanoma, ovarian, lung, prostate, breast 
and colorectal cancer. The specific functions of EVs in cancer include participation in the 
following processes: proliferation, extracellular matrix remodeling, invasion, migration, 
angiogenesis and the metastatic cascade. Also, EVs from tumour cells can also mediate 
drug resistance and immunosuppression 170-172. 
 Recently, several studies have identified EVs as important mediators of the 
dissemination of cancer drug resistance traits 173-176, by two main mechanisms. The first 
mechanism consists in the sequestration of drugs by the EVs, making them unavailable to 
the target cancer cells 177. The second mechanism consists in the intercellular transfer of 
MDR mediators, by EVs, from MDR (donor) cells to drug-sensitive (recipient) cells (Figure 
6). Following this transfer, drug-sensitive recipient cells may acquire a more resistant 
phenotype, similar to the one of the MDR donor cells. Indeed, several players associated 
with MDR in cancer may be transferred by EVs, being considered responsible for the 
transfer of a MDR phenotype. Some of the described components of the EVs cargo which 
are known to be responsible for the intercellular transfer of a MDR phenotype are drug-
efflux pumps (such as P-gp), microRNAs and lncRNAs (Figure 6) 178. 
 The transfer of P-gp (in a MDR context) was first shown in a neuroblastoma model, 
in which the drug-sensitive cells acquired functional P-gp after co-culture of these cells with 
the MDR counterpart cells (with overexpression of P-gp) 179. By acquiring functional P-gp, 
the drug-sensitive cells became resistant, and the resistant phenotype persisted for 4 
months 179. Having these results into account, Bebawy and colleagues 180 demonstrated for 
the first time, by flow cytometry, that functional P-gp may be transferred by EVs. These 
authors showed that EVs transfer P-gp from resistant to drug-sensitive human acute 
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lymphoblastic leukaemia cells. A subsequent study described the role of EVs in transferring 
P-gp, which was associated with docetaxel-resistance, in prostate cancer cells 180. The 
importance of P-gp transfer by EVs was also confirmed in breast cancer cells 172 and ovarian 
cancer cells 181. Interestingly, besides showing the P-gp transfer between docetaxel-
resistant breast cancer cells and their drug-sensitive counterparts, the authors also showed 
an increase in the P-gp levels of the recipient cells which was proportional to the amount of 
EVs co-cultured with those cells 172. The transfer of P-gp was also confirmed in vivo 173,179. 
For example, Lechvenko and co-workers used a neuroblastoma xenograft mouse model of 
drug-sensitive cells, drug-resistant cells and a mixture of the two populations to show P-gp 
transfer in vivo 179. Interestingly, they showed that the transfer of P-gp in vivo was more 
effective than in vitro 179, which could indicate higher efficiency of P-gp transfer by EVs in a 
more physiological environment. 
 In summary, P-gp carried by EVs plays a prominent role in the intercellular transfer 
of MDR, by providing the receiving cells with means to efflux chemotherapeutic drugs.   
  
 
 
 
 
 
 
 
 
 
Figure 6 – Intercellular transfer of P-gp mediated MDR by extracellular vesicles (EVs) in 
cancer. 
 
Several studies have associated metabolic alterations with the shedding and cargo 
of extracellular vesicles (EVs) 182,183,184. Following these results, a set of evidence supporting 
a role for EVs in drug metabolism was provided by several proteomic studies, which have 
revealed the presence of different xenobiotic metabolizing enzymes on EVs. For example, 
in a recent study, proteomic analysis allowed the identification of several proteins related to 
drug metabolism in the cargo of EVs 185. 
Recently, other studies have highlighted the relevance of EVs in drug metabolism 
since it was shown that an increase of lactate production 182 may be associated with the 
release of EVs, and that EVs are responsible for the transfer of metabolic alterations such 
as the inhibition of glutamine metabolism 183 and alterations in the glucose metabolism 184. 
 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part II – Rationale and Aims 
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Multidrug resistance (MDR) presents a serious challenge to the efficacy of cancer 
treatment. As previously mentioned, MDR is a complex phenomenon involving several 
independent or interconnected mechanisms, with overexpression of drug efflux pumps such 
as P-glycoprotein (P-gp) playing a significant role 39. In addition, it has been documented 
that the release of extracellular vesicles (EVs) by MDR cells allows the transfer of their 
cargo (shed by the releasing/donor cells) to recipient drug-sensitive cells. This EVs-
mediated process appears to be relevant for the transfer of the MDR phenotype from MDR 
to drug-sensitive cells 180,186,187. Moreover, since EVs contain a tissue-disease-type 
signature, consisting of a cargo of proteins and nucleic acids selectively packaged into the 
EVs membrane structure that protects the luminal contents from protease degradation 188, 
EVs could function as excellent molecular targets and biomarkers, namely of MDR. 
To date, there are no clinically-available drugs to counteract the MDR phenotype 
caused by P-gp 189, which justifies the demand for identifying novel molecular targets and 
novel molecules to counteract P-gp mediated MDR. In addition, there is no minimally-
invasive means to diagnose MDR using non-tumour biological samples 189, which justifies 
the need for identifying novel biomarkers of P-gp mediated MDR.  
 
 
Thus the aims of the present work were to: 
 
 
1. Identify new targets for overcoming P-gp mediated MDR in cancer  
 
To address this main objective, two lines of research were followed:  
 
 
1.1.  Identify metabolic alterations associated with the P-gp mediated MDR 
phenotype  
To address this issue, two pairs of MDR and their drug-sensitive counterpart cell 
lines, from two different cancer models (chronic myeloid leukaemia and non-
small cell lung cancer) were analyzed by proteomics, using label-free liquid 
chromatography - mass spectrometry quantitative profiling. The obtained results 
were further validated by different assays (such as Western blot or analysis of 
GSH and ROS levels). Furthermore, all these cell lines were metabolically 
profiled using the Seahorse technology.  
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1.2.  Verify if the identified metabolic alterations are transferred by EVs 
from MDR cells to drug-sensitive cells 
In order to address this question, the drug-sensitive cancer cell lines were 
profiled using the Seahorse technology, to analyze possible alterations in the 
glycolytic pathway, following co-culture with EVs shed by MDR cells. 
 
 
2. Identify potential biomarkers of MDR in EVs released by cancer cells 
 
In order to study the relevance of EVs as possible biomarkers of MDR, the cell lines 
and their respective EVs were profiled according to their size and specific protein 
content. 
 
 
3. Find novel molecules to overcome MDR, by identifying curcumin derivatives 
with improved P-gp inhibitory effect   
 
New curcumin derivatives were synthesized by our collaborators (from 
FFUP/CIIMAR) and their biological activity was studied, in terms of antitumor activity 
and anti-P-gp activity. Further identification of compounds with dual activity 
(antitumor and anti-P-gp) was also carried out. 
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Abstract  
 
Multidrug resistance (MDR) is a serious obstacle to efficient cancer treatment. 
Overexpression of P-glycoprotein (P-gp) plays a significant role in MDR. Recent studies 
proved that targeting cellular metabolism could sensitize MDR cells. In addition, metabolic 
alterations could affect the extracellular vesicles (EVs) cargo and release. This study aimed 
to: i) identify metabolic alterations in P-gp overexpressing cells that could be involved in the 
development of MDR and, ii) identify a potential role for the EVs in the acquisition of the 
MDR. Two different pairs of MDR and their drug-sensitive counterpart cancer cell lines were 
used. Our results showed that MDR (P-gp overexpressing) cells have a different metabolic 
profile from their drug-sensitive counterparts, demonstrating decreases in the pentose 
phosphate pathway and oxidative phosphorylation rate; increases in glutathione 
metabolism and glycolysis; and alterations in the methionine/S-adenosylmethionine 
pathway. Remarkably, EVs from MDR cells were capable of stimulating a metabolic switch 
in the drug-sensitive cancer cells, towards a MDR phenotype. In conclusion, obtained 
results contribute to the growing knowledge about metabolic alterations in MDR cells and 
the role of EVs in the intercellular transfer of MDR. The specific metabolic alterations 
identified in this study may be further developed as targets for overcoming MDR.  
 
	
	
	
	
	
	
	
	
Keywords: Multidrug Resistance; P-glycoprotein; Metabolism; Glycolysis; OXPHOS; 
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Introduction 
The development of multidrug resistance (MDR) in cancer is a serious impediment 
to treatment success. MDR is defined as a phenotype of the cells resistant to multiple 
structurally and functionally different drugs. Such resistance is multifactorial and may be 
due to various mechanisms 1,2. There are several important mechanisms involved in MDR 
whose identification has generated valuable information on how to circumvent MDR and 
improve chemotherapy treatment.  
One of the most important known mechanism is the overexpression of ATP-binding 
cassette (ABC) transporters, commonly known as drug efflux pumps, such as P-
glycoprotein (P-gp) 2, which is frequently overexpressed in cancer 3. P-gp transports drug-
substrates across the cell membrane, thus decreasing their intracellular concentrations to 
sub-lethal 4. 
 Several studies pointed to a relation between MDR and alterations in cellular 
metabolism: i) upregulation of hypoxia-induced factor 1 (HIF-1) was shown to be associated 
with chemoresistance 5; ii) leukaemia models with higher glycolytic rates were resistant to 
glucocorticoids 6; iii) modulation of cellular metabolic pathways was demonstrated to 
contribute to acquired resistance in multiple myeloma cells 7; iv) glycolytic pyruvate was 
capable of regulating P-gp expression in multicellular tumour spheroids 8;  and v) hypoxia 
was shown to induceMDR and glycolysis in an orthotopic MDR tumour model in nude mice 
9. Ultimatelly, these studies may contribute to  understanding how MDR could be 
circumvented by application of specific metabolic modulators and inhibitors. Therefore, it is 
important to identify metabolic alterations in MDR cancer cells, which could lead to the 
identification of new metabolic molecular targets to circumvent MDR in cancer. 
The formation of Extracellular vesicles (EVs) and their release have been implicated 
in pathological processes such as cancer 10-12 and shown to be relevant for the intercellular 
transfer of a drug-resistant phenotype 12-14. Indeed, drug-sensitive cancer cells can become 
drug-resistant following intracellular incorporation of EVs shed by drug-resistant cancer 
cells 13-16. We have previously shown that the EVs population shed by MDR cells is different 
from the one shed by drug-sensitive counterpart cells, thus suggesting that MDR cells 
produce more microvesicles and less exosomes than their drug-sensitive counterpart cells 
17. In addition, several studies have stated that metabolic alterations in cancer cells could 
induce alterations in the EVs’ cargo and its release 18-20. So far, it is unclear if these 
metabolic alterations are caused by or could be responsible for the MDR phenotype. 
Here we provide evidence that MDR cancer cell lines (overexpressing P-gp) 
acquired a different metabolic profile from their drug-sensitive counterpart cells and that the 
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EVs released by MDR cells caused a metabolic switch towards the MDR phenotype in the 
recipient cells. 
 
Results 
 
Protein profiling and bioinformatics analysis of MDR and drug-sensitive counterpart 
cell lines identified differentially expressed proteins (DEPs) 
For protein profiling, each of the four biological replicates of each condition was run 
by LC–MS. The data was transferred to Progenesis QI for proteomics to compare drug-
sensitive cancer cells (K562 and NCI-H460) with their MDR counterparts (K562Dox and 
NCI-H460/R). Individual comparisons were carried out for each pair of cell lines: K562 
versus K562Dox and NCI-H460 versus NCI-H460/R. Following Progenesis LC–MS 
analysis, peptide features with ANOVA<0.05 and 1+, 2+ and 3+ charge states were 
subjected to MASCOT database searching. The MASCOT mgf files were then resubmitted 
to the Progenesis software to yield a list of identified proteins. These lists were further 
interrogated to exclude proteins with less than 2 peptides matched, a fold change <1.5 and 
not statistically significant.  
A total of 91 significant (p < 0.05) differentially expressed proteins (DEPs) were 
identified when comparing the K562 vs. K562Dox cells and 67 significant DEPs (p < 0.05) 
were identified when comparing the NCI-H460 vs. NCI-H460/R cells. A full list of the DEPs 
identified for each cell line is available in the Supplementary Information (Tables S1 and 
S2). 
 
Gene Ontology (GO) bioinformatics analysis indicated that the greatest difference 
between MDR cells and their drug-sensitive counterparts occurred in metabolic 
processes 
 Using the Database for Annotation, Visualization and Integrated Discovery (DAVID) 
network analysis tool, the molecular functions/localizations of the DEPs data sets were 
analyzed according to GO functional annotations and categories. GO analysis of cellular 
components, molecular functions and biological processes were performed on the 91 DEPs 
(K562 vs. K562Dox) and 67 DEPs (NCI-H460 vs. NCI-H460/R) identified with the 
Progenesis software. Pie diagrams represent the GO analysis of the identified DEPs (Fig. 
1). The GO analysis revealed that most of the DEPs (for both cancer cell models) have 
cytoplasmic origin (42% in K562 vs. K562Dox and 44% in NCI-H460 vs. NCI-H460/R), 
cytoskeleton origin (17% for both models) and membrane localization (6% in K562 vs. 
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K562Dox and 5% in NCI-H460 vs. NCI-H460/R) (Fig.1A). The functional classification of 
these proteins from both cancer cell models implied that they are mostly involved in catalytic 
activities, structure molecule activities and protein binding activities (Fig.1B). Noteworthy, 
analysis of the biological processes indicated that the greatest difference between the MDR 
cells and their drug-sensitive counterparts occurred in metabolic processes (50% in K562 
vs. K562Dox and 63% in NCI-H460 vs. NCI-H460/R) (Fig.1C). The remaining different 
biological processes were associated with transport, development processes and cell 
organization and biogenesis. 
 
 
 
 
Figure 1 – GO analysis of all the differentially expressed proteins (DEPs) identified with the 
Progenesis QI software in both pairs of counterpart drug-sensitive and MDR cancer cell lines: 
K562 versus K562Dox and NCI-H460 versus NCI-H460/R. A) GO - Cellular component analysis 
of the identified proteins; B) GO - Molecular functional analysis of the identified proteins; and C) GO 
- Biological process analysis of the identified proteins. 
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KEGG pathway enrichment analysis indicated that the most significant active 
pathways enriched in the MDR cells were involved in metabolic processes 
 Following the identification of the DEPs, the most significant active pathways were 
analysed using KEGG pathway enrichment analysis. Results indicated that the most 
significantly active pathways enriched in the MDR cells were those involved in metabolic 
processes. The glutathione metabolism (GSH), pentose phosphate pathway (PPP) and 
glycolysis were found to be the most enriched pathways identified in both cancer cell models 
(Table 1). In the chronic myeloid leukaemia model (K562Dox) the following 4 DEPs were 
found to be involved in the GSH metabolism pathway (G6PD, PRDX2, IDH1 and 6PGD), 3 
DEPs in the PPP pathway (G6PD, ALDOC and 6PGD) and 2 DEPs in the glycolysis 
pathway (ALDOC and PKM2). In the non-small cell lung cancer model the following 5 DEPs 
were found to be involved in the GSH metabolism pathway (G6PD, PRDX2, IDH1, MGST1 
and 6PGD), 4 DEPs in the PPP pathway (G6PD, TALDO1, TKT and 6PGD) and 1 DEP 
involved in the glycolysis pathway (ALDH3A1) (Table 1). 
 
 
Table 1 | Metabolic pathways found enriched with DEPs in MDR cells  
 
 Term Count a ANOVA (P) Genes Symbol 
K562 vs. 
K562Dox 
Glutathione metabolism 4 0.0086 G6PD, PRDX2, IDH1, 6PGD 
Pentose phosphate pathway 3 0.0025 G6PD, ALDOC, 6PGD 
Glycolysis 2 0.01 ALDOC, PKM2 
NCI-H460 vs. 
NCI-H460/R 
Glutathione metabolism 5 0.00064 G6PD, 6PGD. IDH1, MGST1, PRDX2 
Pentose phosphate pathway 4 0.00099 G6PD, 6PGD, TKT, TALDO1 
Glycolysis 1 nd ALDH3A1 
 
Results were analyzed with DAVID software for KEGG pathway enrichment 
a Number of proteins involved in each pathway 
nd – no data 
 
Other DEPs involved in MDR and metabolic processes were identified by 
bioinformatics analysis 
 In addition to the DEPs referred above (Table 1) other DEPs also involved in 
metabolic process and MDR were analyzed in terms of normalized abundance between 
MDR and drug-sensitive counterpart cells (for both cancer cell models) (Table 2).  
The DEP with the highest fold change was P-gp, which was upregulated in 
both MDR cells with a fold change of 18.8 for K562Dox vs. K562 and 64.5 for NCI-
H460/R vs. NCI-H460. In terms of metabolic processes, most of the DEPs involved in the 
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PPP pathway were downregulated in the two MDR models (ALDOC, G6PD, 6PGD and 
TKT) and only TALDO1 was upregulated in the NCI-H460/R cells (Table 2). Regarding GSH 
metabolism, the enzymes responsible for the NADP+ reduction to NADPH (G6PD, 6PGD 
and IDH1) were downregulated in the MDR cells but MGST1 was upregulated in NCI-
H460/R cells. Regarding glycolysis, ALDOC was downregulated in MDR cells but the 
enzyme responsible for the pyruvate production (PKM2) was upregulated. Additionally, 
DEPs involved in the TCA cycle were also identified (ACLY and ACO2). ACLY was 
upregulated whereas ACO2 was downregulated in the MDR cancer cell models (Table 2). 
Interestingly HIOU1 and NDRG1 (both involved in cellular response to hypoxia) and 
MTHFD1 (an enzyme involved in the methionine pathway) were upregulated in the MDR 
cells (Table 2). 
 
Table 2 | DEPs involved in MDR and metabolic processes  
 
aMDR cells/ Drug-sensitive cells 
 
 
 UniProt 
accession 
no. 
Protein description Gene Symbol Peptides 
Mascot 
Score ANOVA (P) 
Fold 
Change a 
K562 vs. 
K562Dox 
Increased 
in MDR 
cells 
P08183 P-glycoprotein MDR1 6 404.08 1.24e-009 18.80 
Q9Y4L1 Hypoxia up-regulated protein 1 HYOU1 4 282.01 3.19e-005 2.05 
Q92597 Protein NDRG1 NDRG1 2 118.12 4.32e-006 1.84 
P53396 ATP-citrate synthase ACLY 5 289.70 7.19e-006 1.84 
P14618 Pyruvate kinase PKM2 10 706,77 4,25E-03 1.52 
P11586 C-1-tetrahydrofolate synthase MTHFD1 2 97,89 9,83E-04 1.51 
Decreased 
in MDR 
cells 
P09972 Fructose-bisphosphate aldolase C ALDOC 7 550.98 0.01 0.66 
P52209 6-phosphogluconate dehydrogenase 6PGD 2 111,38 2,84E-03 0.65 
O75874 Isocitrate dehydrogenase IDH1 3 218,56 2,63E-05 0.65 
P32119 Peroxiredoxin-2 PRDX2 5 372.45 1.35e-003 0.60 
P11413 Glucose-6-phosphate 1-dehydrogenase G6PD 4 250.70 7.79e-007 0.39 
NCI-H460 vs. 
NCI-H460/R 
Increased  
in MDR 
cells 
P08183 Multidrug resistance protein 1 MDR1 2 175.04 9.14E-06 64.52 
P10620 Microsomal glutathione S-transferase 1 MGST1 2 105,19 1.33e-004 1.80 
P37837 Transaldolase TALDO1 2 116.98 4.64e-004 1.53 
Decreased 
in MDR 
cells 
O75874 Isocitrate dehydrogenase IDH1 4 327.28 7.79E-05 0.66 
Q99798 Aconitate hydratase, mitochondrial ACO2 2 132,35 2.38e-003 0.63 
P29401 Transketolase TKT 8 489.12 7.25e-005 0.60 
P52209 6-phosphogluconate dehydrogenase 6PGD 7 570.89 3.89E-06 0.54 
P32119 Peroxiredoxin-2 PRDX2 2 133.35 0.02 0.52 
P11413 Glucose-6-phosphate 1-dehydrogenase G6PD 13 1012.1 1.22E-06 0.41 
P30838 Aldehyde dehydrogenase ALDH3A1 6 352,67 1.74e-005 0.40 
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 Results obtained by quantitative label-free proteomic approach were validated by 
Western blot 
 The expression of P-gp, G6PD, 6PGD and IDH1 were further validated by Western 
blot. We focused the validation on DEPs involved in MDR, glutathione metabolism and 
pentose phosphate pathway. Consistent with the results obtained with the proteomic 
analysis, P-gp was found upregulated while G6PD, 6PGD and IDH1 were downregulated 
in the MDR cells (K562Dox and NCI-H460/R) when compared with their drug-sensitive 
counterpart cells (K562 and NCI-H460) (Fig.2). 
   
 
 
 
 
 
 
Figure 2 – Validation by Western blot analysis of some DEPs initially identified by quantitative 
proteomics. Representative blots were chosen from three independent experiments. Actin was used 
as a loading control. 
 
MDR cells presented higher levels of reduced glutathione (GSH) and lower levels of 
reactive oxygen species (ROS)  
Since most of the proteins that had been identified as DEPs in MDR cells were 
related to metabolic processes such as GSH metabolism and PPP, the GSH (one of the 
main detoxification agents in the cell) and ROS levels were analyzed in both tumour models. 
MDR cells (K562Dox and NCI-H460/R) presented significantly higher levels of GSH 
when compared to their drug-sensitive counterpart cells (K562 and NCI-H460) (Fig. 3A, B). 
In agreement with this higher capacity provided by the higher levels of GSH to respond to 
oxidative stress, MDR cells presented lower levels of ROS when compared to their drug-
sensitive counterpart cells (Fig. 3 C, D). 
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Figure 3 – Comparison of GSH and ROS levels between drug-sensitive and MDR cancer cell 
lines. A) GSH levels in K562 and K562Dox cells. B) GSH levels in NCI-H460 and NCI-H460/R cells. 
GSH levels are represented as Relative Luminescence Units (RLU). C) ROS levels in K562 and 
K562Dox cells. D) ROS levels in NCI-H460 and NCI-H460/R cells. The ROS levels are represented 
as mean fluorescence. Staurosporine was used as a positive control. Results are the mean ± SEM 
of 3 independent experiments. * p ≤ 0.05 and ** p ≤ 0.01. 
 
 
Changes in methionine/S-adenosylmethionine pathway were identified in the MDR 
cancer cells  
 As we found GSH significantly increased in MDR cells, we were also interested in 
studying the metabolic pathways involved in the biosynthesis of GSH. The main cellular 
pathway that generates precursor for the synthesis of GSH corresponds to the 
methionine/S-adenosylmethionine (SAMe) pathway. By UPLC-MS metabolomics 21 we 
have quantified metabolites belonging to this pathway in the MDR and their drug-sensitive 
counterpart cells (Table 3 and Table S3). Methionine was upregulated in both MDR cancer 
cells. On the contrary, S-adenosylhomocysteine (SAH) and spermidine were 
downregulated in both MDR cancer cell lines (K562Dox and NCI-H460/R) (Table 3). In 
addition, no alterations in S-adenosylmethionine (SAMe) were found in both cancer cell 
models (Table 3). Some other metabolites were found altered (such as 5´-deoxy-5´-
methylthioadenosine (MTA, dcSAMe, Betaine, Choline and Serine) but in different manners 
between the two cancer models. 
 Furthermore, the methylation index (SAMe/SAH), which represents the methylation 
capacity of the cells, was higher in MDR cells. In the chronic myeloid leukaemia model, 
K562 cells had a methylation index of 6.97, whereas the methylation index for K562Dox 
cells was 12.05. In the non-small cell lung cancer model, NCI-H460 cells had a methylation 
index of 2.43 whereas the methylation index for NCI-H460/R cells was 9.79. 
 
		76	
RESULTS  AND  D ISC USSION  
Table 3 | Semi-quantitative analysis of metabolites of the methionine/ SAMe pathway 
in two pairs of MDR and their drug-sensitive counterpart cell lines 
 
 
 
a MDR cells / drug-sensitive cells 
 
 
MDR cells (NCI-H460/R) showed an increase in the non-glycolytic acidification, 
glycolysis, glycolytic capacity and glycolytic reserve 
 In order to gain new insights into the metabolic phenotype of MDR cells, the 
extracellular acidification rate (ECAR), which reflects the rate of glycolysis, and the oxygen 
consumption rate (OCR), which reflects the rate of oxidative phosphorylation (OXPHOS), 
were measured in both MDR and sensitive cancer cell cells. Measurements were performed 
 Metabolite description Fold change a 
ANOVA 
(P) 
K562 vs. K562Dox 
Methionine 1.54  2,25E-05  
5´-deoxy-5´-methylthioadenosine (MTA) 1.44  8,37E-04  
S-adenosylhomocysteine (SAH) 0.57  7,67E-06  
S-adenosylmethionine (SAMe) 0.99 8,49E-01  
Spermidine 0.85  3,68E-03  
Betaine 1.02 4,79E-01 
 
Choline 0.63 3,48E-06  
Decarboxylated S-adenosyl methionine (dc-SAMe) 1.42 4,72E-05  
Serine 0.50 0 
Threonine 0.99 8,59E-01  
NCI-H460 vs. NCI-H460/R 
Methionine 1.91  
 
3,55E-05 
 
5´-deoxy-5´-methylthioadenosine (MTA) 1.13 1,44E-01  
S-adenosylhomocysteine (SAH) 0.25  2,42E-05  
S-adenosylmethionine (SAMe) 0.99 7,85E-01 
 
Spermidine 0.81  1,33E-02  
Betaine 1.71 2,78E-04  
Choline 5.94 2,54E-07  
Decarboxylated S-adenosyl methionine (dc-SAMe) 0.50 1,79E-04  
Serine 1.04 1,78E-01  
Threonine 0.99 8,15E-01  
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in both, basal cellular state and after treatments with compounds capable of modulating 
glycolysis and OXPHOS. 
 To analyze the glycolytic function, a glycolysis stress test was performed. The ECAR 
was measured in cells treated sequentially with: their glucose-free assay media as a control 
(Fig. 4A, blue line A); then with glucose to allow the cells to enter into glycolysis (Fig. 4A, 
blue line B); next with olygomycin (an ATP coupler) in order to inhibit ATP synthesis by 
blocking the proton channel and shifting the energy production to glycolysis (Fig. 4A, blue 
line C); and finally with 2-deoxyglucose (2-DG) which is a glucose analog that inhibits 
glycolysis through competitive binding to glucose hexokinase (Fig. 4A, blue line D). The 
resulting data allowed calculating the following parameters: Non-glycolytic acidification (= 
last rate measurement prior to glucose injection); Glycolysis (= maximum rate measurement 
before oligomycin injection – last rate measurement before glucose injection); Glycolytic 
capacity (= maximum rate measurement after oligomycin injection – last rate measurement 
before glucose injection); Glycolytic reserve (= glycolytic capacity – glycolysis).  
In terms of glycolytic function, the MDR cells (NCI-H460/R) showed a statistically 
significant increase in the non-glycolytic acidification, glycolysis, glycolytic capacity and 
glycolytic reserve, when compared to their drug-sensitive counterpart cells (NCI-H460) 
(Fig.4 A). 
 To analyse the mitochondrial respiration, a mitochondrial stress test was performed. 
The OCR was measured during cells’ treatment with: corresponding assay media (Fig. 4B, 
blue line A); then with olygomycin (Fig. 4B,  blue line B); next with FCCP [electron 
transporter chain  accelerator] that is an uncoupling agent which disrupts ATP synthesis 
leading to the collapse of the mitochondrial membrane potential and causing rapid 
consumption of energy and oxygen without the generation of ATP (Fig. 4B,  blue line C); 
and finally with rotenone (complex I inhibitor) which shuts down mitochondrial respiration 
by preventing the transfer of electrons from complex I to coenzyme Q (Fig. 4B,  blue line 
D). These modulators allowed to calculate the following parameters: Non-mitochondrial 
respiration (= minimum rate measurement after rotenone injection); Basal respiration (= last 
rate measurement before first injection - non-mitochondrial respiration rate); Maximal 
respiration (= maximum rate measurement after FCCP injection – non-mitochondrial 
respiration); Proton leak (= minimum rate measurement after olygomycin injection – non-
mitochondrial respiration); ATP production (= last rate measurement before olygomycin 
injection – minimum rate measurement after olygomycin injection); Spare capacity (= 
maximal respiration – basal respiration). 
 Regarding the mitochondrial respiration, the MDR cells showed a statistically 
significant decrease in the non-mitochondrial respiration, basal respiration, maximal 
respiration, proton leak, ATP production and spare capacity (Fig.4 B).  
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Figure 4 –Global metabolic differences between the NCI-H460 and NCI-H460/R counterpart 
cell lines. Cells were metabolically profiled using Seahorse XF-24 Analyser. A – Representative 
results of a glycolysis stress test, which measures extracellular acidification rate (ECAR) following 
addition of glucose-free media (blue line A), glucose (blue line B), oligomycin (blue line C) and 2-
deoxyglucose (blue line D). B - Representative results of a mitochondrial stress test, measuring the 
oxygen consumption rate (OCR) in glucose-containing media, following sequential addition of media 
(blue line A), oligomycin (blue line B), FCCP (blue line C) and rotenone (blue line D). Results are the 
mean ±SEM from three independent experiments, with four to eight replicates per experiment. *p £ 
0.05; **p £ 0.01; ***p £ 0.001 of NCI- H460 vs. NCI-H460/R cells. 
 
PPP inhibitor changed the metabolic phenotype of NCI-H460 cells towards the 
phenotype of their MDR counterparts (NCI-H460/R)  
 As aforementioned, sensitive cells possess more rate limiting enzymes of the PPP 
than their corresponding MDR cells (Tables 1 and 2 and Fig. 2). In addition, they showed a 
decrease in glycolytic parameters (Fig.4 A) and an increase in mitochondrial respiration 
(Fig. 4 B). In order to confirm that the PPP is involved in the MDR phenotype, NCI-H460 
cells (drug-sensitive) were treated with a sub-lethal concentration of dichloroacetate (DCA, 
a PPP inhibitor) and consequent alterations in glycolysis and OXPHOS were observed. 
After DCA treatment, the drug-sensitive cells acquired a metabolic phenotype similar to the 
one observed in the MDR cells, presenting an increase in glycolysis, glycolytic capacity and 
glycolytic reserve, and a decrease in their basal respiration, maximal respiration and ATP 
production by OXPHOS (Fig. 5). The MDR cells (NCI-H460/R) treated with DCA showed 
no changes in glycolytic function and mitochondrial respiration (data not shown).  
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Figure 5 – Alterations in NCI-H460 cell metabolism after treatment with a PPP inhibitor. NCI-
H460 cells were treated with 5 mM DCA for 24 h and subsequently metabolically profiled, using the 
Seahorse XF-24 Analyser. Data represent mean ± SEM from three independent experiments, with 
four replicates per experiment. *p £ 0.05; **p £ 0.01; NCI-H460 vs. NCI-H460+DCA. ECAR - 
extracellular acidification rate; OCR - oxygen consumption rate. 
P-gp inhibitor changed the metabolic phenotype of MDR cells (NCI-H460/R) towards 
the phenotype of their corresponding sensitive cells (NCI-H460) 
In order to confirm the possible influence of P-gp in the observed metabolic 
alterations of the MDR cells, the NCI-H460/R were treated with a sub-lethal concentration 
of a well-known P-gp inhibitor, verapamil, and the levels of glycolysis and OXPHOS were 
analyzed. After treatment with verapamil, the MDR cells acquired a metabolic phenotype 
more similar to the one observed in sensitive cells, presenting a decrease in glycolysis, 
glycolytic capacity, glycolytic reserve and non-glycolytic acidification, and an increase in 
their basal respiration (Fig. 6).  
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Figure 6 –  Alterations in the NCI-H460/R cellular metabolism after treatment with a P-gp 
inhibitor. NCI-H460/R cells were treated with 2 µM verapamil for 15 h  and subsequently 
metabolically profiled using the Seahorse XF-24 Analyser for measuring alterations in glycolysis, 
glycolytic capacity, glycolytic reserve, non-glycolytic acidification, basal respiration, maximal 
respiration and non-mitochondrial respiration. Data represent three independent experiments, with 
four replicates per experiment. *p £ 0.05; **p £ 0.01; NCI-H460/R vs. NCI-H460/R+verapamil. ECAR 
- extracellular acidification rate; OCR - oxygen consumption rate. 
 
EVs from MDR cells were able to transfer their metabolic phenotype to the sensitive 
cells 
Next, we wanted to verify if MDR phenotype could be transferred to the drug-sensitive cells 
via EVs shed by the MDR cells. Therefore, drug-sensitive cells (NCI-H460) were treated 
with EVs isolated from the counterpart pairs of non-small cell lung cancer cells (NCI-H460 
and NCI-H460/R) and chronic myeloid leukaemia cells (K562 and K562Dox) (Fig. S1). After 
15 h incubation, the drug-sensitive cells treated with the EVs shed by MDR cells (NCI-
H460/R - Fig. 7A and K562Dox - Fig. 7B) acquired a metabolic phenotype more similar to 
the MDR cellular phenotype, i.e., an increase in glycolysis and in glycolytic capacity. 
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Figure 7 – Alterations observed in NCI-H460 cellular metabolism after treatment with EVs shed 
by MDR cells. NCI-H460 cells were treated with 18 x 108 EVs for 15 h and subsequently 
metabolically profiled using Seahorse XF-24 Analyser. The results of glycolysis stress test are shown 
as ECAR measurements after addition of glucose-free media (blue line A), glucose (blue line B), 
oligomycin (blue line C) and 2-deoxyglucose (blue line D). A) NCI-H460 cells were treated with their 
own EVs and with EVs isolated from NCI-H460/R cells. B) NCI-H460 cells were treated with EVs 
isolated from the pair chronic myeloid leukaemia counterpart cells, K562 and K562Dox. Data 
represents the results from two independent experiments, with four replicates each. A two-tailed *p 
£ 0.05; **p £ 0.01; ***p £ 0.001 NCI-H460 vs. NCI-H460+EVs NCI-H460; NCI-H460 vs. NCI-
H460+EVs NCI-H460/R; NCI.H460 vs. NCI-H460+EVs K562; NCI-H460 vs. NCI-H460+EVs 
K562Dox. 
Discussion 
Multidrug resistance (MDR) is a major problem in cancer treatment responsible for 
chemotherapy failure 4. MDR cancer cells usually have multiple mechanisms of resistance 
14. One of the most frequent MDR mechanism is the overexpression of ABC transporters, 
such as P-gp 2. Recent findings pointed that altered metabolic pathways help cancer cells 
to proliferate, adapt their metabolism to nutrient limited conditions, and importantly develop 
drug resistant phenotypes 22. Therefore, targeting cellular metabolism could chemosensitize 
MDR cells 9,23,24. Understanding the metabolic adaptations of MDR cancer cells is important 
for the identification of new approaches to counteract this phenotype.  
In the present study, we have identified a complex network of metabolic alterations 
associated with the MDR phenotype that could lead to the identification of more efficient 
therapeutic MDR circumvention strategies. In addition, we have shown that EVs released 
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by MDR cells are capable of stimulating a metabolic alteration (towards a MDR phenotype) 
in recipient drug-sensitive cancer cells. 
We confirmed that comparative proteomic approach is a powerful tool to investigate 
MDR mechanisms in cancer cells. MDR and their corresponding drug-sensitive cell lines 
from two distinct models (chronic myeloid leukaemia and non-small cell lung cancer) were 
subjected to a label-free LC-MS quantitative proteomics. The obtained data allowed a 
comparison between the proteome from MDR cells and the one obtained from their drug-
sensitive counterparts. In terms of biological processes, most of the identified DEPs 
(differentially expressed proteins between drug-sensitive and MDR cells) were involved in 
metabolic processes and the most active pathways enriched were those involved in cellular 
metabolism (GSH, PPP and Glycolysis). Therefore, we showed that the two MDR cell 
models acquired a similar metabolic profile but significantly distinct from the metabolic 
profile observed in their corresponding drug-sensitive cells.  
Interestingly, most of the DEPs involved in the PPP (including the rate limiting 
enzyme, G6PD) were downregulated in the MDR cells. PPP is a pivotal biosynthetic 
pathway branched to glycolysis and one of the main antioxidant cellular defense systems 
25. PPP has a central role as a source of nucleic acid precursors and provides reducing 
power and ribose phosphate to the cell 26. Changes in the PPP activity can affect response 
to anticancer drugs, however the specific role of PPP in MDR phenotype is still unclear. 
Other authors implied that PPP is more active in MDR tumours 27,28. Moreover, evidence 
suggested that elevated levels of NADPH and GSH, together with an active PPP, play an 
important role in MDR 29,30. Our results together with other recent studies 31,32 contradict the 
above mentioned reports, showing that PPP enzymes are downregulated in MDR cells. 
These results are controversial since one of the roles of PPP is to provide reducing power 
to the GSH metabolism and high levels of GSH in tumours have been linked to the 
development of MDR 33. In addition, we found increased GSH levels in both MDR models, 
as previously published by other authors 34,35. Moreover, since GSH is a detoxification agent 
36, the levels of ROS in the MDR cells were decreased. In all, our results suggest that MDR 
cells are capable of maintaining high GSH levels even when PPP is downregulated. 
Therefore, we assumed that MDR cells upregulated another source of GSH. 
The methionine cycle is a key pathway for many methylation reactions (methylation 
of DNA, histones and non-histone proteins, such as transcription factors) and could be the 
source of cysteine residues necessary for GSH synthesis 37. Growing evidence links 
aberrant regulation of methylation to tumourigenesis 38. The epigenetic mechanisms 
underlying drug resistance have not been fully elucidated, although some studies have 
suggested the contribution of an altered chromatin state to drug resistance 39. Our results 
showed considerable differences between MDR and their drug-sensitive cells, in the 
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amount of several metabolites of the methionine/SAMe pathway. Methionine levels were 
significantly increased in the MDR cells, which could lead to the GSH increase observed in 
those cells. In addition, the methylation capacity of the cells was increased in both MDR 
models and this could be attributed to the metabolic alterations in MDR cells during 
development of their resistant phenotype. In agreement with our results, other authors have 
described that treatment with a methylation inhibitor reversed drug resistance indicating that 
the development of some cases of drug resistance could be methylation-dependent 40. Also, 
MTA, dcSAMe, betaine, choline and serine are altered in MDR cells, although not in a 
similar manner. These differentially altered metabolites indicate that among these two MDR 
models there are also metabolic differences, which enhance the idea of the complex 
metabolism associated to MDR. 
The energy dependence of drug transport in MDR cells suggests that during 
development of MDR, cells undergo alterations in the energy utilization pathways. The main 
cell energy carrier, ATP, is produced in two metabolic pathways: glycolysis and/or oxidative 
phosphorylation (OXPHOS) of metabolic fuels 22. One of the fundamental hallmarks of 
cancer cells is the shift in the balance between these two energy-production pathways, in 
favor to glycolysis, known as the Warburg effect 41,42,43. For this reason, glycolysis inhibition 
has attracted significant interest as a possible way to sensitize cancer cells to 
chemotherapy. Indeed, several studies in different cancer models have demonstrated an 
efficient suppression of MDR by glycolytic inhibitors 8,23,24,44,45. Moreover, during the course 
of this work another study has suggested the possibility of an accelerated process of 
glycolysis in MDR cells to increase their energy supply 46. To our knowledge, a comparison 
between MDR and drug-sensitive cells in terms of metabolic energy supply, using different 
modulators of glycolysis and OXPHOS, has never been performed. The results presented 
herein showed a statistically significant increase in glycolysis and in the glycolytic capacity 
of the MDR cells (NCI-H460/R), together with a decrease in the mitochondrial basal 
respiration and in the maximal capacity of the cells to perform OXPHOS compared to the 
drug-sensitive counterparts (NCI-H460). Therefore, our findings indicate that MDR cells, 
when acquiring the resistant phenotype, enhance their switch in the cellular energy supply 
pathways from OXPHOS to glycolysis. This altered metabolic activity in MDR cells could be 
crucial for: i) supporting uncontrolled proliferation, since glycolysis provides the 
intermediates necessary for biosynthetic pathways; ii) allowing the use of the most 
abundant extracellular nutrient (glucose) to produce abundant ATP. Even though the yield 
of ATP per glucose consumed is low, if the glycolytic flux is high enough, the percentage of 
cellular ATP produced by glycolysis can exceed the one produced by OXPHOS 47,48. 
Therefore, this metabolic phenotype could be beneficial for MDR cells at both levels of 
bioenergetics and biosynthesis. 
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Although MDR cells perform less OXPHOS, the application of different OXPHOS 
modulators (oligomycin, FCCP and rotenone) affected more the drug-sensitive than their 
MDR counterpart cells. The OCR levels in the MDR cells have been less affected than the 
OCR levels in drug-sensitive cells. This suggests that MDR cells are more capable of 
sustaining the acquired metabolic phenotype in order to maintain the higher energy 
demand. In accordance, it was reported that the relationship between drug resistance and 
glycolysis may partially be due to the radical scavenging potential of the glycolytic 
intermediates, and the link between them and the cellular redox status 49.  
Furthermore, the increase in glycolysis could be responsible for the decrease in the 
PPP observed in the MDR cells. Since some of the glycolysis and PPP intermediates are 
the same, it is possible that MDR cells are directing these intermediates mostly to glycolysis, 
in order to sustain the energy for the requested biosynthetic pathways. In fact, we 
demonstrated that when the PPP pathway was inhibited (with DCA 50), drug-sensitive cells 
(NCI-H460) acquired a metabolic phenotype similar to that observed in MDR cells by 
increasing glycolysis and decreasing OXPHOS. These results support the hypothesis that 
there is a competition between glycolysis and PPP activity in the MDR phenotype. 
Additionally, in multicellular tumour spheroids and in doxorubicin-resistant human 
breast adenocarcinoma cells, the inhibition of glycolysis raised intracellular ROS, 
downregulated P-gp and reverted the MDR phenotype 8,23. In agreement with these data, 
our work showed that treatment of MDR cells (NCI-H460/R) with a P-gp inhibitor (verapamil) 
switched their metabolic phenotype to that characteristic of sensitive cells (decrease in 
glycolysis and an increase in OXPHOS). 
Several studies have associated metabolic alterations with the shedding and cargo 
of EVs in different types of cells (such as increase lactate production 18, inhibition of 
glutamine metabolism 19 and the presence of several enzymes involved in glucose and 
glutamine metabolism 20). The importance of EVs in the transfer of the MDR phenotype has 
been recently described 13,14,51. Therefore, the acquisition by MDR cells of a different 
metabolic phenotype, could be responsible for the differences in: (i) the type of EVs 
population released by MDR cells; (ii) their cargo and (iii) the capacity to transfer 
phenotypes to receiving cells. In fact, we have recently shown that MDR cells shed a 
different population of EVs (more microvesicle-like EVs and less exosomes) when 
compared to the EVs shed by the drug-sensitive counterpart cells 17,52. Additionally, our 
results showed that drug-sensitive cells (NCI-H460) co-incubated with EVs from MDR cells 
(NCI-H460/R and K562Dox), acquired a metabolic phenotype (increase in glycolysis) 
similar to the one observed in MDR cells. These results showed that, independently of the 
origin of the MDR cells (leukaemia or lung cancer), their EVs are capable of inducing such 
alterations. However, surprisingly, our results showed that the EVs from the sensitive 
 	 85	
RESULTS  AND  D ISC USSION  
leukemic cell line were also capable of inducing alterations in the glycolytic capacity of the 
recipient drug-sensitive cells. The reason for this is unknown, but is possibly due to the 
exposure of cells to high levels of EVs, therefore not related to MDR. Furthermore, a recent 
study has described that glutamine metabolism was altered in cancer cells following 
incubation with large EVs (microvesicles), an effect that was not observed upon incubation 
with exosomes 20. This further highlights the importance of verifying the type of EVs 
released by donor cells, since different EVs may transfer different phenotypes to receiving 
cells. 
 
 
Conclusions 
In conclusion, P-gp overexpressing MDR cells may employ various protective 
metabolic strategies to survive (schematically represented in Fig.8). These include (i) 
alterations in the GSH metabolism, (ii) increasing the methylation index influencing 
epigenetic regulation, (iii) increasing the rates of glycolysis and (iv) changing the phenotype 
of the surrounding drug-sensitive cells, by EVs mediated transfer of new features. Our 
results indicate that the development of MDR is a complex phenomenon that involves 
several simultaneous metabolic alterations.  
We clarified for the first time the complex metabolic network of the various metabolic 
alterations associated with MDR in cancer cells. In addition, that MDR cancer cells are more 
capable than drug-sensitive cells of sustaining its specific metabolic profile. Specifically, we 
showed for the first time that MDR cancer cells, besides increased glycolysis also have 
increased glycolytic capacity and glycolytic reserve, while their OXPHOS rate is decreased. 
In addition, our work found differences between MDR and drug-sensitive cells in the amount 
of several metabolites of the methionine/SAMe pathway which regulates DNA and protein 
methylation, as well as GSH production. Finally, we demonstrated for the first time the 
transfer of metabolic information from MDR to drug-sensitive cancer cells through a specific 
population of EVs. 
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Figure 8 – Schematic representation of the observed metabolic differences between drug-
sensitive cells and their counterpart MDR cells. P-gp overexpressing MDR cancer cells have 
various protective metabolic strategies. These include: increasing rates of glycolysis (1) and 
methylation capacity (2), alterations in the GSH metabolism (3), decreasing rates of PPP (4) and 
OXPHOS (5) and finally changing the phenotype of the surrounding drug-sensitive cells by EVs-
mediated transfer of new features (6). Filled lines and arrows: increased pathways; Dashed lines and 
arrows: decreased pathways; Bold and bigger fonts: increased metabolic processes; Smaller fonts: 
decreased metabolic processes. 
 
Materials and methods 
Cell culture 
The chronic myeloid leukaemia cell line K562 was from European Collection of Cell 
Cultures (ECACC) and its P-gp overexpressing counterpart cell line K562Dox was a kind 
gift of Dr. J.P. Marie (Paris, France) 53,54. The non-small cell lung cancer cell line NCI-H460 
and its drug-resistant P-gp overexpressing counterpart cell line NCI-H460/R were a kind gift 
from Dr. M. Pešić (Belgrade, Serbia) 55,56. All cell lines were genotyped and routinely 
monitored for mycoplasma contamination by PCR (VenorGeM® Advance Mycoplasma 
Detection Kit, Minerva). All cells were routinely grown in RPMI-1640 (with Ultraglutamine I 
and 25mM HEPES) medium (Lonza), supplemented with 10% fetal bovine serum (FBS, 
PAA) at 37ºC in a humidified incubator with 5 % CO2 in air. Cell number and viability were 
analyzed with trypan blue exclusion assay. All experiments were carried out with 
exponentially growing cells having over 90% viability. 
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Sample preparation and mass spectrometry using LC/MS/MS  
Pellets from cells (K562, K562Dox, NCI-H460 and NCI-H460/R) were processed and 
10 µg of proteins were analyzed by mass spectrometry using LC/MS/MS as previously 
described 17. Biological replicates (from 4 independent experiments) were analyzed for each 
sample type.  
 
Label-Free LC-MS quantitative profiling 
Label-free LC–MS analysis was carried out using Progenesis QI for proteomics v4.1 
software (NonLinear Dynamics, UK), essentially as recommended by the manufacturer (see 
www.nonlinear.com for further background to alignment, normalization, calculation of 
peptide abundance, etc.).  
This software extracts quantitative information from MS1 data by aligning the data 
based on the LC retention time of each sample to a reference file (sample run that yielded 
most peptide ions); this allows for any drift in retention time, giving an adjusted retention 
time for all runs in the analysis.  
Results were filtered, based on statistical analysis. The Progenesis peptide 
quantification algorithm calculates peptide abundance as the sum of the peak areas within 
its isotope boundaries. Each abundance value is then transformed to a normalized 
abundance value by applying a global scaling factor. Protein abundance was calculated as 
the sum of the abundances of all peptide ions, which have been identified as coming from 
the same protein. Any peptides with an ANOVA score of p > 0.05 were eliminated. The MS2 
data for the remaining peptides was exported and the resulting MGF file used to search the 
NewUniProtSwissprot database (updated in January 2014) on the MASCOT server 
(www.matrixscience.com) for protein identifications. The search parameters used were as 
follows: 1) species, Homo sapiens; 2) allowed number of missed cleavages, 2; 3) fixed 
modification, carboxylmethyl; 4) variable modifications, methionine oxidation; 5) peptide 
mass tolerance ± 20 ppm; 6) MS/MS tolerance ± 0.6 Da; and 7) peptide charge + 1, +2 and 
+3. Only peptides with ion scores of 40 and above were considered and re-imported back 
into Progenesis QI software for further analysis. Peptide identifications were imported into 
the Progenesis software and assigned to the matching features. Protein scores were based 
on ANOVA values with a cut off of p < 0.05. Differentially expressed proteins (DEPs) 
between drug-sensitive and MDR cells with ≥2 peptides matched and a ≥ 1.5 fold 
differences in abundance were considered as significant. Peptide conflicts occur when a 
peptide is identified as present in more than one protein. These were resolved by assigning 
the peptide to the protein with the greater number of hits, a greater Mascot score or a lower 
mass error; when conflicts could not be clearly resolved, the peptide was excluded from the 
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analysis. 
 
Bioinformatics analysis of the detected DEPs 
The two data sets (DEPs from K562 vs. K562Dox cells and NCI-H460 vs. NCI-H460/R 
cells) were analyzed using bioinformatics methods. Database for Annotation, Visualization, 
and Integrated Discovery (DAVID 6.7) was used to identify protein and molecular pathway 
modifications. UniProt accession numbers were obtained by Progenesis software. To 
understand the high-level functions and utilization of the biological systems from molecular-
level information, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway was 
used. Distributions in subcellular locations, biological processes and molecular functions 
were assigned to each protein based on Gene Ontology (GO) categories. The significantly 
(p < 0.05) enriched categories are presented. 
 
Analysis of Protein Expression by Western Blot 
Cell pellets were lysed in Winman’s Buffer (1% NP-40, 0.1 M Tris-HCl pH 8.0, 0.15 M 
NaCl and 5 mM EDTA) with EDTA-free protease inhibitor cocktail (Roche). Total protein 
content of cell lysates was quantified with “DC Protein assay kit” (Bio-Rad) and 20 µg of 
protein were subjected to SDS-PAGE (12% Bis-Tris gel). Following electrophoretic transfer 
of the proteins into nitrocellulose membranes (GE Healthcare, UK), membranes were then 
incubated with the following primary antibodies: goat anti-Actin (1:2000; Santa Cruz 
Biotechnology), mouse anti-P-gp (P7965) (1:2000; Sigma), G6PD (1:200; Santa Cruz 
Biotechnology), 6PGD (1:200; Santa Cruz Biotechnology) and IDH1 (1:200; Santa Cruz 
Biotechnology). The following secondary antibodies were then used: anti-mouse IgG-HRP; 
anti-rabbit IgG-HRP or anti-goat IgG-HRP (all diluted 1:2000; Santa Cruz Biotechnology). 
Signal was detected using the ECL Western blot Detection Reagents (GE Healthcare, UK), 
the Amersham Hyperfilm ECL (GE Healthcare, UK), and the Kodak GBX developer and 
fixer (Sigma, EUA) 57. The intensity of the bands obtained in each film was further analyzed 
using the software Quantity One – 1D Analysis (Bio-Rad, USA).  
 
GSH/GSSG-GloTM assay 
To measure GSH levels, the GSH/GSSG-GloTM Assay (Promega, USA) was used 
following manufacturer’s instructions. Briefly, 5000 cells/well were plated in white 96-
opaque well plates. NCI-H460 and NCI-H460/R cells were plated in 100µl of RPMI-1640; 
K562 and K562Dox cells were plated in 20µl of Hanks Balanced Salt Solution (HBSS). Total 
glutathione lysis reagent or oxidized glutathione lysis reagent were added to the cells. After 
incubation at room temperature a luciferin generation reagent was added to all samples and 
the plates were incubated for 30 min at room temperature. Luminescence was quantified 
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using a microplate reader (Biotek Instruments Inc. Synergy MX. USA). Positive control (cells 
treated with 5 µM Staurosporine for 4h) and wells with no cells were also included as 
controls. GSH levels were calculated as follows: GSH levels=total glutathione levels – 
oxidized glutathione levels  
 
ROS Detection   
2′,7′-dichlorodihydrofluorescein diacetate (H2DCF-DA) analysis by flow cytometry 
were used to measure ROS concentration in drug-sensitive and MDR cells. K562 and 
K562Dox cells (8x105/well) were plated in 6-well plates; NCI-H460 and NCI-H460/R cells 
(3x105/well) were plated in 6-well plates at for 24h. Cells were harvested and incubated in 
adequate medium with 10 µM CM-H2DCFDA for 45 min at 37 ºC in the dark. Cells were 
subsequently washed twice in PBS and the CM-H2DCFDA fluorescence was analyzed in a 
BD Accuri flow cytometer (FL1-H channel). A positive control (cells treated with 1 µM 
Staurosporine for 6h) was also included. Mean fluorescence intensity was calculated after 
correction for auto-fluorescence. 
 
Semi-quantitative analysis of metabolites of the methionine/S-adenosylmethionine 
pathway  
Total cell pellets (4 independent preparations for each cell line) were lysed in 500 µL 
of a mixture of ice-cold water/metanol/10 mM acetic acid (49/50/1 v/v/v %) with a tissue 
homogenizer (Precellys) in 1 x 20 second cycles at 6000 rpm. Subsequently, 400 µL of the 
homogenate was transferred to a new aliquot and shaken at 1400 rpm for 30 minutes at 
4 °C. Next the aliquots were centrifuged for 15 min at 14000 rpm at 4 °C. 75 µL of the 
supernatant was transferred to a fresh aliquot and placed at -80 °C for 20’. The chilled 
supernatants were evaporated with a speedvac in approximately 3h. The resulting pellets 
were resuspended in 100 µL water/acetonitrile (MeCN)/formic acid (40/60/0.1 v/v/v %, 
resuspension solution).  
Concentrations of methionine, MTA, SAMe, SAH, spermidine and spermine were 
determined with a semi-quantitative method. Calibration curves for these compounds were 
obtained, by measuring serial dilutions of a pooled standard mixture in resuspension 
solution.  The concentrations for all compounds in the dilutions ranged from 100 µM to 0.025 
µM. For the standard mixtures, separate 10 mM stocks of the standards were made. These 
were then pooled and further diluted in resuspension solution in order to obtain the final 
concentrations as used for the calibration curve.  
Samples were measured with a UPLC system (Acquity, Waters, Manchester) coupled 
to a Time of Flight mass spectrometer (ToF MS, SYNAPT G2, Waters). A 2.1 x 100 mm, 
1.7 µm BEH amide column (Waters), thermostated at 40 °C, was used to separate the 
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analytes before entering the MS. Solvent A (aqueous phase) consisted of 99.5% water, 
0.5% formic acid and 20 mM ammonium formate while solvent B (organic phase) consisted 
of 29.5% water, 70% MeCN, 0.5% formic acid and 1 mM ammonium formate. 
In order to obtain a good separation of the analytes the following gradient was used: 
from 5% A to 50% A in 2.4 minutes in curved gradient (#8, as defined by Waters), from 50% 
A to 99.9% A in 0.2 minutes constant at 99.9% A for 1.2 minutes, back to 5% A in 0.2 
minutes. The flow rate was 0.250 mL/min and the injection volume was 2 µL. All samples 
were injected randomly. After every 10 injections a QC sample was injected. All samples 
were injected in duplicate. 
Analytes were measured in enhanced duty cycle (EDC) mode, optimized for the mass 
of the analyte in question. MTA was measured in scan function 1 (EDC at 298), choline was 
measured in scan function 2 (EDC at 104), methionine was measured in scan function 3 
(EDC at 150), SAH was measured in scan function 8 (EDC at 385), SAMe was measured 
in scan function 10 (EDC at 399), spermidine was measured in scan function 12 (EDC at 
146), spermine was measured in scan function 13 (EDC at 203). The cone voltage was 
between 20 and 25 depending on the analyte. A 2 ng/mL leucine-enkephalin solution in 
water/acetonitrile/formic acid (49.9/50/0.1 %v/v/v) was infused at 10 µL/min and used for a 
lock mass which was measured each 47 seconds for 0.5 seconds. Spectral peaks were 
automatically corrected for deviations in the lock mass. 
Extracted ion traces were obtained for methionine (m/z = 150.0589), SAH (m/z = 
385.1294), SAMe (m/z =399.1451), MTA (m/z =298.097), spermidine (m/z =146.1657) and 
Spermine (m/z =203.2236) in a 20 mDa window and subsequently smoothed (2 points, 2 
iterations) and integrated with QuanLynx software (Waters, Manchester). 
 
Extracellular flux assay using Seahorse XF-24 Analyser  
ECAR, reflecting the rate of glycolysis, and OCR, reflecting the rate of OXPHOS, 
were measured using a Seahorse Bioscience (Copenhagen, Denmark) XF24 analyzer. 
Briefly, 2 x 104 cells/well for glycolysis stress test and 3 x 104 cells/well for mitochondrial 
stress test were plated in Seahorse XF24 plates in 200 μl of RPMI-1640 and incubated for 
20-24h at 37ºC in a humidified incubator with 5 % CO2 in air and 1h hour prior to the XF 
assay in a humidified incubator without CO2 with the corresponding assay media. In the 
experiments where the cells were treated with DCA, the treatment was performed for 24h 
with a concentration of 5mM. The verapamil treatment was performed for 15h with 2μM. 
NCI-H460/R treated with DCA and NCI-H460 treated with verapamil were used as controls. 
Basal OCR measurements were made in DMEM containing 10mM sodium pyruvate 
(Invitrogen, California, EUA), 10 mM Glucose (Invitrogen, California, EUA) and 10mM 
 	 91	
RESULTS  AND  D ISC USSION  
Glutamax (Invitrogen, California, EUA) and Basal ECAR measurements were made in 
DMEM without any supplementation. 
Steady-state (baseline) oxygen consumption rates and extracellular acidification 
rates were measured. Non-glycolytic acidification, glycolysis, glycolytic capacity and 
glycolytic reserve were measured, through ECAR, by injecting: glucose, oligomycin and 2-
deoxyglucose. Basal respiration, proton leak, spare capacity, maximal respiration, non-
mitochondrial respiration and ATP production were measured, through OCR, after the 
sequential injection of oligomycin, FCCP and rotenone. All measurements were normalized 
to protein quantity with crystal violet. 
 
Co-culture of NCI-H460 cells with EVs 
EVs were isolated from the culture media of drug-sensitive or MDR cells by various 
centrifugation steps as previously described 17. EVs pellets were re-suspended in 100 µl of 
PBS and frozen at - 80 ºC. NCI-H460 cells were treated with 18 x 108 EVs (quantified by 
nanoparticle tracking analysis as in supplementary information) for 15 hours and were 
subsequently metabolically profiled using Seahorse XF-24 Analyzer. 
 
Statistical analysis 
All presented data resulted from at least three independent experiments (excluding the 
EVs treatment which was performed in two independent experiments only). All data was 
statistically analyzed with the two-tailed unpaired Student’s t-test. Results were considered 
statistically significant when p ≤ 0.05. 
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Nanoparticle Tracking Analysis 
A NanoSight LM10 system (Malvern, U.K.) equipped with a fast video capture and 
particle-tracking software was used to measure the rate of Brownian motion. All settings for 
the camera were fixed and kept constant for all measurements during the session. For each 
sample, at least five videos of 30–60 s with more than 200 detected tracks per video, and 
in at least one dilution, were taken and analyzed using the Nanoparticle Tracking Analysis 
software to obtain the mean, mode, median vesicle size and an estimation of the particle 
concentration. Results represent the mean of all videos acquired for a given sample. 
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Table S1 | Statistically significant DEPs identified with the progenesis software when 
comparing K562 cells with the K562Dox cells. 
	
Accession Peptides Score ANOVA 
(P) 
Highest 
mean 
conditiona 
Description 
P02100 12 1151.5 7,85E-10 K562 Hemoglobin subunit epsilon  
P08183 6 404.08 1,24E-09 K562Dox Multidrug resistance protein 1  
Q96AE4 3 169.33 6,60E-09 K562 Far upstream element-binding protein 1  
P02008 6 671.58 5,46E-08 K562 Hemoglobin subunit zeta  
Q5JQC4 2 116.32 7,57E-08 K562 Cancer/testis antigen 47A  
P13667 9 637.04 8,40E-08 K562Dox Protein disulfide-isomerase  
P21333 17 1078.45 9,94E-08 K562 Filamin-A  
Q96GU1 3 254.71 1,43E-07 K562 P antigen family member 5  
P07237 8 477.65 1,48E-07 K562Dox Protein disulfide-isomerase  
Q14315 7 448.29 1,73E-07 K562 Filamin-C  
P41252 2 103.29 1,77E-07 K562Dox Isoleucine--tRNA ligase, cytoplasmic  
Q8NBS9 4 220.76 2,75E-07 K562Dox Thioredoxin domain-containing protein 5  
P69905 3 333.21 3,53E-07 K562 Hemoglobin subunit alpha  
P08107 10 858.34 5,35E-07 K562 Heat shock 70 kDa protein 1A/1B  
P13489 5 395.69 6,32E-07 K562 Ribonuclease inhibitor  
Q8WUM4 6 340.95 6,84E-07 K562 Programmed cell death 6-interacting protein  
P11413 4 250.7 7,79E-07 K562 Glucose-6-phosphate 1-dehydrogenase  
P50402 2 112.04 9,19E-07 K562 Emerin  
Q53FZ2 2 130.62 1,28E-06 K562Dox Acyl-coenzyme A synthetase ACSM3, 
mitochondrial  
Q15758 2 103.85 1,50E-06 K562 Neutral amino acid transporter B(0)  
P14625 11 707.02 1,56E-06 K562Dox Endoplasmin  
P14314 6 431.33 1,65E-06 K562Dox Glucosidase 2 subunit beta  
P51659 2 133.11 1,77E-06 K562Dox Peroxisomal multifunctional enzyme type 2  
P11310 2 133.95 1,97E-06 K562 Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial  
Q15084 6 478.14 2,15E-06 K562Dox Protein disulfide-isomerase A6  
Q9BXL5 3 203.27 2,59E-06 K562 Hemogen  
P04350 4 262.01 2,87E-06 K562Dox Tubulin beta-4A chain  
O75369 4 259.91 2,95E-06 K562 Filamin-B  
Q9UJZ1 4 319.38 3,22E-06 K562Dox Stomatin-like protein 2, mitochondrial  
Q9Y6G9 2 134.98 3,33E-06 K562Dox Cytoplasmic dynein 1 light intermediate chain 1  
P69892 11 1152.26 3,45E-06 K562 Hemoglobin subunit gamma-2  
Q9Y2B0 2 117.53 3,65E-06 K562Dox Protein canopy homolog 2  
P30101 13 860.94 3,88E-06 K562Dox Protein disulfide-isomerase A3  
P50454 7 483.96 3,90E-06 K562Dox Serpin H1  
P11021;O953
99 
21 1732.04 3,96E-06 K562Dox 78 kDa glucose-regulated protein  
Q92597 2 118.12 4,32E-06 K562Dox Protein NDRG1  
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P21980 3 167.42 4,51E-06 K562 Protein-glutamine gamma-glutamyltransferase 2  
Q02809 2 112.2 4,86E-06 K562Dox Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 1  
P40121 4 231.66 5,10E-06 K562Dox Macrophage-capping protein  
P04083 4 342.1 5,57E-06 K562Dox Annexin A1  
P30040 2 96.26 7,00E-06 K562Dox Endoplasmic reticulum resident protein 29  
P53396 5 289.7 7,19E-06 K562Dox ATP-citrate synthase  
O00584 2 209.89 7,98E-06 K562Dox Ribonuclease T2  
Q9BVA1 3 201.5 9,89E-06 K562Dox Tubulin beta-2B chain  
P02794 5 371.7 9,99E-06 K562 Ferritin heavy chain  
Q15008 2 105.05 1,12E-05 K562 26S proteasome non-ATPase regulatory subunit 
6  
P23284 11 645.7 1,36E-05 K562Dox Peptidyl-prolyl cis-trans isomerase B  
P69891 12 1201.47 1,60E-05 K562 Hemoglobin subunit gamma-1  
P32322 3 167.48 1,98E-05 K562Dox Pyrroline-5-carboxylate reductase 1, 
mitochondrial  
Q15942 2 128.16 3,04E-05 K562 Zyxin  
P49915 3 168.86 3,09E-05 K562 GMP synthase [glutamine-hydrolyzing]  
Q03252 2 139.3 3,19E-05 K562Dox Lamin-B2  
Q9Y4L1 4 282.01 3,19E-05 K562Dox Hypoxia up-regulated protein 1  
P27824 5 349.95 3,35E-05 K562Dox Calnexin  
P13639 10 667.85 3,53E-05 K562Dox Elongation factor 2  
Q13200 3 182.57 4,02E-05 K562 26S proteasome non-ATPase regulatory subunit 
2  
P49321 10 621.17 4,15E-05 K562 Nuclear autoantigenic sperm protein  
P02792 3 153.53 5,15E-05 K562 Ferritin light chain  
Q09666 4 241.99 5,80E-05 K562Dox Neuroblast differentiation-associated protein 
AHNAK  
Q92945 11 679.83 7,93E-05 K562Dox Far upstream element-binding protein 2  
Q15019 2 94.95 8,59E-05 K562 Septin-2  
Q16698 2 163.1 1,15E-04 K562Dox 2,4-dienoyl-CoA reductase, mitochondrial  
Q7KZF4 2 122.97 1,19E-04 K562 Staphylococcal nuclease domain-containing 
protein 1  
Q969H8 2 128.77 1,31E-04 K562Dox UPF0556 protein C19orf10  
P27797 12 729.75 1,43E-04 K562Dox Calreticulin  
O43175 5 343.55 2,09E-04 K562Dox D-3-phosphoglycerate dehydrogenase  
Q14697 5 375.47 2,22E-04 K562Dox Neutral alpha-glucosidase AB  
P02042 2 138.28 2,63E-04 K562 Hemoglobin subunit delta  
Q13162 6 410.59 3,67E-04 K562Dox Peroxiredoxin-4  
Q9Y5M8 2 135.82 3,88E-04 K562Dox Signal recognition particle receptor subunit beta  
O43852 4 262.95 5,64E-04 K562Dox Calumenin  
P51572 2 116.83 5,80E-04 K562Dox B-cell receptor-associated protein 31  
O76070 2 112.31 8,97E-04 K562Dox Gamma-synuclein  
P84095 2 122.1 1,13E-03 K562 Rho-related GTP-binding protein RhoG  
P32119 5 372.45 1,35E-03 K562Dox Peroxiredoxin-2  
O43242 2 100.28 1,56E-03 K562 26S proteasome non-ATPase regulatory subunit 
3  
Q13838 3 145.46 1,72E-03 K562 Spliceosome RNA helicase DDX39B  
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P17174 2 88.59 2,79E-03 K562 Aspartate aminotransferase, cytoplasmic  
P99999 3 230.82 3,20E-03 K562 Cytochrome c  
P04792 4 255.67 3,45E-03 K562Dox Heat shock protein beta-1  
Q01581 5 349.64 3,58E-03 K562Dox Hydroxymethylglutaryl-CoA synthase, 
cytoplasmic  
P49006 3 202.04 3,83E-03 K562 MARCKS-related protein  
Q9NSI8 2 92.03 3,95E-03 K562Dox SAM domain-containing protein SAMSN-1  
O95816 2 93.14 1,09E-02 K562 BAG family molecular chaperone regulator 2  
Q6FI81 2 100.08 1,11E-02 K562 Anamorsin  
Q9BRP8 2 135.58 1,11E-02 K562Dox Partner of Y14 and mago  
P09972 7 550.98 1,29E-02 K562 Fructose-bisphosphate aldolase C  
P09429 2 95.34 1,38E-02 K562Dox High mobility group protein B1  
P51571 2 134.15 1,56E-02 K562Dox Translocon-associated protein subunit delta  
Q14103 2 133.1 1,75E-02 K562 Heterogeneous nuclear ribonucleoprotein D0  
P30613 2 94.94 2,71E-02 K562 Pyruvate kinase PKLR 
	
a Indicates if the protein were upregulated in K562 or K562Dox cells 
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Table S2 | Statistically significant DEPs identified with the Progenesis software when 
comparing NCI-H460 cells with the NCI-H460/R cells. 
 
Accession Peptides Score ANOVA 
(P) 
Highest 
mean 
conditiona 
Description 
Q13509 4 224.36 1,76E-09 NCI-H460 Tubulin beta-3 chain  
P05120 7 398.27 1,24E-08 NCI-H460/R Plasminogen activator inhibitor 2  
P03956 2 147.55 3,55E-08 NCI-H460/R Interstitial collagenase  
P26447 2 120.38 6,86E-08 NCI-H460 Protein S100-A4  
Q9Y2T3 4 294.37 8,20E-08 NCI-H460/R Guanine deaminase  
P14923 3 147.28 9,27E-08 NCI-H460 Junction plakoglobin  
Q04828;P518
57 
12 945.06 1,09E-07 NCI-H460 Aldo-keto reductase family 1 member C1  
Q9UHB6 4 263.19 2,31E-07 NCI-H460/R LIM domain and actin-binding protein 1  
P04350 3 189.21 3,27E-07 NCI-H460 Tubulin beta-4A chain 
P42330 9 719.08 4,61E-07 NCI-H460 Aldo-keto reductase family 1 member C3  
O15067 3 163.69 6,01E-07 NCI-H460 Phosphoribosylformylglycinamidine synthase  
O14745 2 115.52 9,36E-07 NCI-H460 Na(+)/H(+) exchange regulatory cofactor NHE-RF1  
P29966 5 351.65 1,02E-06 NCI-H460/R Myristoylated alanine-rich C-kinase substrate  
P42704 8 429.18 1,15E-06 NCI-H460 Leucine-rich PPR motif-containing protein, 
mitochondrial  
Q15942 5 289.61 1,20E-06 NCI-H460/R Zyxin  
P11413 13 1012.11 1,22E-06 NCI-H460 Glucose-6-phosphate 1-dehydrogenase  
Q96C19 2 139.32 1,34E-06 NCI-H460 EF-hand domain-containing protein D2  
P30043 3 158.45 1,42E-06 NCI-H460 Flavin reductase (NADPH)  
O95994 6 421.56 2,01E-06 NCI-H460/R Anterior gradient protein 2 homolog  
P18206 9 557.89 2,95E-06 NCI-H460 Vinculin  
Q16799 2 118.69 3,10E-06 NCI-H460 Reticulon-1  
P52209 7 570.89 3,89E-06 NCI-H460 6-phosphogluconate dehydrogenase, 
decarboxylating  
P17812 3 149.08 3,93E-06 NCI-H460/R CTP synthase 1  
O43795 2 91.81 4,41E-06 NCI-H460/R Unconventional myosin-Ib  
O60271 3 164.13 4,72E-06 NCI-H460/R C-Jun-amino-terminal kinase-interacting protein 4  
P08107;P170
66 
14 1029.09 5,69E-06 NCI-H460/R Heat shock 70 kDa protein 1A/1B  
O75369 21 1372.59 5,73E-06 NCI-H460 Filamin-B  
O95831 3 192.79 6,91E-06 NCI-H460 Apoptosis-inducing factor 1, mitochondrial  
P08183 2 175.04 9,14E-06 NCI-H460/R Multidrug resistance protein 1  
Q16643 3 252.38 1,32E-05 NCI-H460/R Drebrin  
P20810 2 130.59 1,43E-05 NCI-H460 Calpastatin  
Q96B97 2 153.1 1,48E-05 NCI-H460/R SH3 domain-containing kinase-binding protein 1  
Q92598 4 219.52 1,62E-05 NCI-H460/R Heat shock protein 105 kDa  
Q13501 7 676 1,65E-05 NCI-H460/R Sequestosome-1  
P30838 6 352.67 1,74E-05 NCI-H460 Aldehyde dehydrogenase, dimeric NADP-preferring  
P52597 2 142.8 2,35E-05 NCI-H460 Heterogeneous nuclear ribonucleoprotein F  
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P11717 2 120.61 2,56E-05 NCI-H460 Cation-independent mannose-6-phosphate 
receptor  
P43490 4 203.87 4,30E-05 NCI-H460 Nicotinamide phosphoribosyltransferase  
P04181 2 148.51 6,00E-05 NCI-H460 Ornithine aminotransferase, mitochondrial  
P29401 8 489.12 7,25E-05 NCI-H460 Transketolase  
O75874 4 327.28 7,79E-05 NCI-H460 Isocitrate dehydrogenase [NADP] cytoplasmic  
Q70E73 3 151.34 8,46E-05 NCI-H460/R Ras-associated and pleckstrin homology domains-
containing protein 1 
P55795 3 183.51 8,62E-05 NCI-H460 Heterogeneous nuclear ribonucleoprotein H2  
Q9UBR2 2 95.6 1,18E-04 NCI-H460 Cathepsin Z  
Q13557 2 121.31 1,24E-04 NCI-H460/R Calcium/calmodulin-dependent protein kinase type 
II subunit delta  
P10620 2 105.19 1,33E-04 NCI-H460/R Microsomal glutathione S-transferase 1  
P46821 4 277.49 1,51E-04 NCI-H460 Microtubule-associated protein 1B  
P00492 2 135.13 1,92E-04 NCI-H460 Hypoxanthine-guanine phosphoribosyltransferase  
Q96HC4 4 285.33 1,99E-04 NCI-H460 PDZ and LIM domain protein 5  
Q8TAT6 2 88.72 2,07E-04 NCI-H460/R Nuclear protein localization protein 4 homolog  
Q9Y2B0 2 137.58 2,36E-04 NCI-H460 Protein canopy homolog 2  
Q92804 2 156.39 3,07E-04 NCI-H460 TATA-binding protein-associated factor 2N  
P12277 3 178.13 3,26E-04 NCI-H460 Creatine kinase B-type  
P45880 3 215.06 4,38E-04 NCI-H460 Voltage-dependent anion-selective channel protein 
2  
P37837 2 116.98 4,64E-04 NCI-H460/R Transaldolase  
P13797;Q146
51 
3 184.99 4,83E-04 NCI-H460 Plastin-3  
P21291 4 320.55 5,15E-04 NCI-H460 Cysteine and glycine-rich protein 1  
O43175 5 345.57 7,53E-04 NCI-H460 D-3-phosphoglycerate dehydrogenase  
P46940 7 407.01 2,20E-03 NCI-H460/R Ras GTPase-activating-like protein IQGAP1  
Q99798 2 132.35 2,38E-03 NCI-H460 Aconitate hydratase, mitochondrial  
Q9ULV4 2 105.68 4,90E-03 NCI-H460/R Coronin-1C  
P78527 2 142.87 9,44E-03 NCI-H460/R DNA-dependent protein kinase catalytic subunit  
P22392 6 298.01 1,02E-02 NCI-H460/R Nucleoside diphosphate kinase B  
P31689 2 100.79 1,81E-02 NCI-H460/R DnaJ homolog subfamily A member 1  
P32119 2 133.35 1,83E-02 NCI-H460 Peroxiredoxin-2  
P05141 4 265.29 2,35E-02 NCI-H460 ADP/ATP translocase 2  
P31949 3 185.3 2,80E-02 NCI-H460 Protein S100-A11  
 
a Indicates if the protein were upregulated in NCI-NCI-H460 or NCI-NCI-H460/R cells 
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Table S3 | Intensity and Amount of the Metabolites associated with the methionine/ 
S-adenosylmethionine pathway. 
 
 
*Amount (pmol) per 1e6 cell 
**Intensity (peak *Amount(pmol)per1e6cell **Intensity (peak height)/1e6cell  
 
 
  
 Metabolite description drug-sensitive cells MDR cells 
K562 vs. 
K562Dox 
Methionine * 246.2 ± 3.0 378.2 ± 3.6 
 
5´-deoxy-5´-methylthioadenosine (MTA) * 6.8 ± 0.4 9.8 ± 0.3 
 
S-adenosylhomocysteine (SAH) * 37.5 ± 0.4 21.5 ± 0.5 
 
S-adenosylmethionine (SAMe) * 261.2 ± 3.8 259.1 ± 8.7 
 
Spermidine * 1906.8 ± 25.9 
 
1611.9 ± 40.8 
 
Betaine ** 2041.2 ± 27.43 2084 ± 41.96 
Choline ** 13255 ± 43.57 8301 ± 113.74 
Decarboxylated S-adenosyl methionine (dc-SAMe) ** 520 ± 14.08 738 ± 14.05 
Serine ** 4 ± 0.00 2 ± 0.00 
Threonine ** 222 ±  3.51 220 ± 8.37 
NCIH460 vs. 
NCI-H460/R 
Methionine * 473.5 ± 6.3 905.5 ± 20.4  
 
5´-deoxy-5´-methylthioadenosine (MTA) * 2.4 ± 0.1 2.7 ± 0.1 
 
S-adenosylhomocysteine (SAH) * 143.16 ± 5.2 
 
35.1 ± 0.9 
 
S-adenosylmethionine (SAMe) * 347.3 ± 8.0 
 
343.5 ± 8.2 
 
Spermidine * 2627.8 ± 39.1 
 
2115.9 ± 94.8 
 
Betaine ** 897 ± 22.89 1531 ± 34.79 
Choline ** 650 ± 67.41 3859 ± 71.03 
Decarboxylated S-adenosyl methionine (dc-SAMe) ** 44 ± 1.00 22 ± 0.86 
Serine ** 10 ± 0.37 11 ± 0.40  
Threonine ** 305 ± 7.89 302 ± 8.10 
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Figure S1 
	
	
	
Figure S1 – Analysis of the size distribution of the EVs released from the two pairs of drug-sensitive 
and MDR counterpart cell lines, obtained with the Nanosight nanoparticle tracking system. A – EVs 
isolated from NCI-H460 cells. B – EVs isolated from NCI-H460/R cells. C – EVs isolated from K562 
cells. D -  EVs isolated from K562Dox cells. 
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Background:Multidrug resistance (MDR) is a serious impediment to cancer treatment, with overexpression of
drug efflux pumps such as P-glycoprotein (P-gp) playing a significant role. In spite of being a major clinical
challenge, to date there is no simple, minimally invasive and clinically validated method for diagnosis of the
MDR phenotype using non-tumour biological samples. Recently, P-gp has been found in extracellular vesicles
(EVs) shed by MDR cancer cells. This study aimed to compare the EVs shed by MDR cells and their drug-
sensitive cellular counterparts, in order to identify biomarkers of MDR.
Methods: Two pairs of MDR and drug-sensitive counterpart tumour cell lines were studied as models. EVs were
characterized in terms of size and molecular markers and their protein content was investigated by proteomic
analysis and Western blot.
Results: We found that MDR cells produced more microvesicle-like EVs and less exosomes than their drug-
sensitive counterpart. EVs from MDR cells contained P-gp and presented a different content of proteins known
to be involved in the biogenesis of EVs, particularly in the biogenesis of exosomes.
Conclusions: The determination of the size and of this particular protein content of EVs shed by tumour cells may
allow the development of a minimally-invasive simple method of detecting and predicting MDR.
General significance: This work describes for the first time that cancer multidrug resistant cells shed more
microvesicle-like EVs and less exosomes than their drug-sensitive counterpart cells, carrying a specific content
of proteins involved in EV biogenesis that could be further studied as biomarkers of MDR.
© 2015 Elsevier B.V. All rights reserved.
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1. Introduction
Multidrug resistance (MDR) presents a serious challenge to the
efficacious treatment of cancer. Overexpression of drug efflux pumps
can be a significant cause of cancer drug resistance. MDR cells may
be present in a tumour at the time of diagnosis (intrinsic resistance) or
may arise following drug exposure due to drug-selective pressure
(acquired resistance) [1]. Ultimately, MDR cells will survive treatment
with drugs which are substrates of such drug-efflux pumps and hence
through selection can come to dominate the tumour phenotype. In
spite of the important clinical implications of cancer cell MDR, there
are currently no clinically-available drugs to counteract the effects of
these drug efflux pumps since clinical trials of putative agents have dem-
onstrated poor efficacy. Moreover, there is nominimally-invasivemeans
to diagnoseMDR using non-tumour biological samples, whichwould aid
the identification of a patient population that might be likely to be im-
pacted by such inhibitors [2]. Indeed, a biomarker of MDR would aid
identification of patients at greater risk of treatment failure. Ideally, any
such biomarker would be easily sampled from patient's plasma, for ex-
ample if it was shed by such MDR-overexpressing tumour cells.
Drug efflux pumps such as P-glycoprotein (P-gp), ABCG2 or MRP1
belong to the ATP-binding cassette (ABC) superfamily of transporters
and are responsible for the increased efflux of a variety of structurally
unrelated drugs [3]. P-gp is the best studied efflux pump mediating
MDR. It is a 170 kDa membrane protein [4] and has been associated
with drug resistance in various cancers [1,5]. Several studies, including
some carried out by members of our team [6–9], have attempted to de-
velop compounds that act as P-gp inhibitors but, so far, clinical studies
have failed to demonstrate an improvement in therapeutic efficacy
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and there is no clinically approved P-gp inhibitor [6,8,10]. P-gp expres-
sion has been found to be regulated by a transient receptor potential
channel 5 (TrpC5) protein [11],which is a cation channelwith Ca2+per-
meability involved in vesicular trafficking [12]. Very recently TrpC-5 has
been found in the extracellular vesicles (EVs) shed by adriamycin-
resistant human breast cancer cells [11]. The authors who identified
this characteristic of EVs have suggested that monitoring TRPC-5 con-
taining EVs in circulation could be used to predict drug resistance [13].
EVs are a group of vesicles which include exosomes (with endosomal
origin and sizes ranging from 30 to 100 nm), microvesicles (with plasma
membrane origin and sizes ranging from 50 to 2000 nm) or even apopto-
tic bodies (producedby cells undergoing apoptosis and sizes ranging from
50 to 5000 nm) [14]. EVs are released from all cells and are not only rele-
vant for physiological processes (such as immune response) [15] but have
also been implicated in pathological processes such as cancer [16–18]
[19]. EVs are known to be shed in greater amounts by tumour cells than
from normal cells [17] and have been shown to be relevant for the trans-
fer of the drug resistant phenotype. Indeed, tumour drug-sensitive cells
have been shown to become drug-resistant following incorporation of
EVs shed from tumour drug-resistant cells [20–23]. In addition, EVs
were shown to be involved in the intercellular transfer of functional
P-gp fromMDR donor cells to drug-sensitive recipient cells [20–24].
EVs transport material from the releasing cells (donor cells) such as
proteins, miRNAs or even DNA [25] and may be incorporated by
neighbouring cells (receiving cells), in a process resembling a paracrine
effect, or may circulate in the blood and eventually be incorporated by
distant (receiving) cells thereby causing systemic effects [26]. In this
way, EVs may have tremendous implications in the field of biomarker
discovery [25].
In this work, while studying the relevance of EVs as biomarkers of
MDR, we have discovered that the EVs shed by MDR cells were bigger
than the ones shed by their drug-sensitive cellular counterparts. Addi-
tionally, we have shown that the EVs from MDR cells contain P-gp and
have a different content of proteins known to be involved in the biogen-
esis of EVs, when compared with EVs from drug-sensitive counterpart
cells. In summary, our results suggest that MDR cells produce more
microvesicles whereas their drug-sensitive counterparts produce
more exosomes. To our knowledge, this has never been described.
Additionally, we propose that the determination of the size of the EVs
and of their content in these specific proteins could be further explored
to detect and predict MDR phenotype.
2. Methods
2.1. Cell lines and reagents
The non-small cell lung cancer cell line NCI-H460 (named H460 in
the figures for reasons of space convenience) and its drug-resistant
P-gp overexpressing counterpart cell line RH460 were a kind gift of
Dr. M. Pešić (Belgrade, Serbia) [27,28]. The chronic myeloid leukaemia
cell line K562 was from European Collection of Cell Cultures (ECACC)
and its P-gp overexpressing counterpart cell line K562Dox cells was a
kind gift of Dr. J.P. Marie (Paris, France) [5,29]. All cell lines were geno-
typed. To preserve P-gp expression in the K562Dox cell line, 1 μMdoxo-
rubicin was added to the cells every 2 weeks. All experiments with the
K562Dox cells were performed 6 days after doxorubicin was added to
the cells, in order to maintain the same P-gp expression levels through-
out the experiments. All cells were routinely grown in RPMI-1640 (with
Ultraglutamine I and 25 mM HEPES) medium (Lonza) supplemented
with 10% foetal bovine serum (FBS, PAA) at 37 °C in a humidified incu-
bator with 5% CO2 in air. Cells were routinelymonitored by PCR for pos-
sible mycoplasma contamination (VenorGeM® Advance Mycoplasma
Detection Kit, Minerva). Cell number and viability were analysed with
trypan blue exclusion assay. All experiments were carried out with ex-
ponentially growing cells having over 90% viability. For experiments in-
volving EVs, the following antibodies were used for Western blotting:
TSG101 (4A10) (1:1000) from Gentex; Clathrin LCB (sc-28277)
(1:200), Syntenin-1 (sc-100336) (1:200), Actin (sc-1616) (1:2000), cy-
tochrome c (sc-13560) (1:1000), CHMP4B (sc-82556) (1:100), goat
anti-rabbit IgG-HRP (Sc-2004) (1:2000), goat anti-mouse IgG-HRP
(Sc-2031) (1:2000), donkey anti-goat IgG-HRP (Sc-2020) (1:2000)
from Santa Cruz; P-gp (P7965) (1:2000) from Sigma and Hsp70
(EXOAB-Hsp70A-1) (1:500), CD63 (EXOAB-CD63A-1) (1:1000),
CD81 (EXOAB-CD81A-1) (1:500) from SBI. The following antibodies
were used for flow cytometry: cytochrome c (sc-13,560) (1:5), CD63
(sc-5275) (1:5), CD81 (sc-7637) (1:5) from Santa Cruz and rabbit
anti-mouse FITC (F 0261) (1:20) from Dako.
2.2. Extracellular vesicle isolation
EVs were collected from equivalent amounts of EV-depleted culture
medium (Fig. S3), conditioned by equivalent amounts of cells. EVs were
isolated from these culture media by various centrifugation steps at
4 °C: 10 min at 500 g to remove cells and 10 min at 2000 g to remove
debris (centrifuge 5810R, Eppendorf); 30 min at 10,000 g to remove
larger vesicles and apoptotic bodies (high speed centrifuge AVANTI
J-25, Beckman Coulter) and 60min at 100,000 g to pellet the EVs, follow-
ed by one wash (in PBS) and another centrifugation at 100,000 g for
60 min to remove soluble serum and secreted proteins (Optima XE-
100 Ultracentrifuge, Beckman Coulter) [30]. EV pellets were processed
according to different protocols as follows.
2.3. Dynamic light scattering
The EV size/diameter was measured by dynamic light scattering
(DLS), using a Nano series Malvern Zetasizer Instrument (Prager Instru-
ments). The mean hydrodynamic diameter of exosomes was calculated
by fitting a Gaussian function to the measured size distribution. Prior to
the DLS measurement, each EV pellet was re-suspended in 100 μL of
PBS and added to a cuvette with a 10 mm path length. DLS measure-
ments were conducted at 20 °C, operating at 633 nm and recording the
back scattered light at an angle of 173°. The sample temperature was
allowed to equilibrate for 7min before eachmeasurement. Themeasure-
ment durationwas adjusted automaticallywith threemeasurements per
sample. Results (from 4 independent experiments) were represented as
light scattering intensity (percentage) vs. size (nm). Outliers were de-
tected and rejected by calculation of the Dixon's Q ratio, using P = 0.05.
2.4. Transmission electron microscopy
EVs were re-suspended in PBS, deposited onto Formvar-carbon
coated electron microscopy grids and maintained in the dark at room
temperature for 2 min to allow the membranes to adsorb. EVs were
then stained with 5% uranyl acetate. EVs were visualized in a JEM
1400 transmission electron microscope at an accelerating voltage of
80 kV (Jeol). Digital images were obtained using Orius 1100 W
(Gatan). Images of at least 200 EVs (per sample, from 3 independent
experiments) were taken and ImageJ software was used to determine
particle size. Microsoft's Excel software was used to analyse data and
create particle size distribution histograms.
2.5. Western blotting
EVs or the corresponding donor cells were washed in PBS and then
re-suspended in Winman's buffer (1% NP-40, 0.1 M Tris–HCl pH 8.0,
0.15 M NaCl, and 5 mM EDTA) with EDTA-free protease inhibitor cock-
tail (Roche), and quantified using a modified Lowry assay (Bio-Rad).
After quantification, proteins (5–8 μg in the case of EVs and 20–40 μg
in the case of cells)were separated on a 12% Bis–Tris SDS-PAGE gel load-
ed and transferred onto a nitrocellulose membrane (GE Healthcare).
Membranes were then incubated with the previousmentioned primary
antibodies. Signal was detected using the ECL Western blot Detection
619V. Lopes-Rodrigues et al. / Biochimica et Biophysica Acta 1860 (2016) 618–627
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Reagents (GE Healthcare), the Amersham Hyperfilm ECL (GE
Healthcare), and the Kodak GBX developer and fixer (Sigma) [31]. Pro-
teins were analysed from two or three independent experiments. The
intensity of the bands obtained in each film was further analysed
using the software Quantity One—1D Analysis (Bio-Rad, USA). The sta-
tistical analysis of the Western blots densitometry was carried out
using the Student's t-test. Datawas analysedwith the unpaired test. Dif-
ferences were considered statistically significant if P ≤ 0.05 in drug-
sensitive versus MDR.
2.6. Flow cytometry
EVs were re-suspended in PBS, loaded into 4-mm-diameter alde-
hyde/sulphate latex beads (Interfacial Dynamics, Life Technologies)
and incubated overnight at 4 °C under agitation. Vesicle-coated beads
were further incubated for 30minwith 100mMglycine to block the re-
maining binding sites. The bead–EV complexes were washed three
times in PBS with 0.5% BSA. The bead–EV complexes were incubated
with the primary antibodies previous described (CD63, CD81 and cyto-
chrome c — corresponding isotype control) for 30 min at 4 °C, before
being washed three times in PBS with 0.5% BSA. The bead–vesicle com-
plexes were then incubated with the secondary antibody (goat anti-
mouse FITC, Dako) for 30 min at 4 °C and washed twice in PBS with
0.5% BSA [30]. Samples from the NSCLC model were analysed with a
BD Accuri Flow cytometer (BD Biosciences) and samples from the
CML model were analysed with the same cytometer or with the
FACSCalibur (BD Biosciences) flow cytometer. The flow cytometry
data (from three or four independent experiments) was analysed
using the FlowJo Software (Tri Star Inc.).
2.7. Sample preparation and mass spectrometry using LC/MS/MS
Pellets from EVs were lysed in lysis buffer (7 M urea, 2 M thiourea,
30mMTris, 4% CHAPS). Following a clean-up step of the protein lysates
using the “Ready Prep 2-D clean up kit” (Bio-Rad), protein was quanti-
fied using the “Quick Start Bradford assay” (Bio-Rad). Protein extracts
from EVs (3 μg) were re-suspended in 50 mM ammonium bicarbonate,
reduced in 0.5mMDTT at 56 °C for 20min, allowed to cool to room tem-
perature and alkylated using 55 mM Idoacetamine for 15 min at room
temperature. Proteins were digested with Trypsin Gold (Promega;
ratio of 1:19 trypsin:protein) overnight at 37 °C. Samples were then ad-
ditionally cleaned up using “Pep-clean C18 spin columns” (Thermo
Fisher Scientific), spun in a vacuum centrifuge until dried and stored
at−20 °C. Before the mass spectrometry analysis, dried peptides were
re-suspended in 25 μL of 0.1% formic acid in 2% acetonitrile.
Nano LC–MS/MS analysis was carried out using an Ultimate 3000
nanoLC system (Dionex) coupled to a hybrid linear ion trap/Orbitrap
mass spectrometer (LTQ Orbitrap XL; Thermo Fisher Scientific). Five
μL of digest was loaded onto a C18 trap column (C18 PepMap, 300 m
ID × 5 mm, 5 m particle size, 100 Å pore size; Dionex) and desalted
for 3 min using a flow rate of 25 μL/min in 0.1% TFA in 2% ACN. The
trap column was then switched online with the analytical column
PepMap C18, 75 μm ID × 500 mm, 3 μm particle and 100 Å pore size;
(Dionex) and peptides were eluted with the following binary gradients
of solvents A and B: 0–25% solvent B in 240min and 25–50% solvent B in
a further 60min,where solvent A consisted of 2% acetonitrile (ACN) and
0.1% formic acid in water and solvent B consisted of 80% ACN and 0.08%
formic acid in water. Column flow rate was set to 350 nL/min. Data was
acquired in data-dependent mode and externally calibrated, with
Xcalibur software, version 2.0.7 (Thermo Fisher Scientific). Survey
scan MS data were acquired in the Orbitrap on the 400–1800 m/z
range with the resolution set to a value of 30,000 at 400 m/z. Up to
three of the most intense multiply charged ions (1+, 2+ and 3+)
per survey scanwere CID fragmented in the linear ion trap. Collision en-
ergy was normalized to 35%. A dynamic exclusion windowwas applied
within 40 s. Full scan mass spectra were recorded in profile mode and
tandem mass spectra in centroid mode. Biological replicates (from 4
independent experiments) were analysed for each sample type.
MS data analysis was carried out using the workflow in Proteome
Discoverer software 1.4.0 (Thermo Scientific) for processing LTQ
Orbitrap raw file with Sequest HT and Mascot. Database searches were
performed using the UniProtKB/SwissProt Human database (SwissProt
fasta databasewas downloaded in January 2014). The search parameters
usedwere as follows: Peptidemass tolerance set to 20 ppm,MS/MSmass
tolerance set at 0.6 Da; up to twomissed cleavages were allowed, carba-
midomethylation set as a fixed modification and methionine oxidation
set as a variable modification. The following filters were applied: maxi-
mum peptide delta Cn = 0.1; for charge state 1, XCorr N 1.9; for charge
state 2, XCorr N 2.2; for charge state 3, XCorr N 3.75; Mascot significance
threshold = 0.05; peptide ion scores ≥ 40. Protein identifications were
accepted if they passed the above statistical criteria. A protein was
considered identified in the EVs when it was recognized at least in one
of the four biological replicate samples. The proteins involved in the bio-
genesis of EVs were identified the in the following number of indepen-
dent experiments: once in the case of Clathrin LCB, twice in the case of
TSG101 and three times in the case of Syntenin-1, CHMP4B and Alix.
3. Results
3.1. Multidrug resistant cells produce larger EVs than their sensitive cellular
counterparts
In this work, two different pairs of isogenic cell line models were
used, chronic myeloid leukaemia, CML (K562 and its MDR counterpart,
overexpressing P-gp—K562Dox) and non-small cell lung cancer, NSCLC
(NCI-H460 and its MDR counterpart, overexpressing P-gp — RH460).
Cells were genotyped to confirm their origin (data not shown) and con-
firmation of the MDR phenotype in the K562Dox and RH460 cells
(when compared to their drug-sensitive counterparts) was also carried
out with two different drugs, doxorubicin and etoposide (Fig. S1). EVs
from the two different models were collected by ultracentrifugation
and characterized in terms of size and presence of EV markers (Fig. 1).
The size of the isolated populations of EVswas analysed by two different
approaches: dynamic light scattering (DLS) and transmission electron
microscopy (TEM). EVs have been described as including vesicles of dif-
ferent sizes (including exosomes andmicrovesicles) [14] and indeed the
results obtained showed heterogeneous populations of EVs, with size
ranging from 10 to 1000 nm by DLS and 10 to 300 nm by TEM (Fig. 1A
and B). CD63, CD81 and Hsp70 (markers of EVs) were observed in the
populations analysed (EVs from the two pairs of isogenic models) and
the absence of cytochrome c was confirmed, which excluded possible
contamination by cellular debris in the populations analysed (Fig. 1C).
P-gp expression was only detected in EVs shed by the MDR cell lines
(K562Dox and RH460; Fig. 1C) and not in their sensitive counterparts,
in agreement with the fact that this drug-efflux pump is only present
in the MDR cell lines (Figs. 1C and S1).
Interestingly, when carefully analysing the populations of EVs in
terms of size, a clear difference was observed between the sensitive
EVs and their MDR counterparts. Indeed, EVs produced by MDR cells
had an average diameter bigger than the diameter of EVs produced by
their sensitive counterparts (Fig. 1A and B). This was observed in both
cell line models used (CML and NSCLC) and by the two different size
characterization methods performed, DLS and TEM. Even though both
techniques used to analyse sizes indicated the same trend, i.e. bigger
EVs inMDR cells, slight quantitative differenceswere observed between
the two techniques. This is probably due to the fact that unlike TEM, DLS
is an indirect method that measures the light scattered by the particles,
therefore it is less sensitive in distinguishing single particles fromaggre-
gates, when compared to TEM. Indeed, when analysing TEM results for
both pairs of cell lines (direct EVs observation) it was verified that EVs
from sensitive cells presented a size range between 10 and 80 nm,
which was lower than the size range between 40 and 200 nm of the
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EVs isolated from the MDR cells. These results showed that MDR cells
shed EV populationswith a different size (and possibly a different intra-
cellular origin)when compared to their drug- sensitive cellular counter-
parts. In addition, MDR cells seem to produce more EVs than the
sensitive counterpart cell lines, as can be seen by the DLS count rate
and protein quantification (Table 1 in [32]).
3.2. Multidrug resistant cells shed EVs with a different signature of proteins
known to be involved in the biogenesis of EVs
Given the fact that the EVs isolated from the MDR cells were bigger
in size than their drug-sensitive counterparts, the possibility that
these vesicles had different intracellular origins and therefore different
protein contents was raised. Thus, an extensive proteomic analysis of
the content of EVs shed from the pair of chronic myeloid leukaemia
cells (K562 and K562Dox) was carried out using LC/MS/MS technology.
For the two types of isolated vesicles, a total of 304 proteins were iden-
tified. This technique allowed to identify 232 proteins in EVs shed from
K562 cells and 207 proteins in EVs shed from K562Dox cells, of which
135 proteins overlapped in the two models of EVs (Table 2 in [32]). A
PHANTER analysis was performed, but no major differences were ob-
served between the two types of EVs, in terms of protein clusters in-
volved in biological processes, molecular functions or pathways (Fig. 1
in [32]). Overall, most of the proteins identified in this study were in
agreement with proteins previously identified in EVs produced
by other cells (according to the ExoCarta exosome database, www.
Fig. 1.Multidrug resistant cells (K562Dox and RH460) produce EVs with bigger sizes than their sensitive cellular counterparts (K562 and NCI-H460). A— Size distribution of EVs isolated
from K562 and K562Dox cells (left panel) or from NCI-H460 and RH460 cells (right panel) analysed by dynamic light scattering. Results are the mean of 4 independent experiments
(biological replicates) and were generated by the Zetasizer software v7.03. B — Size distribution histograms of EVs isolated from: K562 and K562Dox cells (left panel) or from NCI-
H460 and RH460 cells (right panel) analysed by transmission electron microscopy. Results are expressed as mean ± SEM from 3 independent experiments (biological replicates)
(with representative TEM image), in which at least 200 EVs were analysed. Scale bar = 200 nm. C — Expression of EV markers in cells and EVs isolated from the four cell lines (K562,
K562Dox, NCI-H460 and RH460) analysed by Western blot (upper panels). Image refers to crop blots from samples run under the same experimental conditions (Fig. 1 in [32]). Flow
cytometry analysis of EV markers on EVs isolated from the four cell lines (lower panels). EVs were coated with beads prior to being incubated with the appropriate antibodies and
analysed by flow cytometry. Results are the mean of at least 3 independent experiments (biological replicates).
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exocarta.org). In addition, these results from the detailed protein analy-
sis further supported the fact that EVs were accurately isolated in this
study (as had been previously shown with the data presented above,
in Fig 1). LC/MS/MS results were then carefully analysed in order to
identify proteins previously known to be relevant for the biogenesis of
EVs, which could present different patterns of expression in the EVs
from the two cell lines. From the 304 proteins identified, 4 of them
were described as being involved in the biogenesis of EVs: Alix
(Q8WUM4), Clathrin light chain B (P09497), Syntenin-1 (O00560)
and TSG101 (Q99816) (Table 1). Alix, Clathrin light chain B and
Fig. 1 (continued).
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TSG101 were only detected in EVs from K562Dox cells, whereas
Syntenin-1was only detected in EVs fromK562 cells. In addition, anoth-
er protein known to be involved in the biogenesis of EVs, CHMP4B
(Q9H444), was identified in the EVs shed from both cell lines.
We then sought to validate these proteomic findings usingWestern
blot analysis. These analyses were performed in the EVs from the leu-
kaemia pair of MDR and drug-sensitive cells and also extended to the
EVs from the NSCLC pair of MDR and drug-sensitive cells, in order to
confirm if there was a “protein signature” common to EVs shed by
MDR cells independently of their cellular context (in this case CML vs.
NSCLC). In addition to the expression of 4 referred proteins, the levels
of CD63 (EV marker), were also analysed (Fig. 2).
Results from the comparison of protein expression between EVs of
MDR cells and their drug-sensitive counterparts, by Western blot anal-
ysis, showed that TSG101, Syntenin-1, Clathrin light chain B, CHMP4B
and CD63 proteins had higher expression in the EVs from the drug-
sensitive cells (K562 and NCI-H460) (Fig. 2). These results show that
some of the proteins previously described as being involved in the bio-
genesis of exosomes are less packaged into the EVs shed fromMDR cells,
when compared to their sensitive counterparts. This suggests that EVs
shed by MDR cells not only are larger but have a different type of
biogenesis from the EVs shed by drug-sensitive cells.
Furthermore, the expression levels of these proteins were also
analysed in the cell lines that gave origin to those EVs (the pairs of
MDR and drug-sensitive counterparts from CML and NSCLC), by West-
ern blot (Fig. 3). The results showed no significant differences between
theMDR cells and the drug-sensitive counterparts, in both the lung and
leukaemiamodels, contrary towhatwas previously observed in the EVs,
indicating that there is selectively packaging of the previously men-
tioned proteins into the EVs.
4. Discussion
Since multidrug resistance (MDR) is a major cause of cancer treat-
ment failure [1], biomarkers ofMDR are urgently needed to guide better
treatment decisions.
In the present study, we demonstrate thatMDR cells shed bigger EVs
andwith a particular protein content. Nevertheless, these proteinswere
detected with similar expression levels in the pairs of MDR and drug
sensitive cell lines, which suggests that there is selective packaging of
those proteins into the EVs. Selective packaging of EVs has been previ-
ously described in several studies. Valadi and collaborators reported
that secretory EVs from mast cells contain not only a distinctive set of
proteins but also of mRNAs and microRNAs [33]. Recently, other group
also demonstrated a selective packaging of miRNAs in the EVs cargo,
upon release from the donor cells [34]. Additionally, they have also
shown that EVs selectively incorporate transcripts of the vesiculation
machinery (floppase and scramblase) [34]. Our work adds knowledge
and impact to the previous studies as we have shown selective packag-
ing of other proteins involved in the biogenesis of EVs themselves,
associated with different sizes of EVs. We believe that this finding
could be further studied in order to develop a “biomarker of MDR”.
We do not know if these characteristics (typical size and protein con-
tent) are specific of MDR, of P-gp overexpression or of drug resistance
in general, since in this study we only used MDR cell models (with P-
gp overexpression) and some authors previously noted intensive for-
mation of membrane vesicles in an atypical MDR cell line (without
overexpression of P-gp) [35].
Different types of EVs, including exosomes and microvesicles, have
different intracellular origin and biogenesis (exosomes having
endosomal origin and smaller sizes and microvesicles having a plasma
membrane origin and bigger sizes) [14]. Therefore, exosomes and
microvesicles probably have different composition and function as
well. We found that the drug-sensitive cells produce smaller EVs con-
taining greater amounts of proteins described to be mainly involved in
the biogenesis of exosomes,whereasMDR cells produce bigger EVs con-
taining smaller amounts of those proteins. This is true for both theMDR
models used in this study (CML and NSCLC), which suggests that a dif-
ferent generalized intercellular origin of the EVs shed from MDR cells
or sensitive cells may exist. It is possible that MDR cells produce more
microvesicles,whereas drug-sensitive cells producemore exosomes. In-
deed, regarding the sizes of the vesicles, the EVs shed from the drug-
sensitive cells had a size range between 10 and 80 nm which is closer
to the “exosomes size range” (30 to 100 nm [14]). In the EVs isolated
from the MDR cells, the sizes oscillated between 40 to 200 nm, closer
to themicrovesicle size range of 50 to 2000 nm [14]. Moreover, proteins
such as TSG101 [36–39], CHMP4 [37], CD63 [14], Syntenin-1 [37] and
Clathrin [40], here found to be increased in the drug-sensitive EVs (in
the Western blot results) have been described to be mainly involved
in the biogenesis of exosomes.
Exosomes are formed within the endosomal network. They are re-
leased from late endosomal compartments to the plasma membrane
through the fusion of multivesicular bodies. The key step in exosome
formation is the reorganization of endosomal membrane proteins
(CD9 and CD63) into microdomains. Next, endosomal sorting com-
plexes required for transport (ESCRTs) are recruited to the site of bud-
ding. ESCRT-I and -II drive endosomal membrane budding via Alix
that simultaneously binds to TSG101 (component of the ESCRT-I) and
CHMP4 (component of ESCRT-III) [14,41]. Syntenin-1 has been shown
to interact directly with Alix in the exosomes formation [37] and
Clathrin is the protein that forms a coat in the EVs membrane, playing
a major role in the internalization of EVs [42].
The development of methods to discriminate between microvesicles
and exosomes is one of the main goals of the EV field. Unfortunately,
there is still a lack of necessary knowledge todistinguish different EVpop-
ulations according to their size, structure or protein compositions. Some
proteins were described as being specifically involved in the biogenesis
of microvesicles [43] [14], but recently some of them were also found to
be important for the biogenesis of exosomes (such as ARF6 and PLD2
[44]). Nevertheless, a conventionally accepted hypothesis is that the
microvesicles formation is inducedby translocation of phosphatidylserine
to the outer-membrane leaflet through the activity of flippases, leading to
theplasmamembrane curvature [45]. Our data raise thepossibility that P-
gpmight be involved in this process since it has beenpreviously described
to act as aflippase for simple glycosphingolipids [46] and since our results
indicate that the MDR cells, which overexpress P-gp, shed bigger EVs
(possibly microvesicles) with lower amounts of proteins involved in bio-
genesis of exosomes. This hypothesis needs to be investigated.
Table 1
Proteins involved in EV biogenesis identified by mass spectrometry in K562 and K562Dox EV preparations.
Protein name UniProt accession a Function in EV biogenesis Mass (kDa) b ∑Coverage % by amino acid ∑Unique peptides K562 EVs K562Dox EVs
Alix Q8WUM4 Binds the ESCRT-I with ESCRT-III 96 19.01 12 ND Detected
CHMP4B Q9H444 Component of ESCRT-III 24.9 20.09 4 Detected Detected
Clathrin LCB P09497 Coats the early endosome membrane 25.2 4.37 1 ND Detected
Syntenin-1 O00560 Interacts directly with Alix 32.4 7.72 2 Detected ND
TSG101 Q99816 Component of ESCRT-I 43.9 2.56 1 ND Detected
ND—not detected.
a Accession number in the UniProt database.
b Molecular weight of the protein.
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Fig. 2. EVs shed by MDR cells exhibit a different signature of proteins involved in the biogenesis of EVs, when compared to their sensitive counterparts. EV's protein content was analysed
byWestern blot and the levels of proteins involved in the biogenesis of EVs, together with the levels of CD63 (EVs marker), were compared between the EVs shed by the MDR cells and
their sensitive counterparts. Blots are representative of three independent experiments (biological replicates). Image refers to crop blots from samples run under the same experimental
conditions (Fig. 1 in [32]). Densitometry analysis was performed and results are represented as a % of relative protein expression (comparing the EVs shed fromMDR cells, with the EVs
from the drug-sensitive counterpart cells). Intensity of the bands was normalized with a corresponding internal control (actin), as previously published by other authors [52]. Each bar
represents the mean ± SE from three independent experiments (biological replicates). * indicates P ≤ 0.05.
624 V. Lopes-Rodrigues et al. / Biochimica et Biophysica Acta 1860 (2016) 618–627
		116
RESULTS  AND  D ISC USSION  
  
Another relevant observed difference was that the MDR cells pro-
duced more EVs than the sensitive counterpart cell lines. The fact that
MDR cells produce more EVs has been previously described in other
studies. In 2012, Goler-Baron et al. showed that the inhibition of Akt sig-
nalling in a MDR breast cancer cell line resulted in the re-localization of
ABCG2 from the EVs to the plasma membrane, which possibly led to a
decrease in number and size of EVs [47]. Other work demonstrated
that the increased expression of Annexin A3, in platinum-resistant
ovarian cancer cells, resulted in the formation of increased numbers of
multivesicular bodies (MVBs) in the cytoplasm [48]. Finally, another
group demonstrated that the intracellular compartment of exosome as-
sembly (MVB formation) was regulated by the ATP-binding cassette
transporter A3 (ABCA3), associated with MDR. They observed a huge
exosome release mediated by ABCA3 [49]. According to these reports
and our own results, P-gp is possibly involved in the regulation of the
EVs release in some way, since it is a common overexpressed protein
Fig. 3. MDR cells and their sensitive counterparts do not present differences in the expression of most of the proteins involved in the biogenesis of EVs. Cellular protein content was
analysed by Western blot and the levels of proteins involved in the biogenesis of EVs were compared between the MDR cells and their sensitive counterparts. Blots are representative
of three independent experiments (biological replicates). Image refers to crop blots from samples run under the same experimental conditions. In the densitometry analysis charts,
results are presented as % of relative protein expression comparing MDR cells with the drug-sensitive counterpart cells. Intensity of bands was normalized with the corresponding
internal control (actin). Each bar represents the mean ± SE from 3 independent experiments (biological replicates). * indicates P ≤ 0.05.
625V. Lopes-Rodrigues et al. / Biochimica et Biophysica Acta 1860 (2016) 618–627
 	 117	
RESULTS  AND  D ISC USSION  
  
between the twomodels used in the present study (CML and NSCLC). It
would be interesting to study if and how P-gp could be regulating the
release and content of EVs. It is known that EVsmay be isolated in path-
ological states and that those EVs contain a tissue-disease-type signa-
ture where a cargo of proteins and RNA are selectively package.
Besides, EVs present a membrane structure that helps to protect the lu-
minal contents from protease degradation and they are a less complex
sample when compared to whole bodily fluids. Therefore, they could
function as excellent molecular biomarkers to be used for diagnosis
and prognosis [50,51], particularly given the fact that EVs can be easily
collected frombody fluids in a non-invasive approach,making them op-
timal biomarkers in order to diagnose cancer and even other diseases
such as ones caused by microorganisms which shed EVs.
Combining this knowledge with our results, we propose that the
specific size and protein content that we have here identified for the
EVs shed by the MDR cells may have diagnostic significance in cancer
as biomarkers to identify the MDR phenotype. However, the present
work was only performed in vitro (in cell lines) and this hypothesis
needs in vivo validation in mice and human samples. Therefore, our
future work will investigate this hypothesis by monitoring these bio-
markers in plasma of nude mice xenografted with human tumours
and in plasma of patients with MDR tumours.
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Supplementary Methods 
 
Response of cells to chemotherapeutic drugs 
For the analysis of the response of the pair of chronic myeloid leukaemia cells (K562 and 
K562Dox) to drugs, cells (3 x105/ml, plated in 24-well plates) were treated for 48 h with 
serial dilutions of etoposide (ranging from 50 to 800 nM; Sigma) or doxorubicin (ranging 
from 7.5 to 120 nM; Sigma). Cell number and viability was then determined with the trypan 
blue exclusion assay. For the analysis of the response of the pair of non-small cell lung 
cancer cells (H460 and RH460) to drugs, the sulforhodamine B (SRB) assay was carried 
out (with cells in 5% FBS supplemented medium). Briefly, cells (5x103/well) were plated in 
96-well plates and incubated for 24 h. Cells were then treated with serial dilutions of 
etoposide (ranging from 20 nM to 1.6μM) or doxorubicin (ranging from 15 to 240 nM). 
Following 48 h, plates were fixed with 10% ice cold trichloroacetic acid, washed with water 
and stained with SRB. After washing with 1% acetic acid, SRB was solubilized with 10 mM 
Tris base and absorbance (510 nm) was measured in a microplate reader (Synergy Mx, 
Biotek Instruments Inc.). In all experiments, the effect of the drug solvent (DMSO) was 
analysed by treating with the maximum concentration used. 
 
Ponceau-S staining 
Proteins isolated from EVs (5 to 8 μg) were separated on a 12% Bis-Tris SDS– PAGE gel 
and transferred onto a nitrocellulose membrane (GE Healthcare).  The molecular weight 
marker Precision Plus Protein Standards, Dual color, Catalog #161-0374 from BIO-RAD (3 
μl) was also included. For loading control, membranes were stained with a Ponceau-S 
solution (Sigma).  
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Supplementary Figure Legend 
 
Figure S1: K562Dox and RH460 are multidrug resistant and overexpress P-
glycoprotein. Dose-response curves of K562/K562 Dox cells (A) and H460/RH460 cells 
(B) following 48 h treatment with doxorubicin and etoposide (upper panel). P-gp protein 
expression levels in these pairs of cells lines analysed by Western blot (lower panel). 
 
Figure S2: Ponceau-S staining of the Western Blot membranes with the proteins isolated 
from the EVs shed by the two pairs of isogenic cell lines, in order to confirm equal loading 
of the proteins extracted from the EVs. Left panel refers to Figure 2; Middle and right panels 
refer to Figure 1C. 
 
Figure S3: FBS depleted do not express TSG101, P-gp, Syntenin-1 and Clathrin LCB. 
FBS depleted and EVs protein content was analysed by Western blot and the levels of 
proteins involved in the biogenesis of EVs and P-gp expression were compared between 
the FBS depleted and EVs isolated from K562 and K562Dox cells. Image refers to crop 
blots from samples run under the same experimental conditions. 
 
Supplementary Figures 
 
Figure S1 
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Figure S2  
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To date, there are no simple and minimally invasive methods to
diagnose MDR. Extracellular vesicles (EVs) are shed by all cells, carry
a specific cargo from the donor cells and are present in several body
fluids, which means that they can potentially be easily collected
from cancer patients and become the source of biomarkers to
diagnose cancer. This data article contains a full list of the proteins
identified in the EVs shed by an isogenic pair of chronic myeloid
leukaemia cells (MDR cells and their drug-sensitive counterparts)
by LC/MS/MS analysis, together with their GeneOntology analysis. In
addition, it also contains data from protein content analysis and
Dynamic light scattering count-rate events of the referred EVs as
well as of the EVs shed from an isogenic pair of non-small cell lung
cancer cells (MDR cells and their drug-sensitive counterparts). The
interpretation of the data presented in this article and further
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extensive insights can be found in “Multidrug resistant tumour cells
shed more microvesicles-like EVs and less exosomes than their
drug-sensitive counterpart cells” [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Specifications Table
Subject area Health sciences
More specific sub-
ject area
Cancer Multidrug resistance, Extracellular vesicles
Type of data Tables and figure
How data was
acquired
Optima XE!100 Ultracentrifuge, Beckman Coulter; Nano series Malvern
Zetasizer Instrument (Prager Instruments); Ultimate 3000 nanoLC system
(Dionex) coupled to a hybrid linear ion trap/Orbitrap mass spectrometer (LTQ
Orbitrap XL; Thermo Fisher Scientific).
Data format Analyzed
Experimental
factors
Multidrug resistance
Experimental
features
Extracellular vesicles (EVs) isolated from multidrug resistant (MDR) cells
(overexpressing P-glycoprotein) and from their drug-sensitive counterpart cells
were used to obtain the data.
Data source
location
– i3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto,
Portugal
– Cancer Drug Resistance Group, IPATIMUP – Institute of Molecular Pathology
and Immunology of the University of Porto, Porto, Portugal
– NICB – National Institute for Cellular Biotechnology, Dublin City University,
Dublin 9, Ireland
Data accessibility Data within this article
Value of the data
" These data describe the quantification of EVs isolated from MDR cells and from their drug sensitive
counterpart cells.
" Data regarding the use of LC–MS/MS analysis to compare EVs isolated from MDR and drug-
sensitive counterpart cells.
" EVs isolated from MDR and their drug-sensitive counterpart cells could be valuable for future
research on the acquisition of MDR phenotype and improving knowledge in the diagnosis of MDR.
Data
The protein content and DLS count-rate events of EVs isolated from MDR and drug-sensitive cells
have been shown (Table 1). In Table 2 a list of proteins identified by mass spectrometry, in EVs iso-
lated from CML cells (K562 – drug-sensitive cells and K562Dox – MDR cells) have been mentioned.
Moreover, Fig. 1 shows Gene Ontology analysis performed in the protein list obtained by LC/MS/MS of
V. Lopes-Rodrigues et al. / Data in Brief 6 (2016) 1023–10271024
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EVs isolated from K562 and K562Dox cells, based on the biological processes, molecular functions and
pathways.
1. Experimental design, materials and methods
EVs were isolated from two pairs of isogenic cell lines (MDR and the drug-sensitive counterpart)
from two different cancer models, non-small cell lung cancer-NSCLC (H460 – drug-sensitive cells and
K562 EVs
B
M
P
GO 
iological 
process 
GO 
olecular 
function 
athways 
K562Dox EVs
Fig. 1. Gene Ontology analysis based on biological process, molecular function and pathway. The analysis was performed in the
protein list obtained by LC/MS/MS analysis in the EVs isolated from K562 and K562Dox cells.
Table 1
Protein content and DLS count-rate events of EVs isolated from MDR and drug-sensitive cells from both models (CML and
NSCLC).
Protein content (μg) Count Rate (kcps)
K562 970.7 167.372.28
K562Dox 1471.5 265.977.71
H460 772.2 149.579.3
RH460 1172.8 168.475.8
EVs were isolated from the two pairs of (MDR and drug-sensitive) cell lines (from CML and NSCLC). Proteins were extracted and
quantified. Count rate was determined by DLS. Data refers to protein quantity (μg) and count rates obtained for EVs isolated
from the same number of cells. Results refer to mg7S.E. or to kcps7S.E.
V. Lopes-Rodrigues et al. / Data in Brief 6 (2016) 1023–1027 1025
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RH460 – MDR cells) [2,3] and chronic myeloid leukaemia-CML (K562 – drug-sensitive cells and K562Dox
– MDR cells) [4,5]. Cells were used to isolate EVs, for protein quantification (Table 1), Dynamic light
scattering (Table 1) and proteomic experiments (Table 2 and Fig. 1).
1.1. Isolation of Extracellular vesicles
EVs were collected from the supernatant of equivalent amounts of cells, cultured in EVs-depleted
culture medium. EVs were isolated from these culture media as previously published [6,1] by various
centrifugation steps.
1.2. Protein quantification
Protein amount of the isolated EVs was quantified as previous published [1].
1.3. Count rate analysis using dynamic light scattering
EVs count rate was measured by dynamic light scattering (DLS), using a Nano series Malvern
Zetasizer Instrument (Prager Instruments) as previously published [1].
1.4. Sample preparation and mass spectrometry
Pellets of EVs were prepared using previously established methods [1]. Nano LC–MS/MS analysis
was carried out using an Ultimate 3000 nanoLC system (Dionex) coupled to a hybrid linear ion trap/
Orbitrap mass spectrometer (LTQ Orbitrap XL; Thermo Fisher Scientific) [1]. MS data analysis was
carried out as previously described [1]. A protein was considered as being identified in the EVs when
it was recognized at least in one of the four biological replicate samples.
1.5. PHANTER analysis
Proteins identified in the samples of EVs were analysed using GeneOntology (GO) in the PANTHER
database to identify biological processes, molecular functions and pathways (http://www.pantherdb.
org/).
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Supplementary data associated with this article can be found in the online version at http://dx.doi.
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Dear Editor, 
This letter aims to emphasize the importance of proper handling and storage of 
protein lysates for downstream applications such as Western blot, when analyzing the 
expression of the protein ALIX (programmed cell death 6-interacting protein). 
The increasing interest in extracellular vesicles (EVs) has provided more relevance 
to the analysis of this protein, since it has been defined as one of the best well known 
molecular markers of EVs (particularly for exosomes) 1. ALIX is a cytosolic protein that was 
initially identified due to its association with pro-apoptotic signaling 2. More recently, ALIX 
was found to regulate other cellular mechanisms such as endocytic membrane trafficking 
and cell adhesion 3. Much of the recent progress in tackling the function of ALIX has been 
centered on its connection to the endocytic membrane trafficking. This protein interacts with 
several ESCRT (endosomal sorting complexes required for transport) proteins in order to 
participate in the budding and abscission processes that ultimately can lead to the formation 
of exosomes 2,4. 
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The predicted expression pattern of ALIX in Western Blot analysis is composed of a 
single band, with an approximate size of 93 kDa 4.  However, several recent studies show 
more than one band when presenting Western Blots for ALIX expression. Indeed, several 
bands have been observed, in Western Blots containing protein lysates from both cell lines 
or EVs 5-10. In some of these studies 5,6,8, ALIX is presented as having two (or even more) 
bands, a major one on the predicted size (approximately 93 kDa) and  other(s) with smaller 
sizes. In other studies, although ALIX is presented as only one band within the expected 
size 7,9,10,  the supplementary information (in which the respective uncropped blots are 
shown) clearly demonstrates the presence of other band(s) which are not identified. Given 
the increase interest in ALIX in the last few years 9,11 and our own need to analyse the 
expression of this protein, we decided to further understand the divergence on the 
expression pattern of ALIX. 
It is known that a proper storage temperature is one of the most important factors in 
order to maintain protein’s integrity over an extended period of time 12. Therefore, we 
analyzed total protein cell lysates from a chronic myeloid leukaemia cell line (K562) for ALIX 
protein expression by Western blot, using two of the most commonly used antibodies (ALIX 
sc-49268 from Santa Cruz Biotechnology and ALIX #2171 from Cell Signaling 
Technologies). The samples were kept at -20 ºC (with or without phosphatase inhibitors) 
and at -80 ºC for different periods of time (1, 2, 3 or 6 weeks). After performing Western blot 
analysis, of the frozen samples, we detected at least two bands (using either antibody) 
(Figure 1): i) one with a molecular weight similar to the predicted one, 93 kDa (93 kDa - 
ALIX) and ii) another with approximately 75 kDa (75 kDa – ALIX). In order to confirm that 
the antibody was specifically detecting ALIX in both bands, we performed a mass 
spectrometry analysis. We detected 20 peptides related to ALIX in the 93 kDa protein band 
corresponding to the N-terminus peptide 24-41 and the C-terminus peptide 716-745. In the 
75kDa band, we still detected the N-terminus peptide but the C-terminus 716-745 peptide 
was absent. This led us to conclude that the 75 kDa protein band corresponds to a degraded 
form of ALIX in which the C-terminal is missing.  
When analyzing the samples kept at -20 ºC over time (1, 2, 3 or 6 weeks), both in 
the presence or absence of phosphatase inhibitors, we noticed that the C-terminal specific 
degradation of ALIX depended on the duration of the samples storage at -20 ºC (Fig. 1). In 
fact, over time and at -20 ºC, the expression levels of the 93 kDa – ALIX band decreased 
while the levels of the degraded form (75 kDa – ALIX) increased. In addition, under the 
same conditions (- 20ºC storage), the presence of a phosphatase inhibitor had no effect on 
the level of degradation of this protein (Figure 1). 
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Figure 1 – Expression of ALIX in K562 cells following several storage conditions. Fresh total 
cell protein lysates were immediately stored at: -20 ºC, -20 ºC with a phosphatase inhibitor cocktail 
(+ Ph. Inh) or at -80 ºC. Samples were kept frozen for 1, 2, 3 or 6 weeks. (A) Representative Western 
blot images; (B) Densitometry analysis of the Western blots, represented as mean ± SEM from three 
independent experiments. Actin was used as a loading control. * p ≤ 0.05 when comparing protein 
levels in samples stored at -20 ºC (- Ph. Inh.) vs. other storage conditions (- 80ºC or – 20ºC + Ph. 
Inh.). 
 
 
 Nevertheless, when analyzing the samples stored at -80 ºC for the same period of 
time (1, 2, 3 or 6 weeks), no major degradation of ALIX was observed. In fact, the expression 
level of the 93 kDa – ALIX remained unaltered during the 6 weeks’ period and no increase 
of the degraded form of ALIX (75 kDa – ALIX) was observed (Figure 1).  
Storage of protein lysates for long term periods at -80 ºC was previously advised 12, 
but -20 ºC is commonly used for shorter storage periods. Therefore, the degradation 
observed in ALIX after a short storage (1 or 2 weeks) at -20 ºC was rather unexpected. 
In summary, the obtained results demonstrate that analysis of ALIX protein 
expression should be only carried out when using samples which are either fresh or have 
been properly stored at -80ºC, even for a short time storage period. This would avoid 
misleading information resulting from the analysis of ALIX expression in protein lysates 
which have not been properly frozen to avoid its degradation. 
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Yours sincerely, 
Vanessa Lopes-Rodrigues 
Cristina P. R. Xavier 
Diana Sousa 
Hugo Osório 
Raquel T. Lima 
M. Helena Vasconcelos 
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Abstract  
 
Cancer multidrug resistance (MDR) is a major limitation to the success of cancer 
treatment and is highly associated with the overexpression of drug efflux pumps such as P-
glycoprotein (P-gp). In order to achieve more effective chemotherapeutic treatments, it is 
important to develop P-gp inhibitors to block/decrease its activity. 
Curcumin (1) is a secondary metabolite isolated from the turmeric of Curcuma longa 
L.. Diverse biological activities have been identified for this compound, particularly, MDR 
modulation in various cancer cell models. However, curcumin (1) has low chemical stability, 
which severely limits its application. In order to improve stability and P-gp inhibitory effect, 
two potential more stable curcumin derivatives were synthesized as building blocks, 
followed by several curcumin derivatives. These compounds were then analyzed in terms 
of antitumor and anti-P-gp activity, in two MDR and sensitive tumour lines (from chronic 
myeloid leukaemia and non-small cell lung cancer). We identified from a series of curcumin 
derivatives a novel curcumin derivative (1,7-bis(3-methoxy-4-(prop-2-yn-1-
yloxy)phenyl)hepta-1,6-diene-3,5-dione, 10) with more potent antitumor and anti-P-gp 
activity than curcumin (1). This compound (10) was shown to promote cell cycle arrest (at 
the G2/M phase) and induce apoptosis in the MDR chronic myeloid leukaemia cell line. 
Therefore, it is a really interesting P-gp inhibitor due to its ability to inhibit both P-gp function 
and expression. 
 
 
 
 
 
 
 
 
 
Keywords: curcumin; curcumin derivatives; multidrug resistance; P-glycoprotein 
inhibition; antitumor. 
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1. Introduction  
One of the main causes for the failure of cancer therapy is multidrug resistance (MDR) 
[1]. MDR occurs when cells resist to the treatment with several structurally and functionally 
different compounds, and may either be intrinsic (occurring from the beginning of the 
treatment) or acquired (during treatment) [2, 3]. Multiple mechanisms have been identified 
as being responsible for MDR [4], but although these mechanisms have been intensively 
studied, not all of them have been completely elucidated. One of those mechanisms is the 
increasing activity and/or overexpression of drug efflux pumps, such as P-glycoprotein (P-
gp).  
P-gp is one of the ATP-binding cassette (ABC) transporters whose (over)expression 
frequently confers chemoresistance in cancer [5, 6] [7, 8]. ABC transporters are active 
transporter proteins that use the energy derived from the hydrolysis of ATP to ADP to 
transport their substrates across the cellular membrane, maintaining cellular homeostasis 
and detoxifying the cells from potentially toxic substances [9, 10]. Consequently, these 
proteins, and mainly P-gp, have been targets of several studies to identify novel compounds 
to counteract MDR. 
Although most of the compounds that were designed and used as MDR inhibitors did 
not reach the clinical purpose for which they were developed; the three generations of MDR 
inhibitors identified so far helped to set ground knowledge for the development of novel 
inhibitors [11]. In the last decade, several studies have reported natural compounds (such 
curcumin, 1 or marine compounds) and compounds that were not originally used or 
approved for MDR cancers (e.g. tyrosine kinase inhibitors) as promising drug candidates to 
overcome MDR, mostly due to their intrinsic antitumor activity [5, 12]. In particular, great 
interest has been given to curcumin (1) [13, 14] since this major component of turmeric 
obtained from Curcuma longa L. has been shown to overcome MDR in various cancer cell 
models, also by downregulating MDR1 gene expression [15]. 
Curcumin (1) has been used in Ayurvedic medicine for thousands of years, for its anti-
inflammatory properties and wound healing properties (Figure 1) [16-18]. Nowadays, 
curcumin (1) is being extensively studied for its many biological activities and molecular 
targets. Regarding its anticancer potential, curcumin (1) has been described as being 
responsible for the inhibition of STAT3 and NF-kB signaling pathways [19], associated with 
cancer development and progression, and as an inducer of apoptosis and cell cycle arrest 
in tumours/human tumour cell lines [20].  
Curcumin (1) has low toxicity level, which increases the interest in its possible use as 
an anticancer agent to overcome MDR. However, due to its low bioavailability and poor 
solubility [21, 22], it is necessary to obtain derivatives and analogues with similar anticancer 
		144
RESULTS  AND  D ISC USSION  
potential but without these disadvantages. Several curcumin (1) derivatives have been 
synthesized since the interest in this natural product and antitumor properties were 
disclosed [23]. In the present study, we aimed to synthetize new derivatives that could 
concomitantly reveal tumour cell growth inhibition and P-gp inhibitory activity and to analyze 
the hit compounds in terms of stability. A new curcumin derivative (1,7-bis(3-methoxy-4-
(prop-2-yn-1-yloxy)phenyl)hepta-1,6-diene-3,5-dione, 10) which is more potent than 
curcumin (1) in inhibiting P-gp and decreasing tumour cell growth via cell cycle arrest and 
induction of apoptosis is described.  
 
 
Figure 1 – Chemical structure of curcumin (1). 
	
2. Materials and methods 
2.1. General Methods 
All reagents and solvents were purchased from Sigma-Aldrich, except 2-azidoethyl 2-
acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-galactopyranoside which was purchased from 
LC scientific Inc, Canada (AL356), and had no further purification process, except for 2-
bromo-N,N-diethylethan-1-amine hydrobromide that was submitted to liquid extraction 
(NaOH, CH2Cl2) to be in the non-ionized form. Solvents were evaporated using rotary 
evaporator under reduced pressure, Buchi Waterchath B-480. All reactions were monitored 
by thin layer chromatography carried out on precoated plates with 0.2 mm of thickness 
using Merck silica gel 60 (GF254). MW reactions were performed in glassware open vessel 
reactors in a MicroSYNTH 1600 Microwave Labstation from Millestone (ThermoUnicam, 
Portugal). The internal reaction temperature was controlled by a fiber-optic probe sensor. 
Purification of the synthesized compounds was performed by chromatography flash and 
semi-flash columns using Merck silica gel 60 (0.040-0.063 mm and 0.063-0.200 mm, 
respectively), chromatography flash cartridge (GraceResolv®, Grace Company, Deerfield, 
IL, USA), Discovery® DSC-SAX SPE anionic exchange cartridge, and preparative thin layer 
chromatography using Merck silica gel HPLC60 RP-18 (GF254) plates (Merck, Germany). 
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Melting points (mp) were measured in a Köfler microscope and are uncorrected. Infrared 
(IR) spectra were obtained in KBr microplates in a Fourier transform infrared spectroscopy 
spectrometer Nicolet iS10 from Thermo Scientific with Smart OMNI-Transmisson accessory 
(Software OMNIC 8.3) (cm-1). NMR spectra were performed in University of Aveiro, 
Department of Chemistry, and were taken in CDCl3 (Deutero GmbH) at room temperature 
(r.t.) on Bruker Avance 300 spectrometer (300.13 MHz for 1H an 75.47 for 13C). 13C NMR 
assignments were made by 2D (HSQC and HMBC) NMR experiments (long-range 13C-1H 
coupling constants were optimized to 7 Hz). 
Analytical HPLC-DAD (high-performance liquid chromatography-diode array 
detector) analyses were performed on a SpectraSYSTEM (Thermo Fisher Scientific, Inc, 
USA) equipped with a P4000 pump, a AS3000 autosampler and a diode array detector 
UV8000. The separation was carried out on a 250 × 4.6 mm i.d. FortisBIO C18 (5 µm) 
(FortisTM Technologies Ltd, Cheshire, UK). ChromQuest 5.0 (version 3.2.1) software 
(Thermo Fisher Scientific Inc.) managed chromatographic data. Methanol (HPLC grade) 
was obtained from Carlo Erba Reagents, (Val de Reuil, Italy), acetic acid (HPLC grade) was 
obtained from Romil Pure Chemistry (Cambridge, UK) and HPLC grade water (Simplicity® 
UV Ultrapure Water System, Millipore Corporation, USA). Prior to use, mobile phase 
solvents were degassed in an ultrasonic bath for 15 min. All samples were dissolved and 
filtered through a PTFE syringe filter of 0.2 µm pore size and 4 mm diameter (Thermo Fisher 
Scientific) before injection. To determine the purity of compounds 2, 4, 5 and 11, HPLC 
analysis was performed by isocratic elution using a mixture of MeOH:H2O:acetic acid 
(50:50:1), for compound 8 a mixture of MeOH:H2O:TEA (50:50:1), and for compounds 3 
and 10 a mixture of MeOH:H2O:TEA (70:30:1) as mobile phase. The flow rate was set at 1 
mL/ min. The injected volume was 10 µL and the eluent was monitored at 254 nm for every 
compound except compound 3 which was monitored at 399 nm. The final concentration of 
the tested compounds was 100 µg/mL. The detector was set at a wavelength range of 220–
500 nm with a spectral resolution of 1 nm. The purity parameters included a 95% active 
peak region and a scan threshold of 5 mAU. With these general conditions compounds 6 
and 7 could not be detected (with different mobile phases, with and without ionic 
suppressors).  
Qualitative GC-MS analyses were performed on a Trace GC 2000 Series 
ThermoQuest gas chromatography equipped with ion-trap GCQ Plus ThermoQuest 
Finnigan mass detector. Chromatographic separation was achieved using a capillary 
columm (30 m × 0.25 mm × 0.25 µm, cross-linked 5% diphenyl and 95% dimethyl 
polysiloxane) from Thermo Scientific™ and high-purity helium C-60 as carrier gas. An initial 
temperature of 80 ºC was maintained for 1 min, increased to 310 ºC at 10 ºC/min, and held 
for 5 min giving a total run time of 33 min. The flow of the carrier gas was maintained at 1.5 
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mL/min. The injector port was set at 280 ºC. Analyses were performed with splitless injection 
in the full-scan mode in the scan range of m/z 50-700. For derivatized samples 30 µL of N-
methyl-N-(trimethylsilyl)trifluoroacetamide were added and samples heated at 80ºC for 30 
min to accomplish silylation. An aliquot of 1 µL of the derivatized extract was injected into 
the GC-MS system. HRMS (high resolution mass spectrometry) results were obtained in 
the services of C.A.C.T.I. (Vigo, Spain). 
 
2.2. Synthesis 
2.2.1. Synthesis of 4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one (2) 
Compound 2 was synthesized and isolated according to a previously described 
protocol [24].  
Yield: 64%. mp 127-129oC (EtOH) (lit. 127-128 oC n-hexane: ethyl acetate (EtOAc) 
[24]). Purity: 96%. 1H NMR (CDCl3, 300 MHz) δ: 7.45 (1H, d, J= 16.2 Hz, H-3), 7.09 (1H, 
dd, J= 8.1 and 1.9, H-6’), 7.05 (1H, d, J= 1.9, H-2’), 6.93 (1H, d, J= 8.1 Hz, H-5’), 6.59 (1H, 
d, J= 16.2 Hz, H-2), 6.00 (1H, s, H-4’), 3.92 (3H, s, 3’-OCH3), 2.37 (3H, s, H-1’’); 13C NMR 
(75.47 MHz, CDCl3) δ: 198.7 (C-1), 148.4 (C-4’), 147.0 (C-3’), 144.0 (C-3), 126.8 (C-1’), 
124.9 (C-2), 123.6 (C-6’), 114.9 (C-5’), 109.4 (C-2’), 56.0 (3’-OCH3), 27.3 (C-1’’).  
 
2.2.2. Synthesis of 1,5-bis(4-hydroxy-3-methoxyphenyl)penta-1,4-
dien-3-one (3) 
Compound 3 was synthesized and isolated according to a previously described 
protocol [25]. 
Yield: 5%. mp 74-79oC (n-hexane:EtOAc) (lit. mp 68-70oC MeOH [25]). Purity 72%. 
1H NMR (CDCl3, 300 MHz) δ: 7.68 (2H, d, J= 15.5 Hz, H-3), 7.18 (2H, dd, J= 8.2 and 1.8 
Hz, H-6’), 7.11 (2H, d, J= 1.8 Hz, H-2’), 6.92 (2H, d, J= 8.2 Hz, H-5’), 6.94 (2H, d, J= 15.5 
Hz), 5.99 (2H, brs, H-4’), 3.95 (6H, s, 3’-OCH3); 13C NMR (75.47 MHz, CDCl3) δ: 188.9 (C-
1), 148.2 (C-4’), 147.2 (C-3’), 143.3 (C-3), 127.5 (C-1’), 123.4 (C-2), 123.3 (C-6’), 114.9 (C-
5’), 109.8 (C-2’), 56.0 (3’-OCH3). HRMS- Electrospray ionization (ESI) (+) m/z: Anal. Calc. 
for C19H19O5 [M-H]+ 327.123250, found: 327.12265. 
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2.2.3. Synthesis of 4-(4-(allyloxy)-3-methoxyphenyl)but-3-en-2-one (4) 
To a solution of 4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one (2, 102.9 mg, 0.315 
mmol) and allyl bromide (60 µL, 0.693 mmol) in acetone (20 mL), Cs2CO3 (121.2 mg, 0.37 
mmol) was added and placed in a opened microwave reactor. The mixture under stirring 
was irradiated at 200 W for 2 h, at a final temperature of 65oC. The solid was then removed 
by filtration with a sintered glass Buchner funnel under reduced pressure. The yellow-
orange solution was evaporated and the product purified by semi-flash chromatography 
(SiO2; petroleum ether: diethyl ether: several proportions). The fractions that eluted with 
petroleum ether: diethyl ether 8:2 were gathered and concentrated furnishing a yellow solid 
of 4-(4-(allyloxy)-3-methoxyphenyl)but-3-en-2-one (4, 70 mg, 56%). 
mp 52-55oC (petroleum ether: diethyl ether). Purity 98%. IR (KBr) υmax cm-1 2960, 
2924, 1664, 1639, 1624, 1593, 1511, 1418, 1362, 1252, 1164, 1134, 997, 969, 800. 1H 
NMR (CDCl3, 300 MHz) δ: 7.46 (1H, d, J= 16.2 Hz, H-3), 7.11 (1H, d, J= 2.0 Hz, H-6’), 7.08 
(1H, s, H-2’), 6.88 (1H, d, J= 8.1 Hz, H-5’), 6.61 (1H, d, J= 16.2 Hz, H-2), 6.15-6.02 (1H, m, 
-HC=CH2), 5.46-5.39 (1H, m, -HC=CH2), 5.35-5.30 (1H, m, -HC=CH2), 4.67-4.65 (2H, dt, 
J= 5.4 and 1.4 Hz, 4’-OCH2-), 3.92 (3H, s, 3’-OCH3), 2.38 (3H, s, H-1’’); 13C NMR (75.47 
MHz, CDCl3) δ: 198.4 (C-1), 150.3 (C-4’), 149.6 (C-3’), 143.6 (C-3), 132.7 (-HC=CH2), 127.5 
(C-1’), 125.3 (C-2), 122.8 (C-6’), 118.5 (-HC=CH2), 112.8 (C-5’), 110.0 (C-2’), 69.7 (4’-
OCH2-), 55.9 (3’-OCH3), 27.4 (C-1’’). EI-MS (70 eV) m/z (rel. Intensity, %): 233 (M+1, 18), 
232 (M+, 100), 191 (95), 163 (28), 135 (22). HRMS- ESI (+) m/z: Anal. Calc. for C14H16O3 
[M-H]+ 233.11777, found 233.11722. 
 
2.2.4. Synthesis of 4-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)but-3-
en-2-one (5) 
4-(4-Hydroxy-3-methoxyphenyl)but-3-en-2-one (2, 1.00 g, 3.07 mmol) and propargyl 
bromide (1 mL, 11.22 mmol) were dissolved in acetone (180 mL), Cs2CO3 (680.03 mg, 2.08 
mmol)  was added and placed in an open vessel microwave reactor. The mixture under 
stirring was irradiated at 200 W for 1h 30 min, at a final temperature of 65oC. The solid was 
then removed by filtration with a sintered glass Buchner funnel under reduced pressure. 
The yellow solution was concentrated and the product submitted to a semi-flash 
chromatography (SiO2; petroleum ether: diethyl ether: several proportions). The fractions 
that eluted with petroleum ether: diethyl ether 8:2 were gathered and after solvent 
evaporation a recrystallization from diethyl ether: petroleum ether (4:1) was performed 
providing a white solid of 4-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)but-3-en-2-one (5, 101 
mg, 8%). 
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mp 110-111oC (diethyl ether: petroleum ether). Purity 96%. IR (KBr) υmax cm-1 3258, 
2922, 2851, 1673, 1597, 1515, 1424, 1372, 1272, 1247, 1225, 1168, 1145, 1034, 1006, 
984, 805, 723, 682. 1H NMR (CDCl3, 300 MHz) δ: 7.46 (1H, d, J= 16.2 Hz, H-3), 7.13 (1H, 
d, J= 8.2 Hz, H-6’), 7.09 (1H, s, H-2’), 7.04 (1H, d, J= 8.2 Hz, H-5’), 6.62 (1H, d, J= 16.2 Hz, 
H-2), 4.81 (2H, s, 4’-OCH2-), 3.91 (3H, s, 3’-OCH3), 2.53 (1H, s, -C≡CH), 2.37 (3H, s, H-1’’); 
13C NMR (75.47 MHz, CDCl3) δ: 198.4 (C-1), 149.8 (C-4’), 149.0 (C-3’), 143.3 (C-3), 128.5 
(C-1’)125.7 (C-2), 122.5 (C-6’), 113.6 (C-5’), 110.2 (C-2’), 77.9 (-C≡CH), 76.3 (-C≡CH), 56.6 
(4’-OCH2-), 55.9 (3’-OCH3), 27.4 (C-1’’). EI-MS (70 eV) m/z (rel. intensity, %): 231 (M+1, 25), 
230 (M+, 88), 191 (100), 163 (22). HRMS- ESI (+) m/z: Anal. Calc. for C14H14O3 [M-H]+ 
231.10212, found 231.10157. 
 
2.2.5. Synthesis of 4-(4-(2-(diethylamino)ethoxy)-3-
methoxyphenyl)but-3-en-2-one (6) 
To a solution of 4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one (2, 106.1 mg, 0.325 
mmol) and 2-bromo-N,N-diethylethan-1-amine (175.1 mg, 0.972 mmol) in acetone (20 mL), 
K2CO3 (174.7 mg, 1.26 mmol) was added and placed in a opened microwave reactor. The 
mixture under stirring was irradiated at 200 W for 3h, at a final temperature of 65oC.  When 
the reaction was finished, the solid was removed by filtration with a sintered glass Buchner 
funnel under reduced pressure. After removal of acetone under reduced pressure the crude 
product was dissolved in dichloromethane, acidified with an aqueous solution of HCl 5N 
and extracted with H2O. The aqueous phase was basified with a 20% NaOH aqueous 
solution and extracted with CH2Cl2 (3 × 100 mL). The organic phase was dried with 
anhydrous sodium sulfate, filtrated, and concentrated under reduced pressure to furnish a 
yellow solid of 4-(4-(2-(diethylamino)ethoxy)-3-methoxyphenyl)but-3-en-2-one (6, 5.0 mg, 
3%). 
mp 207-209 oC (CH2Cl2). IR (KBr) υmax cm-1 2959, 2925, 2855, 1729, 1629, 1425, 
1384, 1273, 1124, 669 . 1H NMR (CDCl3, 300 MHz) δ: 7.46 (1H, d, J= 16.2 Hz, H-3), 7.11 
(1H, dd, J= 8.3 and 1.9 Hz, H-6’), 7.07 (1H, d, J= 1.9 Hz, H-2’), 6.91 (1H, d, J= 8.3 Hz, H-
5’), 6.61 (1H, d, J= 16 Hz, H-2), 4.24 (2H, t, J= 6.2 Hz, H-7’), 3.89 (3H, s, 3’-OCH3), 3.08 
(2H, t, J= 6.2 Hz, H-8’), 2.81 (4H, q, J= 7.2 Hz, H-9’), 2.38 (3H, s, H-1’’). 1.17 (6H, t, J= 7.2 
Hz, H-10’); 13C NMR (CDCl3, 75.47 MHz) δ: 198.4 (C-1), 150.3 (C-4’), 149.6 (C-3’), 143.5 
(C-3), 127.8 (C-1’), 125.4 (C-2), 122.9 (C-6’), 112.7 (C-5’), 110.0 (C-2’), 66.4 (C-7’), 55.9 
(3’-OCH3), 51.2 (C-8’), 47.7 (C-9’), 27.4 (C-1’’), 11.0 (C-10’). HRMS- ESI (+) m/z: Anal. Calc. 
for C17H25NO3 [M-H]+ 292.19127, found 292.19072. 
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2.2.6. Synthesis of tert-butyl (2-(2-methoxy-4-(3-oxobut-1-en-1-
yl)phenoxy)ethyl)carbamate (7) 
4-(4-Hydroxy-3-methoxyphenyl)but-3-en-2-one (2, 202.5 mg, 0.621 mmol), 2-(boc-
amino) and ethyl bromide (274 mg, 1.22 mmol) were dissolved in acetone (40 mL), K2CO3 
(204.5 mg, 1.48 mmol) was added and placed in a opened microwave reactor. The mixture 
under stirring was irradiated at 200 W for 3 h, at a final temperature of 65 oC. The solid was 
removed by filtration with a sintered glass Buchner funnel under reduced pressure. The 
yellow solution was purified by semi-flash chromatography (SiO2; petroleum ether: diethyl 
ether: several proportions). The fractions that eluted with petroleum ether: diethyl ether 7:3 
were gathered and the product purified by preparative chromatography with CHCl3: 
acetone: trielthylamine (9:1:0.1) affording an yellow solid of tert-butyl (2-(2-methoxy-4-(3-
oxobut-1-en-1-yl)phenoxy)ethyl)carbamate (7, 4 mg, 1.1%). 
mp 89-92 oC (CHCl3: acetone). IR (KBr) υmax cm-1 3447, 2920, 2852, 1636, 1385, 
1099, 668. 1H NMR (CDCl3, 300 MHz) δ: 7.45 (1H, d, J= 16.2 Hz, H-3), 7.10 (1H, dd, J= 8.1 
and 1.8 Hz, H-6’), 7.06 (1H, d, J= 1.8 Hz, H-2’), 6.94 (1H, d, J=8.1 Hz, H-5’), 6.59 (1H, d, 
J= 16.2 Hz, H-2), 4.91 (2H, m, H-7’), 3.94 (3H, s, 3’-OCH3), 3.23-3.18 (2H, m, H-7’), 2.37 
(3H, s, H-1’’), 2.17 (9H, s, H-10’); 13C NMR (75.47 MHz, CDCl3) δ: 198.5 (C-1), 160.5 (C-
9’), 148.2 (C-4’), 146.9 (C-3’), 143.8 (C-3), 127.0 (C-1’), 125.0 (C-2), 123.6 (C-6’), 114.8 (C-
5’), 109.3 (C-2’), 68.2 (C-7’), 56.0 (3’-OCH3), 29.7 (C-11’), 27.3 (C-1’’). EI-MS (70e V) m/z 
(rel. intensity, %): 335 (M+, 26), 281 (100), 234 (63), 74 (82). HRMS- ESI (+) m/z: Anal. 
Calc. for C18H25NO5 [M-H+Na]+ 358.18109, found 358.16249. 
 
2.2.7. Synthesis of tert-butyl (3-(2-methoxy-4-(3-oxobut-1-en-1-
yl)phenoxy)propyl)carbamate (8) 
A mixture of 4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one (2) (101.6 mg, 0.311 
mmol), 3-(boc-amino) propyl bromide (137 mg, 0.575 mmol), K2CO3 (105.2 mg, 0.76 mmol), 
and acetone (30 mL), was placed in an opened microwave reactor. The mixture under 
stirring was irradiated at 200 W for 3 h, at a final temperature of 65 oC. The solid was 
removed by filtration with a sintered glass Buchner funnel under reduced pressure. The 
yellow solution was purified by semi-flash chromatography (SiO2; n-hexane: diethyl ether: 
several proportions). The fractions that eluted with n-hexane: diethyl ether 7.5:2.5 were 
gathered and after solvent evaporation a recrystallization from diethyl ether: petroleum 
ether (4:1) was performed providing a yellow solid of tert-butyl (3-(2-methoxy-4-(3-oxobut-
1-en-1-yl)phenoxy)propyl)carbamate (8,16.6 mg, 9%). 
		150
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mp 108-110oC (diethyl ether: petroleum ether). Purity 96%. IR (KBr) υmax cm-1  3377, 
1686, 1669, 1644, 1621, 1595, 1518, 1273, 1260, 1225, 1167, 1138, 1033, 975. 1H NMR 
(CDCl3, 300 MHz) δ: 7.46 (1H, d, J= 16.2 Hz, H-3), 7.11 (1H, d, J= 8.2 Hz, H-6’), 7.07 (1H, 
s, H-2’), 6.86 (1H, d, J= 8.2 Hz, H-5’), 6.61 (1H, d, J= 16.2 Hz, H-2), 5.50 (1H, brs, H-10’) 
4.14 (2H, t, J= 5 Hz, H-7’), 3.92 (3H, s, 3’-OCH3), 3.38 (2H, d, J= 5 Hz, H-9’), 2.38 (3H, s, 
H-1’’), 2.04 (2H, t, J= 5 Hz, H-8’), 1.46 (9H, s, H-11’); 13C NMR (75.47 MHz, CDCl3) δ: 198.4 
(C-1), 156.1 (C-10’), 150.5 (C-4’), 149.5 (C-3’), 143.5 (C-3), 127.6 (C-1’), 125.3 (C-2), 122.9 
(C-6’), 112.2 (C-5’), 109.7 (C-2’), 79.0 (C-11’), 68.2 (C-7’), 55.8 (3’-OCH3), 38.9 (C-9’), 30.9 
(C-8’), 28.5 (C-12’), 27.4 (C-1’’). EI-MS (70e V) m/z (rel. Intensity, %): 349 (M+, 96), 308 
(32), 261 (38), 253 (52). HRMS- ESI (+) m/z: Anal. Calc. for C19H27NO5 [M-H]+ 350.19675, 
found 350.19620. 
 
2.2.8. Synthesis of methyl 2-(2-methoxy-4-(3-oxobut-1-en-1-
yl)phenoxy)acetate (9) 
4-(4-Hydroxy-3-methoxyphenyl)but-3-en-2-one (2, 150 mg, 0.78 mmol) and methyl 2-
bromoacetate (80 µL; 0.78 mmol) were dissolved in acetone (20 mL) and K2CO3 (261 mg; 
1.89 mmol) was added. The mixture was placed in an opened microwave reactor where it 
was irradiated at 200 W for 3 h, at a final temperature of 65 oC with stirring. The solid was 
removed by filtration with a sintered glass Buchner funnel under reduced pressure. After 
acetone evaporation, the crude product was dissolved in a basified aqueous solution with 
20% NaOH and extracted with CH2Cl2 (3 × 100 mL). The organic phase was dried by 
anhydrous sodium sulfate, filtrated, and concentrated under reduced pressure to furnish a 
yellow solid of methyl 2-(2-methoxy-4-(3-oxobut-1-en-1-yl)phenoxy)acetate (9, 7.9 mg, 4%). 
mp 79-81oC (CH2Cl2). IR (KBr) υmax cm-1 2918, 2849, 1733, 1634, 1515, 1463, 1262, 
1111, 668. 1H NMR (CDCl3, 300 MHz) δ:7.45 (1H, d, J= 16.2 Hz, H-3), 7.09 (2H, dd, J= 6.7 
and 1.9 Hz, H-6’ and H-2’), 6.80 (1H, d, J= 6.7 Hz, H-5’), 6.61 (1H, d, J= 16.2 Hz, H-2), 4.76 
(2h, s, H-7’), 3.93 (3H, s, 3’-OCH3), 3.81 (3H, s, H-8’), 2.38 (3H, s, H-1’’); 13C NMR (75.47 
MHz, CDCl3) δ: 198.4 (C-1), 169. (C-8’), 149.7 (C-4’), 149.3 (C-3’), 143.2 (C-3), 128.8 (C-
1’), 125.5 (C-2), 122.5 (C-6’), 113.4 (C-5’), 110.5 (C-2’), 66.0 (C-7’), 56.0 (3’-OCH3), 52.4 
(C-9’), 27.4 (C-1’’). HRMS- ESI (+) m/z: Anal. Calc. for C14H16O5 [M-H]+ 265.10760, found 
265.10705. 
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2.2.9. Synthesis of 1,7-bis(3-methoxy-4-(prop-2-yn-1-
yloxy)phenyl)hepta-1,6-diene-3,5-dione (10) 
Curcumin (1) (500 mg, 1.35 mmol), anhydrous Cs2CO3 (4.40 g, 13.5 mmol; 5 
equiv/OH) and Bu4NBr (4.35 g, 13.5 mmol; 5 equiv/OH), were mixed in acetone (10 mL), 
then propargyl bromide solution (80% wt % in toluene, 2 mL; 5 equiv/OH) was added. The 
mixture was refluxed at 60oC during 4 h and filtered. After concentration under reduced 
pressure, the residue was dissolved in CHCl3 and extracted twice with aqueous NaOH 20%. 
The combined organic layers were dried over anhydrous sodium sulfate, filtered, 
concentrated under reduced pressure, and then purified by crystallization with CHCl3/EtOH 
to give a orange solid of 1,7-bis(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)hepta-1,6-diene-
3,5-dione (10, 86.30 mg, 14%).  
mp: 149-151 oC (CHCl3/EtOH). Purity 94%. IR (KBr) υmax cm-1  3287, 2920, 2850, 
1671, 1592, 1507, 1464, 1423, 1375, 1265, 1221, 1167, 1139, 1080, 1020, 807, 669. 1H 
NMR (CDCl3, 300 MHz) δ: 7.74 (2H, d, J=15.0 Hz, H-4, H-4’), 7.15 (2H, dd, J=8.4 and 2.0 
Hz, H-10, H10’), 7.03 (2H, d, J=2.0 Hz, H-9, H-9’), 6.99 (2H, s, H-6, H-6’), 6.67 (2H, d, 
J=15.0 Hz, H-3, H-3’), 4.81-4.79 (4H, s, 8-OCH2-, 8’-OCH2-), 3.91 (6H, s, 7-OCH3, 7’-OCH3), 
3.17 (2H, d, J=2.0 Hz, H-1), 2.52 (2H, s, -C≡CH, -C≡CH’). 13C NMR (75.47 MHz, CDCl3) δ: 
193.5 (C-2), 149.7 (C-8), 149.5 (C-7), 145.6 (C-4), 127.9 (C-5), 123.5 (C-3), 118.4 (C-10), 
113.4 (C-9), 110.7 (C-6), 78.9 (-C≡CH), 72.1 (-C≡CH), 56.5 (8-OCH2-), 56.1 (7’-OCH3), 21.2 
(C-1). HRMS (ESI+) m/z  Anal. Calc. for C27H25O6 [M-H]+ 445.16456, found 445.16442. 
 
2.2.10. Synthesis of (2R,4S,5R)-5-acetamido-2-(acetoxymethyl)-6-
(2-(4-((2-methoxy-4-((E)-3-oxobut-1-en-1-yl)phenoxy)methyl)-1H-
1,2,3-triazol-1-yl)ethoxy)tetrahydro-2H-pyran-3,4-diyl diacetate 
(11) 
A mixture of 4-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)but-3-en-2-one (5, 60.0 mg, 
0.149 mmol), 2-azidoethyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-galactopyranoside 
(123.6 mg, 0.297 mmol), CuSO4.5H2O (80.1 mg, 0.32 mmol), sodium ascorbate (131.1 mg, 
0.66 mmol) and tetrahydrofuran/ H2O solvent mixture (2:1; 7 mL), were placed in a opened 
microwave reactor. The non-homogeneous mixture under stirring was irradiated at 200 W 
for 10 min, at a final temperature of 70oC. After filtration, THF was evaporated under 
reduced pressure and the aqueous solution was extracted with CHCl3 (3 x 100 mL). The 
organic phase was dried with anhydrous sodium sulfate, filtrated and concentrated under 
reduced pressure to furnish a light-brown solid of (2R,4S,5R)-5-acetamido-2-
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(acetoxymethyl)-6-(2-(4-((2-methoxy-4-((E)-3-oxobut-1-en-1-yl)phenoxy)methyl)-1H-1,2,3-
triazol-1-yl)ethoxy)tetrahydro-2H-pyran-3,4-diyl diacetate (11, 63.4 mg, 38%).  
mp 84-86oC (CHCl3). Purity 97%. IR (KBr) υmax cm-1  1748, 1667, 1596, 1513, 1424, 
1371, 1251, 1165, 1140, 1083, 1047. 1H NMR (CDCl3, 300 MHz) δ: 7.83 (1H, s,  
-C=CH-N), 7.45 (1H, d, J= 16.2 Hz, H-3), 7.12-7.08 (3H, m, H-6’, H-2’ and H-5’), 6.61 
(1H, d, J= 16.2 Hz, H-2), 5.54 (1H, d, J= 8.8 Hz, 7’’-NH), 5.32 (2H, dd, J= 13.1 Hz, -N-CH2-
CH2-O-), 5.30 (1H, s, -O-CH2-triazole), 5.15 (1H, dd, J= 13.1 and 3.2 Hz, N-CH2-CH2-O-), 
4.65-4.55 (3H, m, H-6’’’, H-7’’’, and H-8’’’), 4.30-4.25 (1H, m, H-9’’’), 4.13 (1H, d, J= 1.68 
Hz, -CH2-OAc), 4.07-4.00 (1H, d, -CH2-OAc), 4.07-4.00 (1H, m, H-10’’’), 3.89 (3H, s, 3’-
OCH3), 2.37 (3H, s, H-1’’), 2.15, 2.04, 1.99 (9H, s, -COCH3), 1.85 (3H, s, -COCH3); 13C NMR 
(75.47 MHz, CDCl3) δ: 198.2 (C-1), 170.7 (7’’-NH-C=O), 170.4 (O=C-CH3 and O=C-CH3), 
170.1 (O=C-CH3), 149.9 (C-4’), 149.6 (C-3’), 143.2 (C-3), 143.2 (-C=CH-N), 128.2 (C-1’), 
125.7 (C-2), 125.7 (-C=CH-N), 122.9 (C-6’), 113.6 (C-5’), 110.3 (C-2’), 101.0 (C-6’’’), 70.9 
(C-10’’’), 69.8 (C-8’’’), 67.4 (-N-CH2-CH2-O-), 66.1 (C-9’’’), 62.8 (-O-CH2-triazole), 61.4 (-
CH2-OAc), 55.9 (3’-OCH3), 51.2 (C-7’’’), 50.2 (-N-CH2-CH2-O), 27.4 (C-1’’), 23.2 (O=C-CH3), 
20.7 (O=C-CH3 and O=C-CH3), 20.6 (O=C-CH3). HRMS- ESI (+) m/z: Anal. Calc. for 
C30H38N4O12 [M-H]+ 647.25645, found 647.25590. 
 
2.2.11. Synthesis of (2S,4R,5S)-5-acetamido-6-(2-(4-((4-((1E,6E)-7-
(4-((1-(2-(((3R,4S,6R)-3-acetamido-4,5-diacetoxy-6-
(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethyl)-1H-1,2,3-
triazol-4-yl)methoxy)-3-methoxyphenyl)-3,5-dioxohepta-1,6-
dien-1-yl)-2-methoxyphenoxy)methyl)-1H-1,2,3-triazol-1-
yl)ethoxy)-2-(acetoxymethyl)tetrahydro-2H-pyran-3,4-diyl 
diacetate (12) 
A mixture of 1,7-bis(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)hepta-1,6-diene-3,5-
dione (10, 60.0 mg, 0.13 mmol), 2-azidoethyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-
galactopyranoside (123.6 mg, 0.297 mmol), CuSO4.5H2O (80.1 mg, 0.32 mmol), sodium 
ascorbate 131.1 mg, 0.66 mmol) and tetrahydrofuran/H2O solvent mixture (2:1; 10 mL), 
were placed in a opened microwave reactor. The non-homogeneous mixture under stirring 
was irradiated at 200 W for 15 min, at a final temperature of 70oC. After filtration, THF was 
evaporated under reduced pressure. Insolubilization of the product was verified during 
liquid-liquid extraction with EtOAc (3 x 100 mL) furnishing a brown solid of (2S,4R,5S)-5-
acetamido-6-(2-(4-((4-((1E,6E)-7-(4-((1-(2-(((3R,4S,6R)-3-acetamido-4,5-diacetoxy-6-
(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-3-
methoxyphenyl)-3,5-dioxohepta-1,6-dien-1-yl)-2-methoxyphenoxy)methyl)-1H-1,2,3-
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triazol-1-yl)ethoxy)-2-(acetoxymethyl)tetrahydro-2H-pyran-3,4-diyl diacetate (12, 66 mg, 40 
%). 
mp: 167-170 oC (MeOH). IR (KBr) υmax cm-1  2921, 2851, 1744, 1659, 1578, 1510, 
1466, 1375, 1260, 1139, 1049. 1H NMR (CDCl3, 300 MHz) δ: 8.07 (1H, s, -C=CH-N), 7.80-
6.98 (5H, m, H-4, H-10, H-6, H-9, H-3), 5.22-5.14 (2H, -N-CH2-CH2-O-, 7’’-NH), 4.96-4.93 
(2H, m, -O-CH2-triazole, N-CH2-CH2-O-), 4.57-4.50 (4H, m, H-6’’’, H-7’’’, H-8’’’, H-9’’’), 4.05-
3.78 (8H, s, 7-OCH3, -CH2-OAc, H-10’’’, H-1a, H-1b), 2.10, 1.99, 1.89, 1.70 (12H, s, 
COCH3). 
2.3. Stability studies 
Standard solutions of curcumin (1), compound 2, 3, and 10 were prepared and 
injected in the HPLC equipment with a final concentration of 1 mg/mL in DMSO, at r.t. and 
immediately after being prepared. Regarding pH stability assay, five pH values were 
selected and obtained with following buffers: HCl pH 1.0, sodium acetate pH 5.0, potassium 
phosphate pH 6.7, PBS pH 7.4, and sodium boric acid pH 9.1. A stock solution of each 
compound was prepared with the initial concentration of 10-2 M in DMSO. Then the 
compounds were dissolved in each buffer in a final concentration of 10-4 M. The solutions 
were allowed to incubate overnight at r.t., except in HCl buffer that incubated only for 75 
min, protected from light exposure. After overnight or 75 min of incubation, certain 
compounds precipitated. In such cases, the precipitate was filtrated and dissolved in 4 mL 
of MeOH before being also injected.  
The biological buffer assay was performed with cell culture medium. Cell culture 
medium composition was: 87.5 % RPMI medium, 2.5% N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid (HEPES) supplemented with10% fetal bovine serum (FBS). The 
compounds were incubated for 5, 10, 20, and 30 min at 37 oC in biological buffer, protected 
from light exposure, at a final concentration of 1.5 × 10-3 M. Before being injected the 
samples were filtrated. 
Solutions at 10-4 M in DMSO of each compound were prepared and store at -20 oC, 4 
oC and r.t. for 6, 15, and 21 days for the temperature/storage time assay. After the indicated 
storage time, where the samples were protected from light exposure, the solutions were 
filtrated and injected. All samples were filtrated using 0.80 µm Minisort ® filters (Sartorius 
Stedim Biotech). 
 
		154
RESULTS  AND  D ISC USSION  
2.4. Cell culture 
The chronic myeloid leukaemia cell line, K562, was from European Collection of Cell 
Cultures (ECACC) and its P-gp overexpressing counterpart cell line K562Dox cells was a 
kind gift of Dr. J.P. Marie (Paris, France) [26, 27]. The non-small cell lung cancer cell line, 
NCI-H460, and its drug-resistant P-gp overexpressing counterpart cell line RH460 were a 
kind gift of Dr. M. Pešić (Belgrade, Serbia) [28, 29]. All cell lines were genotyped and 
routinely monitored for mycoplasma contamination by PCR (VenorGeM® Advance 
Mycoplasma Detection Kit, Minerva). All cells were routinely grown in RPMI-1640 (with 
Ultraglutamine I and 25mM HEPES) medium (Lonza) supplemented with 10% FBS (PAA) 
at 37 ºC in a humidified incubator with 5 % CO2 in air. Cell number and viability were 
analyzed with trypan blue exclusion assay. All experiments were carried out with 
exponentially growing cells having over 90 % viability. 
 
2.5. Sulforhodamine B assay 
The Sulforhodamine B (SRB) assay is an assay that measures cell growth indirectly 
by measuring the total protein of the cells. Was performed in NCI-H460 and RH460 cell 
lines according to procedure used by the NCI’s Developmental Therapeutics Program [30-
33]. Briefly cells were seeded in 96-well plates (5000 cells / well) and incubated for 24 h at 
37 ºC. Cells were then treated in duplicate with 5 serial dilutions of each compound (at a 
maximum of 150 µM) for 48 h. Cells were fixed with 10% (w /v) trichloroacetic acid (TCA) 
and then washed with distilled water. After staining the proteins with 0.4% (w /v) SRB, cells 
were washed with 1% (v /v) acetic acid, the bound SRB was solubilized with 10 mM Tris 
base and absorbance was measured at 510 nm in a multi plate reader (Synergy Mx, Biotek 
Instruments Inc.). For each compound analyzed, the GI50 (the concentration that inhibits 
50% of cell growth) was determined by interpolation of the dose-response curve graphic 
obtained using a NCI datasheet. 
 
2.6. Tumour cell growth inhibition analysis using presto blue assay 
Presto blue assay measures cell growth indirectly by measuring the metabolism 
of the cells. Analysis of K562 and K562Dox cell growth inhibition was carried out using 
Presto Blue assay (Bio Source, Invitrogen, UK). Briefly, cells were seeded in 96 plates 
(5000 cells / well) and incubated for 24 h at 37 ºC. Cells were then treated in duplicate 
with 5 serial dilutions of each compound (at a maximum of 150 µM) at 37 ºC and 5% CO2. 
After 48 h incubation, Presto Blue (10%) was added to the cells and further incubated for 
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2 h. Fluorescence was measured in multiplate reader (Synergy Mx, Biotek Instruments 
Inc., excitation at 560 and emission at 590 nm). For each compound analyzed, the GI50 
(the concentration that inhibits 50% of cell growth) was determined by interpolation of the 
dose-response curve graphic obtained. 
 
2.7. Rhodamine-123 efflux assay  
K562 and K562Dox (5 × 106 cells) were incubated for 1 h at 37 ºC with 10 µM of the 
synthesized compounds and 1 mM rh123. Verapamil (10 µM), a known P-gp inhibitor [34], 
as well as curcumin (1, 10 µM), were used as controls.  After incubation, cells were washed 
twice, resuspended in ice cold PBS and kept at 4 ºC in the dark until analysis in a BD 
AccuriTM C6 Flow cytometer (BD Biosciences). Cells shown in forward scatter and side 
scatter were electronically gated and acquired through the FL1 channel. For simple 
interpretation, the ratio of rh123 accumulation was calculated as (Mean FL1 K562Dox+compound 
- Mean FL1 K562Dox) / Mean FL1 K562Dox.  At least 20,000 events? were analyzed per sample. 
 
2.8. Cell treatments with curcumin (1) and compound 12 
K562Dox cells (2 × 106 cells/well) were plated in 6-well plates and treated with 
compound 12 (2.7 µM, 4.1 µM, or 5.4 µM) and curcumin (20 µM, 30 µM, or 40 µM) for 48 
h. Cells were also treated with complete medium (Blank) or with the maximum 
corresponding concentration of the extract solvent (DMSO). Following treatment, cells 
were processed according to different protocols, as follows. 
 
2.8.1. Analysis of cell cycle profile by flow cytometry 
Following 48 h treatment, cell pellets were fixed in ice-cold 70% EtOH for at least 
12 h. Cells were then resuspended in 5 µg/mL propidium iodide and 0.1 mg/mL RNase A 
in PBS. Cellular DNA content was analyzed using a BD AccuriTM C6 Flow cytometer after 
cell debris and aggregates exclusion and plotting at least 20,000 events per sample [35]. 
FlowJo 7.6.5 software (Tree Star, Inc., Ashland, OR, USA) was used to determine the 
percentage of cells in the different phases of cell cycle (G0/G1, S, and G2/M) and in the 
sub-G1 peak. 
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2.8.2. Analysis of apoptosis by flow cytometry 
Analysis of apoptotic cell death was performed using Annexin V-FITC Apoptosis 
Detection kit (Bender MedSystems, Vienna, Austria) as previously described [36]. Cells 
were analyzed by flow cytometry using the BD AccuriTM C6 Flow cytometer. Data analysis 
was carried it using FlowJo 7.6.5 software (Tree Star, Inc., Ashland, OR, USA) evaluating 
at least 20,000 events per sample. 
 
2.8.3. Analysis of protein expression by Western blot 
Total protein extracts were obtained by lysing cell pellets. After treatment of 48 hours, in 
Winman’s Buffer (1% NP-40, 0.1 M Tris-HCl pH 8.0, 0.15 M NaCl, and 5 mM EDTA) with 
EDTA-free protease inhibitor cocktail (Roche). The “DC Protein assay kit” (Bio-Rad) was 
used to quantify the total protein content and 20 µg of protein were subjected to SDS-PAGE 
(12% Bis-Tris gel). Following electrophoretic transfer of the proteins into nitrocellulose 
membranes (GE Healthcare), membranes were incubated with the following primary 
antibodies: goat anti-Actin (1:2000; Santa Cruz Biotechnology), mouse anti-P-gp (P7965) 
(1:2000; Sigma), rabbit anti-PARP-1 (1:2000; Santa Cruz Biotechnology), anti-caspase-3 
(1:2000; Upstate), mouse anti-p53 (1:5000; Santa Cruz Biotechnology) and rabbit anti-
cyclin B1 (1:1000; Cell Signaling). The following secondary antibodies were then used: anti-
mouse IgG-HRP; anti-rabbit IgG-HRP or anti-goat IgG-HRP (all diluted 1:2000; Santa Cruz 
Biotechnology). Signal was detected using the ECL Western blot Detection Reagents (GE 
Healthcare), the Amersham Hyperfilm ECL (GE Healthcare), and the Kodak GBX developer 
and fixer (Sigma) [37]. The intensity of the bands obtained in each film was further analysed 
using the software Quantity One – 1D Analysis (Bio-Rad, USA).  
 
2.9. Statistical analysis 
All presented data resulted from at least three independent experiments. All data was 
statistically analyzed with the two-tailed paired Student’s t-test. Results were considered 
statistically significant when p ≤ 0.05. 
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3. Results 
 
3.1. Synthesis of curcumin mono-carbonyl analogues and analogues 
synthesized directly from curcumin 
 
Curcumin (1) has shown to be a promising compound in therapeutics; however, the 
chemical stability and extensive metabolism are substantial limitations to its potential use 
[38, 39]. Therefore, we aimed to synthesize two mono-carbonyl building blocks chemically 
more stable, eliminating the unstable portion of the molecule, namely, the methylene portion 
of the β-diketone moiety. In order to improve the P-gp modulatory activity different 
derivatives of the phenolic groups were obtained (alkyl, glucosamines, amines, carbamates, 
and esters).  
Claisen-Schmidt condensation reactions were used for the synthesis of the building 
blocks 2 and 3, according to previously described protocols [24, 25]. Subsequently, stability 
studies were performed for compounds 1 and 2-3 (see section 3.9) and following, several 
enone 2 derivatives (4-9, 11) were synthetized (Figure 2, Scheme 1) along with the new 
curcumin derivatives 10 and 12 (Scheme 2 and 3). The synthesis approach used to obtain 
derivatives 4-9 followed a microwave (MW) assisted synthesis [40]. 
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Figure 2 - Structure of compounds 2-12. 
 
 
Scheme 1 – Reaction conditions for the synthesis of compounds 4-9, (i): K2CO3 or Cs2CO3, 
acetone, MW, 200 W, 65 oC, 2 h or 3 h. 
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 Scheme 2 - Reaction conditions for the synthesis of compound 10, (i): Cs2CO3, Bu4NBr, acetone, 
propargyl bromide, 60 oC, 4 h. 
 
The synthesis of the glycosylated derivatives 11 and 12 was accomplished using click 
chemistry, more precisely, the Huisgen 1,3-dipolar cycloaddition [41, 42] herein used for 
the first time, to our state of knowledge, to obtain potential bioactive derivatives of curcumin 
(1). To synthesize compound 11, the derivative 5 was added to 2-azidoethyl 2-acetamido-
3,4,6-tri-O-acetyl-2-deoxy-β-D-galactopyranoside using a copper (II) salt (CuSO4.5H2O) as 
a catalyst in the presence of sodium ascorbate, the reducing agent ( 
 
Scheme 3) [42]. Although the structure of compound 4 is protected in a patent 
application for the treatment of hypertension [43], the synthesis and structure elucidation of 
derivatives 4-12 is herein described for the first time. 
 
 
 
Scheme 3 - Reaction conditions for the synthesis of compound 11 and 12, (i): compound 4, 
CuSO4.5H2O, sodium ascorbate, H2O: THF (1:2), MW, 200 W, 70oC, 10 min; (ii): compound 10, 
CuSO4.5H2O, sodium ascorbate, H2O: THF (1:2), MW, 200 W, 70 oC, 10 min. 
3.2. Most of the synthesized compounds inhibited the growth of 
human tumour cell lines  
To evaluate the effect of the synthesized compounds (2-5, 8-12) in human tumour 
cells, two MDR and sensitive tumour lines were used. One cell line was from chronic 
myeloid leukaemia (CML) consisting of a sensitive cell line (K562) and its MDR counterpart 
overexpressing P-gp (K562Dox). The other cell line was from non-small cell lung cancer 
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(NSCLC) consisting of a sensitive cell line (NCI-H460) and its MDR counterpart 
overexpressing P-gp (RH460). The effect of the compounds was first analyzed to study the 
growth of human tumour cell lines with the Sulforhodamine B assay (for the solid tumour 
cells) or with the Presto Blue assay (suspension cell lines). The GI50 concentrations 
determined for most of the compounds were similar for both the MDR and the drug-sensitive 
counterpart cells (Tables 1 and 2). When comparing our series of synthesized compounds 
with curcumin (1), , compounds 3 and 10 presented more potent antitumor activity (Tables 
1 and 2). Compound 10 was even more potent in the MDR cell lines (mostly in K562Dox) 
(Table 1 and 2) than in the sensitive cells and its GI50 concentration determined for the 
K562Dox cells (2.73 µM) was lower than the one previously published for doxorubicin 
treatment (11.62 µM, [44]),  used as control. Additionally, compound 3 was significantly 
more potent in K562 than in K52Dox cells (Table 2), with GI50 concentrations of 9.33 ± 1.67 
µM and 20.67 ± 2.85 µM, respectively. Also, compounds 5 and 8 were found to be only 
active in the non-small cell lung cancer model. This could be important for future targeted 
therapy studies. Regarding acetate 9 or the glucosamine acetate derivatives 11-12, none 
of them were found to be active in the two pairs of cell lines studied. 
 
Table 1 – GI50 concentrations of the synthesized compounds in the non-small 
cell lung cancer sensitive and MDR counterpart cell lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values were determined with the Sulforhodamine B assay and are the mean ± SEM of at least 3 independent experiments. 
Doxorubicin was used as a positive control (GI50 concentrations were the following: 20 nM ± 5.04 in NCI-H460 cells and >150 
nM in RH460 cells). 
 
GI50 (μM) 
NCI-H460 RH460 
Curcumin (1) 27.3 ± 1.86 26 ± 0.24 
2 64.75 ± 6.91 62.67 ± 7.75 
3 1.47 ± 0.27 1.8 ± 0.25  
4 41.5 ± 3.07 39.3 ± 2.19 
5 52.67 ± 6.67 41.67 ± 2.96 
8 55.25 ± 4.68 41 ± 5.29 
9 > 150 > 150 
10 3.4 ± 0.84 2.6 ± 0.25 
11 > 150 > 150 
12 > 150 > 150 
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Table 2 – GI50 concentrations of the synthesized compounds in the leukaemia 
sensitive and MDR counterpart cell lines 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values were determined with the Presto Blue assay and are the mean ± SEM of at least 3 independent experiments. 
Doxorubicin was used as positive control (GI50:65 nM ± 13.23 in K562 cells and >150 nM in K562Dox cells). * p ≤ 0.01, K562 
vs. K562Dox 
 
From the analysis of the data presented in Tables 1-2, the following general 
observations can to be made: i) the presence of two aromatic rings seems to improve the 
inhibitory activity (e.g. curcumin 1 and dienone 3 vs. enone 2; compound 10 vs. 5); ii) the 
hydroxyl group in scaffolds 1, 2, and 3 and the di-carbonyl moiety of curcumin (1) are not 
essential for cell growth inhibition, as previously described in structure-activity relationship 
studies of curcumin derivatives in several cell lines [23]. 
3.3. Some of the synthesized compounds inhibited P-gp activity  
In order to analyze the effect of the derivatives on P-gp activity, the rhodamine-123 
(rh123) efflux assay was performed. This assay relies on the quantification of the relative 
fluorescence accumulation of rh123 (a P-gp substrate) as an indirect way to study the P-gp 
inhibitory potency of different compounds [45]. As expected, K562 cells (which do not 
express P-gp) presented increased rh123 accumulation when compared to K562Dox cells, 
in which the accumulation of rh123 was represented as zero (Fig. 3). Also, K562Dox cells 
in the presence of verapamil, a known first-generation P-gp inhibitor [46] used as a positive 
GI50 (μM) 
K562 K562Dox 
Curcumin (1) 21.67 ± 4.63  19,67 ± 4.18  
2 85.33 ± 7.42  92 ± 13.32   
3 9.33 * ± 1.67   20.67 ± 2.85   
4 68.67 ± 3.06  63.33 ± 11.62   
5 > 150 133.33 ± 3.33   
8 > 150 > 150 
9 > 150 > 150 
10 6.3 ± 0.95   2.73 ± 0.61  
11 > 150 > 150 
12 > 150 > 150 
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control, showed an accumulation of rh123 more similar to the one observed in K562 cells 
(Fig.3). When analyzing the effect of the studied compounds (at 10 µM concentrations) in 
the K562Dox cells, differences in rh123 accumulation were observed. Treatment with 
compounds 8 and 10 resulted in a significant increase in the accumulation ratio of rh123, 
compatible with a possible P-gp inhibition. In contrast, treatments with curcumin (1), 
compounds 5 and 12 showed a significant decrease in the rh123 accumulation, compatible 
with a possible P-gp activation.  
 
Figure 3 - Relative rh123 accumulation ratios in K562 or K562Dox cells. The accumulation on 
K562Dox (untreated) cells is represented as zero. Accumulation ratios superior to zero correspond 
to rh123 accumulation superior to the one obtained in K562Dox cells, (potential P-gp inhibitor). 
Verapamil (10 µM) was used as a positive control (P-gp inhibitor). Results are the mean ± SEM of 3 
independent experiments. * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001 K562Dox untreated cells (with no 
drug) vs. K562Dox treated cells. 
3.4. Curcumin (1) and compound 10 decreased P-gp expression 
Curcumin (1) is known to not only inhibit P-gp function but also to inhibit P-gp 
expression [47, 48]. Since compound 10 presented better anti-P-gp activity than curcumin 
(1), the effect of compound 10 on the inhibition of P-gp expression was also assessed and 
compared to curcumin (1). With this purpose, P-gp levels of MDR K562Dox cells were 
analysed after 48 h treatement with different concentrations of the two compounds, : 
compound 10 (2.7 µM and 4.1 µM) and curcumin (1) (20 µM and 30 µM) corresponding to 
the previously determined GI50 and 1.5 x GI50 ]Results from the Western blot analysis 
showed a statistically significant decrease in the expression of P-gp protein following 
treatment with the two compounds (Fig. 4). 
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Figure 4 - Expression of P-gp in K562Dox cells treated with compound 10 and curcumin (1). 
Cells were treated with medium (Blank), different concentrations of with the GI50 and 1.5 x 
GI50 concentrations of compound 10 (2.7 µM and 4.1 µM) or curcumin (1) (20 µM and 30 
µM), or with the highest vehicle/solvent (DMSO) concentration. Actin was used as a loading 
control. (A) Representative Western blot images of three independent experiments; (B) 
Densitometry analysis of the Western blots. Results are the mean ± SEM of 3 independent 
experiments. * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001, when comparing DMSO vs. treatment. 
	
3.5. Curcumin (1) and compound 10 caused alterations in the cell cycle 
profile of K562Dox cells 
Since compound 10 presented a more potent tumour cell growth inhibitory activity 
than curcumin (1), its mechanism of action was further studied and compared to curcumin 
(1). To analyze the effect of these compounds in the cell cycle profile, K562Dox cells were 
analyzed by flow cytometry after 48 h treatment with the compounds Increasing 
concentrations were used in order to evaluate a possible dose dependent effect. Therefore, 
treatment with compound 10 was carried out with 2.7 µM, 4.1 µM, and 5.4 µM and treatment 
with curcumin (1) was carried out with 20 µM, 30 µM, and 40 µM, corresponding to the 
previously determined GI50, 1.5xGI50, and 2xGI50 concentrations.  Results showed clear 
alterations in the cell cycle profile of K562Dox cells following treatment with the two 
compounds (Fig. 5). Treatment with the GI50 concentration of both compounds [2.7 µM of 
compound 10 and 20 µM of curcumin (1)] caused an increase in the % of cells in G2/M and 
a decrease in the % of cells in the G0/G1 and S phases of the cell cycle.  However, different 
effects were observed for both compounds when tested at higher concentrations. Cells 
treated with higher concentrations of compound 10 continued to arrest at the G2/M phase of 
the cell cycle, while. cells treated with the higher concentrations of curcumin (1) showed an 
arrest in the G0/G1 phase of the cell cycle and a decrease in the % of cells in the G2/M 
phase.  
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Figure 5 - Cell cycle distribution of K562Dox cells after treatment with compound 10 and 
curcumin (1). Cells were treated with medium (Blank), with the GI50, 1.5xGI50, and 2xGI50 
concentrations of compound 10 (2.7 µM, 4.1 µM, and 5.4 µM) or curcumin (20, 30 and 40 µM), or 
with the highest vehicle (DMSO) concentration. Results are the mean ± SEM of 3 independent 
experiments. * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001, DMSO vs. treatment. 
 
3.6. Curcumin (1) and compound 10 induced apoptosis in the K562Dox 
cells 
To understand if the cell growth inhibition observed in the K562Dox cells following 
treatment with curcumin (1) and compound 10 could also be due to an induction of apoptosis, 
an analysis of apoptosis was carried out. Results showed that both compounds induced 
apoptosis (Table 3). The levels of cellular apoptosis increased from 6.3% in the DMSO 
treatment to 11.8%, 26.9%and 32.0% following treatment with curcumin (1, 20 µM, 30 µM, 
and 40 µM respectively) and to 9.3%, 11.3%and 14.8% following treatment with compound 
10 (2.7 µM, 4.1 µM, and 5.4 µM, respectively).  
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Table 3. Apoptosis levels in K562Dox cells treated with curcumin (1) or compound 
10.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results are the mean ± SEM of 3 independent experiments. * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001, DMSO vs. 
treatment 
 
 
3.7. Curcumin (1) and compound 10 caused alterations in P53 and 
cyclin B1 protein levels in K562Dox cells 
To further examine the mechanism of the above mentioned arrest of the cell cycle at 
the G2/M phase (with all the tested concentrations of compound 10 and with the GI50 
concentration of curcumin) and at the G0/G1 phase (only with the two highest 
concentrations of curcumin), the expression levels of the p53 and cyclin B1 proteins were 
analyzed. The results from the Western blot analysis showed an increase in p53 levels in 
the K562Dox cells following the 48 h treatment with either of the compounds (Fig. 6, panels 
A and B). In addition, the levels of cyclin B1 were found decreased in K562Dox cells 
following treatment with either of the compounds (Fig. 6, panels C and D).  
 % Apoptosis 
Blank 3.9 ± 1.2 
DMSO 6.3 ± 2.0 
Curcumin (1) 
20 µM 11.8 ± 2.3  
30 µM 26.9 ± 0.9 * 
40 µM 32.0 ± 3.7 ** 
Compound 10 
2.7 µM 9.3 ± 1.1  
4.1 µM 11.3 ± 1.4 *** 
5.4 µM 14.8 ± 2.4 ** 
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Figure 6 - Expression of p53 and cyclin B1 in K562Dox cells following treatment with compound 10 
or curcumin (1). Cells were treated with medium (Blank), with the GI50, 1.5xGI50, and 2xGI50 
concentrations of compound 10 (2.7 µM, 4.1 µM, and 5.4 µM) or curcumin (20, 30 and 40 µM),, or 
with the highest vehicle (DMSO) concentration. Actin was used as a loading control. (A and C) 
Representative Western blot images of three independent experiments; (B and D) Densitometry 
analysis of the Western blots. Results are the mean ± SEM of 3 independent experiments. * p ≤ 0.05, 
** p ≤ 0.01, and *** p ≤ 0.001, when comparing DMSO vs. treatment. 
	
 
3.8. Curcumin (1) and compound 10 caused alterations in PARP-1 and 
caspase 3 protein levels in K562Dox cells 
 
To further confirm the involvement of apoptosis in the mechanism of action of 
compound 10 and  curcumin (1), the levels of PARP-1 cleavage and pro-caspase 3 protein 
expression were analysed. Results showed an increase in PARP cleavage  and a decrease 
in pro-caspase 3 levels in K562 Dox cells following treatment of cells with both compounds 
(Fig. 7).  
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Figure 7 - Expression of PARP-1 and pro-caspase 3 in K562Dox cells following treatment with 
compound 10 or curcumin (1). Cells were treated with medium (Blank), with the GI50, 1.5xGI50, and 
2xGI50 concentrations of compound 10 (2.7 µM, 4.1 µM, and 5.4 µM) or curcumin (20, 30 and 40 
µM), or with the highest vehicle (DMSO) concentration. Actin was used as a loading control. (A and 
C) Representative Western blot images of three independent experiments; (B and D) Densitometry 
analysis of the Western blots. Results are the mean ± SEM of 3 independent experiments. * p ≤ 0.05, 
** p ≤ 0.01, and *** p ≤ 0.001, when comparing DMSO vs. treatment. 
 
 
3.9. Among the studied compounds curcumin (1) showed to be the 
most unstable  
 
Under neutral and basic pH conditions, curcumin (1) is very unstable, and eventually 
is degraded to ferulic acid and feruloylmethane [38, 39]. Besides being prone to hydrolysis 
under alkaline conditions, curcumin (1) is also very susceptible to photochemical 
degradation [39]. Given these curcumin (1) characteristics, the building blocks enone 2 and 
dienone 3 were initially investigated for stability and the hit compound 10 was also 
investigated following the in vitro studies and compared with curcumin (1). 
Stability studies with different pH, solvents, temperature, and storage time were 
performed by high-performance liquid chromatography (HPLC). Overall results showed that 
regarding the pH buffers assay, dienone 3 is the most stable compound, followed by enone 
2 and compound 10. Among the studied compounds curcumin (1) showed to be the most 
unstable. 
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Figure 8 - Compounds content rate after incubation with five buffers with different pH values at r.t. 
overnight (except for pH 1, which incubated for 75 min). 
 
The biological buffer assay has shown that compounds 1, 2, and 3 did not degrade in 
this medium. Although the cell medium showed a higher interference in the chromatograms 
of compound 10 than in the other compounds chromatograms, compound 10 is still present.  
 
 
Figure 9 - Compounds content rate after incubation with cell culture medium at 37 oC for different 
time intervals. 
 
The temperature/storage time assay showed that all of the tested compounds are 
unstable along the temperature and storage times tested. Curcumin (1) and compound 2 
and 10 exhibited similar stability; and compound 3 has proven to be the most unstable in 
the described conditions. 
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Figure 10 - Compounds content rate after incubation in DMSO for 6, 15, and 21 days at -20 oC, 4 oC 
and r.t.. 
 
4. Discussion 
Drug resistance is one of main causes for chemotherapy failure. P-gp activity and 
expression have been the most investigated mechanisms by which MDR occurs. Since the 
discovery of P-gp, several studies and clinical trials have attempted to circumvent MDR 
using well known P-gp inhibitors, such as verapamil and cyclosporine. However, none of 
these compounds have been successful, due to undesirable side effects as well as low 
effectiveness [4, 49, 50]. 
Nature provides a large variety of molecules, with different degrees of complexity and 
many biological activities. Curcumin (1) is an example of such molecules, which has been 
associated with several interesting biological activities. However, extensive metabolism and 
instability have prevented curcumin (1) from being used at its full potential. In this study, we 
present a small library of new curcumin derivatives and tested their antitumor and P-gp 
modulatory activities. 
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The study of the cell growth inhibitory effect of the synthesized compounds revealed 
that the GI50 concentrations determined for most of the compounds were similar between 
the MDR and the drug-sensitive counterpart cells (Tables 1 and 2), probably indicating that 
these compounds were not P-gp substrates. Interestingly, previous studies using other 
curcumin derivatives and analogues have also described their growth inhibitory effect to be 
similar in drug-sensitive and drug resistant cells [51, 52]. From the studied compounds, 
compound 10 was even more potent in the MDR cell lines than in the sensitive cells, 
possibly due to an ability of the compound to affect MDR cells selectively over the sensitive 
cells from which they were derived, named collateral sensitivity [53].   
Regarding the capacity of MDR reversal of the P-gp overexpressing cell line K562Dox 
(by inhibiting function and expression of P-gp), results showed that  compounds 10 and 12 
presented P-gp inhibitory function (Fig. 3). Previous studies had described curcumin (1) as 
a P-gp inhibitor [15, 47], but the concentrations (e.g. 50 µM) and time of treatment (e.g. 2 
hours) used in those studies were higher than the concentration (10 µM) and treatment 
duration (1 hour) used in the present work. From all the studied compounds, compound 10 
showed the strongest effect on rh123 accumulation, indicating that it was the most potent 
P-gp inhibitor. Interestingly, this compound was also one of the compounds which 
presented the most potent antitumor effect (Tables 1 and 2). The corresponding enone 
analogue 5, even though having the same pattern of substitution in the aromatic ring as 
compound 10, was also shown to interfere with the accumulation of rh123, but eliciting an 
opposite effect. 
In terms of inhibition of P-gp expression, results from the Western blot analysis 
showed a statistically significant decrease in the expression of P-gp protein following 
treatment with compound 10 (and also curcumin) (Fig. 4). However, since the 
concentrations used for compound 10 (GI50 and 1.5 times GI50) were much lower than the 
concentrations used for curcumin, it can be concluded that compound 10 was a stronger 
inhibitor of P-gp expression. The inhibition of P-gp expression by curcumin (1) has been 
previously described [54, 55] but, to our knowledge, this activity had not been explored for 
synthetic curcumin derivatives and analogues. Therefore, compound 10 is a very interesting 
P-gp inhibitor since it simultaneously inhibits the function and the expression of P-gp. 
Inhibitors of P-gp expression are very important chemical tools because they can be used 
as controls of P-gp expression in several pharmacological studies, including inhibition of P-
gp expressed in [56] and transferred by extracellular vesicles. 
The study of the mechanism of action of compound 10 (and curcumin) in the MDR 
chronic myeloid leukaemia model (K562Dox) showed that cells treated with GI50 
concentrations of curcumin presented an arrest at the G2/M phase of the cell cycle but when 
treated with higher concentrations presented an arrest in the G0/G1 phase. Compound 10, 
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independently of the concentration, arrested cells at G2/M phase (Fig. 5). Interestingly, 
previous studies using other synthesized curcumin analogues and derivatives had shown 
similar effects (arrest at G2/M) in different cell lines (particularly in another resistant chronic 
myeloid leukaemia cell line) [51, 52, 57, 58]. Also, the effect in the cell cycle profile observed 
for the curcumin (1) treatment (i.e. increase in the % of cells in G2/M with the lowest 
concentrations and decrease in the % of cells in G2/M with the higher concentrations) has 
also been previously described in non-small cell lung cancer cells [20]. Our results suggest 
that compound 10 is associated a different mechanism of action when compared to curcumin 
(1). 
Regarding induction of apoptosis, our results showed that both compounds (10 and 
curcumin) induced apoptosis (Table 3). Even though the levels of apoptosis were lower for 
compound 10 than for curcumin (1), the concentrations tested for compound 10 were also 
considerably lower (since the GI50 concentration of this compound was much lower). 
Therefore, it can be concluded that both compounds induced apoptosis in the K562Dox cells. 
Several studies have previously described the apoptotic activity of curcumin (1) and of other 
synthesized curcumin derivatives and analogues, in other human tumour cell lines such as 
in other non-small cell lung cancer cell lines [20, 51, 57, 58].  
In addition to the above mentioned arrest of the cell cycle (at G2/M phase) (Fig. 5) and 
induction of apoptosis (Table 3), treatments with compound 10 (or curcumin) increased 
cellular p53 levels and cyclin B1 levels (Fig. 6), which is in agreement with the fact that p53 
activation (being the guardian of the genome) usually results in a cell cycle arrest and a 
consequent induction of apoptosis [59]. Also, cell cycle is controlled by a serious of actions 
performed by cyclin dependent kinases in association with cyclin proteins. Cyclin B1 
(establishing a complex with CDK1) regulates progression of G2 and mitosis [60]  and 
therefore its downregulation promotes cell cycle arrest at the G2/M phase, which is in 
agreement with the above mentioned observed results. Other published studies have also 
shown similar alterations in the expression levels of these proteins (increased p53 and 
decreased cyclin B1) in tumour cells following treatment with curcumin (1) and other 
curcumin derivatives [20, 57, 58]. 
The mitochondrial pathway of apoptosis functions in response to several types of 
stress. Following a trigger of apoptosis, a serious of events leads to caspase 3 activation 
(with a decrease in pro-caspase 3 levels). Once activated, caspase 3 cleaves cytoskeletal 
and nuclear proteins such as PARP-1 (with a decrease in total PARP-1 levels) [61]. By 
treating cells with compound 10 (or curcumin) a decrease in total PARP-1 and pro-caspase 
3 levels and an increase in the expression levels of cleaved PARP-1 were observed (Fig. 
7). This is in agreement with an activation of the mitochondrial apoptotic pathway. Several 
studies have previously described such alterations in different cancer models following 
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treatment with curcumin (1) [20, 52]. Moreover, some synthesized curcumin derivatives and 
analogues have previously been described to induce apoptosis through caspase 3 
activation and PARP-1 cleavage [51, 52, 57, 58]. 
Given the fact that curcumin (1) is an unstable compound, three stability assays were 
performed in order to evaluate the stability of curcumin (1), the building blocks enone 2, and 
dienone 3 and the hit compound 10. Considering the stability results, it was very similar for 
the tested compounds; however, compound 3 was shown to be very stable in most of the 
assays, which indicates that this is the most stable of the four compounds. Compound 2, 
10 and curcumin (1) are subsequently less stable. Overall, the results obtained are 
consistent with the chemical structure of these compounds: compounds 2 and 3 lack the β-
diketone moiety responsible for the chemical instability associated to curcumin (1) and 
compound 10. 
None of the investigated derivatives was found to be very stable in the range of 
conditions assessed, which highlights the difficulty in investigating both chemical and 
biological properties of curcumin (1); nevertheless, this work shows the potential of 
synthesizing new curcumin derivatives to improve curcumin (1) stability and characterized 
the promising dual activity (antitumor and anti-P-gp) of a curcumin derivative (10). These 
results could be useful in future pharmacological studies whenever an inhibitor of P-gp 
expression and function is needed. Also, the use compound 10 as an inhibitor of P-gp 
expression in tumour cells shedding extracellular vesicles (carrying P-gp on their cargo) 
could help the inhibition of the non-genetic transfer of P-gp from MDR to drug-sensitive 
cancer cells.  
 
5. Conclusions 
From the series of synthesized curcumin derivatives and analogues, a newly 
synthesized curcumin derivative (compound 10) that presented more potent antitumor and 
anti-P-gp activity than curcumin (1) itself was identified. In addition, the study of its 
mechanism of action in a MDR chronic myeloid leukaemia cell line showed that it caused 
cell cycle arrest at the G2/M phase and increased cell death by apoptosis.  
 
6. Abbreviations 
ABC = ATP-binding cassette; DMSO = Dimethyl sulfoxide; EtOAc = Ethyl acetate; EtOH = 
Ethanol; FBS = Fetal bovine serum; h = Hours; HPLC = High-performance liquid 
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chromatography; HRMS-ESI = High resolution mass spectrometry-Electrospray ionization; 
MDR = Multidrug resistance; MeOH = Methanol; min = Minutes; mp = Melting point; MW = 
Microwave; PBS = Phosphate buffered saline; P-gp = P-glycoprotein; r.t. = Room 
temperature; SRB = Sulforhodamine B; THF = Tetrahydrofuran. 
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The development of multidrug resistance (MDR) in cancer is a serious impediment 
to treatment success. MDR is defined as a phenotype in which cells are resistant to multiple 
structurally different drugs. Such resistance is multifactorial and could be due to various 
mechanisms 39,190. Some of the most important mechanisms of MDR are: the 
overexpression of ABC transporters [such as P-glycoprotein (P-gp)] 39, alterations in 
apoptosis, increase drug detoxification and metabolic phenotype alterations 191. 
Interestingly, the release of extracellular vesicles (EVs) by MDR cells and their transfer to 
drug-sensitive cells may confer a MDR phenotype in the recipient cells 187. The identification 
and the study of MDR mechanisms and of potential molecular targets and biomarkers is 
important, in order to generate valuable information and tools to circumvent this phenotype 
and further improve cancer chemotherapy treatment.  
Thus, driven by the need to circumvent P-gp mediated MDR , we aimed to: i) 
identify new targets for overcoming P-gp mediated MDR in cancer, by  identifying 
metabolic alterations associated with P-gp mediated MDR in cancer and by verifying 
if those alterations are transferred by EVs from MDR cells to drug-sensitive cells; ii) 
identify potential biomarkers of MDR in EVs shed by cancer cells; and iii) find novel 
molecules to overcome MDR, by identifying curcumin derivatives with improved P-
gp inhibitory effect. 
In this work we used two different cancer cell models, a chronic myeloid leukaemia 
model (CML) and a non-small cell lung cancer model (NSCLC), in order to identify possible 
mechanisms and molecular targets of MDR that were not specific of a particular cancer. 
Thus, the K562/K562Dox (CML) and the NCI-H460/RH460 (NSCLC) cell lines were used 
as models of P-gp mediated MDR cancer cells and their respective drug-sensitive 
counterparts. These two pairs of cells were established and kindly provided to our group by 
Dr. J. P. Marie (Paris, France) 192 and by Dr. M. Pesic (Belgrade, Serbia) 193,194 respectively. 
They have the remarkable feature of being two pairs of counterpart cell lines, in which the 
parental cell lines (K562 and NCI-H460) are drug-sensitive and the counterpart cell lines 
(K562Dox and RH460) are MDR and have overexpression of P-gp. 
 The results presented in this thesis clearly identified a complex network of 
metabolic alterations that are associated with the MDR phenotype. Furthermore, we 
have shown that comparative proteomic approaches are powerful tools to investigate MDR 
mechanisms in cancer cells. Indeed, by performing a label-free LC-MS quantitative profiling 
we showed that, in terms of biological processes, most of the identified DEPs (differentially 
expressed proteins between MDR and drug-sensitive cells) (e.g. G6PD, IDH1 and PGD) 
were involved in metabolic processes and the most active pathways that were found 
enriched were the ones involved in cellular metabolism, namely GSH, PPP and glycolysis. 
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 Interestingly, most of the DEPs involved in the PPP (including the rate limiting 
enzyme, G6PD) were found downregulated in the MDR cells. Data presented in this thesis 
also shows that GSH levels were increased in MDR cells (from both tumour models), as 
previously published by other authors.  195,196 Since GSH is a detoxification agent 118, the 
levels of ROS in the MDR cells, as expected, were decreased. Evidence suggests that 
elevated levels of NADPH and GSH, together with an active PPP, play a critical role in MDR 
104,197. However, the results here presented together with other recent studies 110,111 
contradict those reports, showing that PPP enzymes may be downregulated in MDR cells. 
Therefore, this work shows that MDR cells are capable of maintaining high levels of 
GSH in order to decrease ROS, even when PPP is downregulated. This suggests that 
MDR cells must have upregulation of another source of GSH. 
 The present work also showed clear differences between MDR and drug-
sensitive cells, in the amount of several metabolites of the methionine/S-
adenosylmethionine pathway and an increase in the methylation index of both MDR 
(K562Dox and RH460) cell lines. Methionine levels were significantly increased in the 
MDR cells, which could be involved in the GSH increase observed in those cells. Indeed, 
the methionine cycle leads to cysteine production, a rate-limiting factor in cellular GSH 
biosynthesis 198. Also, the fact that the methylation capacity of the cells (methylation index) 
was increased in the MDR cells could be due to the metabolic alterations that MDR cells 
suffer when developing the resistance phenotype. In agreement with these results, other 
authors have described that cell treatment with a methylation inhibitor reversed drug 
resistance, which indicates that the development of drug resistance in some cases could 
be methylation-dependent 136. 
Importantly, this study raised the possibility that MDR cells, when acquiring 
the resistant phenotype, switch their main energy supply from OXPHOS to glycolysis 
in order to fulfill the high demand for energy and biomass of these cells. Indeed, the 
results here presented showed a statistically significant increase in glycolysis (and in the 
glycolytic capacity) of MDR cells (RH460), together with a decrease in the mitochondrial 
basal respiration and in the maximal capacity of these cells to perform OXPHOS, when 
compared to the drug-sensitive counterpart cells (NCI-H460). In agreement with these 
results, several studies in different cancer models have demonstrated an efficient 
suppression of MDR by glycolytic inhibitors 23,45,81,91,199. This altered metabolic activity of 
MDR cells could be crucial for: i) supporting uncontrolled proliferation, since glycolysis 
provides cells with intermediates needed for biosynthetic pathways and ii) allowing the use 
of the most abundant extracellular nutrient (glucose) to produce abundant ATP. Even 
though the yield of ATP per glucose molecule consumed is low, if the glycolytic flux is high 
enough, the percentage of cellular ATP produced by glycolysis can exceed the one 
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produced by OXPHOS 63,200. Also, it was reported that an association between drug 
resistance and glycolysis may partially be due to the radical scavenging potential of the 
glycolytic intermediates, and the link between them and the cellular redox status 201.  Indeed, 
the results here presented are in agreement with this report, since the MDR cell models 
studied showed a decrease in ROS levels and an increase in glycolysis, when compared to 
their drug-sensitive counterpart cells. 
The present work also demonstrates that following PPP pathway inhibition 
(with DCA 202)  the drug-sensitive cells (NCI-H460) acquire a metabolic phenotype 
more similar to the one of the MDR cells, by increasing glycolysis and decreasing 
OXPHOS. These results support a direct interaction between glycolysis and PPP activity in 
the MDR phenotype. Since some of the intermediates from glycolysis and PPP are the 
same, it is possible that MDR cells may be directing these intermediates mostly to 
glycolysis, in order to sustain the energy and the production of intermediates to the cellular 
biosynthetic pathways request. 
We found that following P-gp inhibition (with verapamil 203) in P-gp 
overexpressing MDR cells (RH460), those cells acquire a metabolic phenotype more 
similar to the one of drug-sensitive cells, with a decrease in glycolysis and an 
increase in OXPHOS. In agreement with these results, it has been reported that, in 
multicellular tumour spheroids and in doxorubicin-resistant human breast adenocarcinoma 
cells, the inhibition of glycolysis raised intracellular ROS, downregulated P-gp and reverted 
the MDR phenotype 23,45. Since inhibition of glycolysis could induce a dramatic reduction in 
the cellular levels of ATP, the mechanism involved may be related to the function of the 
drug-efflux pumps, since the activity of transmembrane transporters is ATPase dependent.  
Further studies, such as through the silencing and/or the overexpression of some of the 
DEPs (e.g. G6PD, IDH1 and PGD) will be essential to verify the hypothesis that these 
proteins may be potential targets to overcome MDR. 
 Interestingly, this work also showed that EVs released by MDR cells are 
capable of causing a metabolic switch in the receiving drug-sensitive cancer cells 
(towards a similar phenotype to the one observed in the donor MDR cells). In fact, 
when the drug-sensitive cells (NCI-H460) were co-incubated with EVs from MDR cells 
(RH460 or K562Dox), they acquired a metabolic phenotype more similar to the one of MDR 
cells (i.e, an increase in glycolysis). The importance of EVs in the transfer of the MDR 
phenotype between cells has been recently described 178,180,186. Therefore, it is possible that 
the acquisition of an altered metabolic phenotype (by MDR cells) could be associated with 
alterations in the type of EVs that are released by those cells, in their cargo and in the 
capacity to transfer phenotypes to receiving cells. Thus, it would be interesting to verify if 
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there is EVs-mediated transfer of some of the proteins involved in glycolysis, from MDR 
cells to drug-sensitive cells. 
 In addition to verifying that EVs (released by MDR cells) are capable of causing 
metabolic alterations in receiving drug-sensitive cells, in this thesis we have raised 
the possibility that MDR cells produce more microvesicles whereas drug-sensitive 
cells produce more exosomes. Indeed, regarding size,  EVs released by the drug-
sensitive cells presented mostly a size range between 10 and 80 nm, which is closer to the 
“exosomes size range” (30 to 100 nm) 143. On the other hand, EVs released by the MDR 
cells presented sizes ranging mostly between 40 and 200 nm, closer to the microvesicles 
size range described in the literature (50 to 2000 nm) 143. Moreover, proteins described to 
be mainly involved in the biogenesis of exosomes, such as TSG101 147,155,204-206, CHMP4 
147, CD63 143, Syntenin-1 147 and Clathrin 206, were here found to have increased levels in 
the EVs shed by drug-sensitive cells (when compared to the ones shed by the MDR cells). 
This was true for both the MDR models used in this thesis (CML and NSCLC), which 
suggests that MDR cells decrease the amount of released exosomes and increase the 
amount of released microvesicles. 
Another highly relevant observed difference was that the MDR cells produced 
more EVs than the sensitive counterpart cells. This fact has been previously described 
in other studies 174,207,208. According to those reports, and the results presented on this 
thesis, P-gp (or drug-efflux pumps in general) may be involved in the regulation of the EVs 
release (though a still unidentified mechanism),	since both MDR models used in this study 
had P-gp overexpression. Thus, it would be interesting to confirm this and to further study 
how P-gp could be involved in the release as well as in the definition of the cargo of EVs. 
Interestingly, a recent study observed that glutamine metabolism was altered in 
cancer cells following incubation with large EVs (microvesicles) released by prostate cancer 
cells, an effect that was not observed upon incubation with exosomes released by the same 
cells 184. With these results in mind, we propose that it is possible that the specific type of 
EVs that are responsible for the transfer of the metabolic phenotype in our cell models may 
be microvesicles, rather than exosomes. This highlights the importance of verifying the type 
of EVs that donor cells release, since different EVs may transfer different phenotypes to 
receiving cells. Additionally, the protein cargo that was found different in the EVs 
released by the two pairs of MDR and drug-sensitive cell lines, was detected with 
similar expression levels in the cell lines that released those EVs, which suggests 
that there is selective packaging of those proteins into the EVs. In fact, the selective 
packaging of EVs has been previously described in several other studies 150,209. However, 
this work adds knowledge and impact to the previous studies, since we have shown 
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selective packaging of proteins involved in the biogenesis of the EVs themselves, which are 
associated with different sizes/types of EVs.  
Additionally, we proposed in this thesis that the specific size and protein content that 
we have here identified in the EVs released by the MDR cells may have diagnostic 
significance in cancer, as biomarkers to identify the MDR phenotype. Further studies are 
needed to validate this hypothesis, such as by monitoring these biomarkers in the plasma 
of nude mice xenografted with MDR human tumours and, more importantly, in the plasma 
of patients with MDR tumours.   
In addition, during this thesis we came across the need to understand if there was 
degradation of the (EV marker) ALIX protein, when freezing samples for Western blots 
analysis. The obtained conclusions regarding the need to freeze these samples at – 80ºC 
will in the future allow to avoid misleading information resulting from the analysis of ALIX 
expression in protein lysates. 
As was previously shown on this thesis, treating MDR cells with a P-gp inhibitor 
significantly altered the metabolic phenotype of these cells, towards a phenotype more 
similar to the one of drug-sensitive cells. This highlights the importance of identifying novel 
P-gp inhibitors. The present study identifies a novel curcumin derivative (compound 
10) that presented more potent antitumor and anti-P-gp activity than curcumin itself. 
In terms of cell growth inhibitory effect, from the eleven studied compounds (curcumin 
derivatives synthesized by our collaborators of FFUP/CIIMAR), compound 10 was the most 
potent, being even more potent than curcumin. Interestingly, this compound was even more 
potent in the MDR cell lines than in the sensitive cells, possibly due to its ability to affect 
MDR cells more selectively than the sensitive cells, a process named collateral sensitivity 
210. 
Regarding the capacity of MDR reversal in the P-gp overexpressing cell line 
K562Dox (by inhibiting the function or expression of P-gp), our results showed that 
compound 10 was also the most potent P-gp inhibitor. Indeed, compound 10 presented 
the strongest effect on rh123 intracellular accumulation and on the inhibition of P-gp 
expression. Since the concentrations tested for compound 10 were much lower than the 
concentrations tested for curcumin, it can be concluded that compound 10 is a stronger 
inhibitor of P-gp expression. The inhibition of P-gp expression by curcumin had already 
been described 211,212 but, to our knowledge, this activity had not been explored for synthetic 
curcumin derivatives and analogues.  
In addition, the study of the mechanism of action of compound 10 indicated 
that it caused a cell cycle arrest at the G2/M phase and an increase in cell death by 
apoptosis. Indeed, treatments with compound 10 (or curcumin) increased cellular levels of 
p53 and cyclin B1, which is in agreement with the fact that p53 activation (being the guardian 
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of the genome) usually results in a cell cycle arrest and a consequent induction of apoptosis 
213. Also, since cyclin B1 (establishing a complex with CDK1) regulates progression of G2 
and mitosis 214, its downregulation promotes cell cycle arrest at the G2/M phase, which is 
in agreement with the observed results. By treating K562Dox cells with compound 10 (or 
curcumin) a decrease in total PARP-1 and pro-caspase 3 levels and an increase in the 
expression levels of cleaved PARP-1 were observed, which is in agreement with an 
activation of apoptosis.  
Unfortunately, none of the investigated derivatives was found to be particularly 
stable in the range of conditions assessed, which supports the difficulty observed by other 
authors in obtaining more stable curcumin derivatives. 
In conclusion, this work allowed to further identify new targets for overcoming 
P-gp mediated MDR in cancer. In addition, these results contributed to clarify the 
complex metabolic network between the various metabolic alterations that are 
associated with P-gp mediated MDR in cancer cells. Moreover, this work 
demonstrated that a EV-mediated transfer of metabolic information related with the 
production of energy by the cell may occur, from MDR cells to drug-sensitive cancer 
cells. Importantly, this work also proved that MDR cells release more microvesicle-
like EVs than exosomes. These microvesicles, shed in higher amounts by MDR cells, 
could potentially be the source of biomarkers of MDR in cancer 215. Finally, in this 
work a novel P-gp inhibitor (derived from curcumin) was described, which 
simultaneously inhibits the function and the expression of P-gp. Inhibitors of P-gp 
expression in particular are very important chemical tools, since they can be used to 
control P-gp expression in several pharmacological studies, not only by inhibiting 
cellular P-gp expression but also by inhibiting its production and therefore its 
intercellular transfer by EVs.  
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